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Abstract 
In the last decade, nanotechnology has emerged as one of the fastest growing area of science. This 
is a highly promising field for the generation of new engineering applications, consumer products, 
medical healthcare and medicine. However, the increasing development of nanomaterials (NMs) is 
not supported by in vivo studies taking systematically into consideration nanoparticles (NPs) types, 
doses and period of treatment that would allow to forecast possible adverse outcomes that might 
occur upon human exposure. 
In our studies, fully characterized silver nanoparticles (AgNPs) and iron oxide nanoparticles (IONP), 
designed for cancer treatment, were used to assess biodistribution and potential toxic effects after 
single intravenous and repeated oral administration in mice. 
Unexpected histopathological findings, strictly related to the physicochemical properties, i.e. size 
and vehicle used for the NPs synthesis, were observed after intravenous administration. This 
confirms that a complete characterization of NPs is of the most importance for the identification of 
in vivo outcomes. NPs mainly localized in organs containing large number of specialized tissue-
resident macrophages belonging to the mononuclear phagocyte system. The retention of NPs in 
these tissues raises concerns about the potential toxicity. 
The 28 days repeated oral administration of AgNPs demonstrated that the brain is the organ where 
Ag accumulation takes place. In fact, Ag it is still detected in brain after the recovery period 
because of its low clearance. Morphological changes observed in the blood brain barrier (BBB), and 
the involvement of glial cells in response to AgNPs administration, suggested a perturbation of 
brain homeostasis that should be taken into consideration and further investigated. 
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Sintesi 
Negli ultimi anni lo sviluppo delle nanotecnologie ha subito un crescente e rapido sviluppo. Le 
peculiari caratteristiche e potenzialità dei nanomateriali hanno permesso la loro applicazione in 
diversi settori, quali l’ingegneria (dispositivi elettronici e meccanici), il campo medico e sanitario 
(come nanovettori per il veicolo di farmaci, come sonde nella diagnostica per immagini, come 
componenti di strumenti chirurgici) e sono inoltre applicati in molti prodotti di largo consumo 
(cosmetici, indumenti, supplementi alimentari, contenitori per alimenti). 
Con l’aumento dell’utilizzo dei nanomatriali, anche il rischio di esposizione umana cresce e con 
esso l’impatto che i nanomateriali hanno sull’organismo. Ad oggi, non sono del tutto chiari e 
identificati gli effetti che i nanomateriali inducono in vivo, questo perché gli studi sperimentali 
condotti sono molto eterogenei in termini di tipo di nanomateriali usati, non comparabili per le 
loro caratteristiche chimico fisiche (dimensione, coating, etc) e per la loro sintesi, ed in termini di 
dosi somministrate e periodi di trattamento considerati. Queste variabili non hanno permesso ad 
oggi l’identificazione e la valutazione del rischio associato all’uso accidentale o intenzionale di 
nanomateriali. 
Data la rilevanza delle caratteristiche chimico-fisiche dei nanomateriali nel conferire le peculiari 
proprietà che li rendono differenti dal materiale di dimensione convenzionale, lo scopo degli studi 
proposti in questa tesi è di valutare l’effetto di queste caratteristiche sulla biodistribuzione e sugli 
eventuali effetti tossici a seguito della somministrazione intravenosa o orale di nanoparticelle 
metalliche. Nello specifico sono state utilizzati due tipi di nanoparticelle, nanoparticelle di argento 
(AgNPs), disponibili commercialmente e nanoparticelle di ossido di ferro (IONP) sintetizzate per 
essere applicate nel trattamento di tumori. 
Dopo la somministrazione intravenosa, le nanoparticelle si distribuiscono negli organi contenenti 
un elevato numero di cellule appartenenti al sistema fagocitico-mononucleato, in maniera 
dipendente dalla dimensione (le più piccole si distribuiscono e si accumulano maggiormente negli 
organi rispetto a quelle di dimensioni maggiori). Anche le lesioni istologiche osservate, non 
comparabili con quelle descritte negli altri studi in letteratura, sono dipendenti dalla dimensione 
delle nanoparticelle e dal veicolo utilizzato per la loro sintesi, caso quest’ultimo delle IONP.  
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La somministrazione ripetuta orale di AgNPs di piccole dimensioni ha permesso di stabilire che esse 
si accumulano nel cervello, seppure in quantità molto bassa rispetto alla dose iniziale 
somministrata. A causa della bassa capacità di clearance di quest’organo, anche dopo il periodo di 
recovery è possibile quantificare una residua dose di argento. I cambiamenti morfologici 
ultrastrutturali osservati a livello della barriera emato-encefalica e le modifiche a carico delle 
cellule gliali (astrociti e microglia) suggeriscono che probabilmente la somministrazione orale di 
AgNPs agisce sull’omeostasi cerebrale. I risultati preliminari ottenuti aggiungono nuove 
informazioni sul potenziale rischio in seguito ad esposizione ripetuta di AgNPs e suggeriscono 
ulteriori approfondimenti per meglio caratterizzare gli effetti osservati. 
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1. INTRODUCTION 
Nano-objects or nanomaterials (NMs)are defined by the European Union as “a natural, incidental 
or manufactured material containing particles, in an unbound state or to an aggregate or an 
agglomerate and where, for 50% or more of the particles in the number size distribution, one or 
more external dimensions is in the size range 1–100nm” [1]. 
At the same time it is specified that “In specific cases and where warranted by concerns for the 
environment, health, safety or competitiveness, the number size distribution threshold of 50 % 
may be replaced by a threshold between 1 and 50 %”, indicating that the legislation aimed to 
ensure a high level of health, safety and environmental protection as far as it should permit access 
to innovative products and promote innovation and competitiveness [1]. 
The number of NMs have increased during the past years, and the total annual quantity of NMs on 
the market at the global level is estimated at around 11 million tons, with a market value of 
roughly 20bn €[2], [3]. The increase in applications of NMs is related to their properties which vary 
according to their size and shape as well as their chemical environment. The structure and 
properties of NMs differ significantly from those of atoms as well as of those of the bulk materials. 
Compared to their bulk material counterparts, the distinct physicochemical properties of the NMs, 
such as size, surface properties, shape, composition, molecular weight, identity, purity, stability 
and solubility, might prove attractive in various industrial applications and are critically relevant to 
particular physiological interactions [4], [5]. 
The small size and corresponding large specific surface area of solid NMs confer speciﬁc properties 
to them, for example, making them desirable as catalysts for chemical reactions. The importance 
of surface area becomes evident when considering that surface atoms or molecules play a 
dominant role in determining bulk properties; the ratio of surface to total atoms or molecules 
increases exponentially with decreasing particle size. The increase on the volume to surface ratio 
increase in the particle surface energy and may render NPs more biological reactive [6]. 
These unique physicochemical properties suggest that they can interact with organs and cells in 
unpredictable ways and this raises concern about their potential toxicity. However, the lack of high 
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quality exposure and dosimetry data both for humans and the environment does not allow to 
single out, quantify and manage the potential risks that might be involved in NMs uses, especially 
the long-term ones and does not allow an adequate risk assessment. Because nanotechnology is so 
novel the challenge for future years will be centered around the knowledge on essential questions 
such as characterization, hazards, exposure, risk assessment and the risk management of NMs[7]. 
1.1. NMs applications 
The properties of NMs make possible to employ them in several applications, such as: 
 Electronics. Remarkable technological progress has come from reductions in the size of 
transistors, thereby increasing the number of transistors possible per chip. It is already 
generating ultrafast semiconductors and microprocessors, low voltage and high brightness 
displays [8], [9] [http://ec.europa.eu/research/industrial_technologies/nanotechnology-
fields_en.html]. 
 Environment. Nanotechnology’s great sustainability promise is to bring about the much needed 
power shift in renewable energy: a new generation of highly efficient photovoltaics, 
nanocomposites for stronger and lighter wind energy rotor blades, but also a new class of 
nanomembranes for carbon capture at fossil fuel power plants, and for the removal of finest 
contaminants of water supplies and mitigation of pollutants in the 
environment[10][http://ec.europa.eu/research/industrial_technologies/nanotechnology-
fields_en.html]. 
 Consumer and healthcare products. A significant portion of products utilize NMs to confer 
antimicrobial protection, to provide protective coatings and for environmental treatment (to 
protect products against environmental damage or to treat air and water in the home). Goods 
containing NMs are clothing, cosmetics, sporting equipment, food packaging, dietary 
supplements. Personal care products includes such products as a hair growth–stimulating 
shampoo, tooth pastes and sunscreens that use NMs because they effectively block ultraviolet 
light [11], [12]. 
 Medicine. Nanomedicine is an emerging field that combines nanotechnology with 
pharmaceutical and biomedical sciences, with the goal of developing drugs and imaging agents 
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with higher efficacy and improved safety and toxicological profiles. It has been defined as the 
monitoring, repair, construction and control of human biological system at molecular level, 
using engineered nanodevices and nanostructures. Current applications of nanotechnology in 
medicine involve engineered molecules to develop drugs, drug delivery techniques, diagnostics, 
medical devices and tissue engineering procedures [9], [11], [13].Nanotechnology contributes 
in the development of novel drugs especially in cancer therapy. In most cases, the 
nanoparticle/drug conjugates achieve their effect through passive targeting, which relies on 
non-specific accumulation in diseased tissue (usually tumors). This approach has been used to 
target solid tumors, since the increased permeability of blood vessels in combination with poor 
lymphatic drainage or transport (the so-called enhanced permeability and retention (EPR) 
effect) leads to accumulation of nanomedicines within the tumor microenvironment [14]. 
Nanomedical research has also focused on creating mechanisms to more effectively deliver 
drugs. The most basic drug delivery systems based on nanotechnology enhance the 
effectiveness of drugs by targeting specific cells that over-express certain cell-surface 
receptors; it can also be achieved by immobilizing ligands (e.g. proteins, antibodies, small 
molecules) to the surface of the nanoparticle, leading to active targeting which results in 
accumulation followed by specific uptake of the nanomedicine into the tissue of interest (e.g. 
tumors) [13], [14]. Another means of drug delivery is to stabilize drug with nanoparticles like 
albumin as natural carrier and for safe administration of high drug doses. Example of that is the 
FDA approved nanoparticle albumin-bound paclitaxel (Abraxane™) resulting in significant 
antitumor activity in patient with metastatic breast cancer [15]. 
Many approaches have been developed to use nanoparticles in biomedical imaging and drug 
delivery. Applications for these systems will provide materials for controlled drug delivery by 
directing carriers to a specific location with magnetic fields or fluorescence biological markers. 
The carrier will then be activated on demand in a limited region. The predictable and extended 
duration of action help to reduce inconvenience of frequent re-dosing, improve patient 
compliance and avoid the side effects that so often result from potent medicines [15], [16]. 
In the field of in vivo imaging and diagnostic the most promising investigated area aims to 
increase the efficiency and accuracy of diagnosis from samples of body fluids. Researchers are 
attempting to develop microchips that use electrodes to identify the dielectric properties of 
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cancerous cells, viruses, and bacteria in body fluids. Furthermore, nanomedicine could result in 
non-invasive devices that can enter the body to determine glucose levels, distinguish between 
normal and cancerous tissue, and provide genetic screening for multiple diseases. It is the case 
of nanoscale needles that can probe cells for carcinogenic chemicals [13]. 
 
1.2. Types of NMs 
NMs exist in a variety of forms, including nanoparticles (NPs), nanofibres, nanotubes and 
nanostructured surfaces and may be tailored for individual properties or uses (Fig. 1) [17]. 
NMs cover a heterogeneous range of materials. In terms of market volume, the main categories on 
the market are: 
 inorganic non-metallic NMs (e.g. synthetic amorphous silica, aluminium oxide, titanium 
dioxide),  
 carbon based NMs (e.g. carbon black, carbon nanotubes), 
 organic, macromolecular or polymeric particulate materials (e.g. dendrimers), 
 metal nanoparticles (e.g. nanosilver) [18].  
Inorganic non-metallic NMs are already in a wide-spread use in the non-medical fields as additive 
to chemical polishing, cosmetics, food, and recently as vehicle for drug delivery (silica NMs), 
sunscreen and cosmetics (titanium dioxide NMs) [19], [20]. 
Carbon nanotubes can be used to deliver a variety of therapeutic agents, including biomolecules, 
to the target disease sites. In addition, their unparalleled optical and electrical properties make 
them excellent candidates for bioimaging and other biomedical applications [21]. 
An increasing number of studies focus on the uses of organic NMs with organic structure for 
regeneration of bone, cartilage, skin or dental tissues [22]. Among these NMs, dendrimers are 
characterized by individual features that make them hopeful candidates for a lot of applications. 
The dendritic polymers are analogous to protein, enzymes, and viruses, and are easily 
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functionalized. The most promising potential of dendrimers is in their possibility to perform 
controlled and specified drug delivery and as a sensor in bioimaging [23]. 
 
Fig.1. Example of different NMs: silica nanoparticles (left, SEM image), carbon based NMs (central), 
chitosan-based nanofibres (right, SEM image). 
1.3. Metallic NPs 
Gold, silver and iron are three most widely used materials that are considered inert to biological 
systems because they are biocompatible and not toxic [24]. 
In fact, NPs are based on small, well defined aggregates of the metals in the zero valent state.  
Two approaches are used in the preparation of ultraﬁne particles. The ﬁrst is the breakdown (top-
down) method by which an external force is applied to a solid that leads to its break-up into 
smaller particles. The second is the build-up (bottom-up) method that produces NPs starting from 
atoms of gas or liquids based on atomic transformations or molecular condensations [4]. 
The preparation of metal NPs is generally based on a wet chemical reduction of a suitable metal 
salt in the presence of a capping or stabilizing agent to prevent both aggregation and oxidation 
away from the reduced state. The size and more importantly the shape of the NPs can be 
controlled by the reducing agent, the capping agent and the reaction conditions used in the 
preparation. While spherical forms are most commonly prepared, rod-like shapes, cubes, 
hexagonal and even hollow forms are known [25]. 
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Numerous techniques have been developed to synthesize metal NPs, including both chemical 
methods (e.g., chemical reduction, photochemical reduction, coprecipitation, thermal 
decomposition, hydrolysis, etc.) and physical methods (e.g., vapor deposition, laser ablation, 
grinding, etc.). Biological methods based on microorganisms (bacteria, fungi and yeast) have been 
also developed for the synthesis of silver NPs. The ultimate goal is to obtain NPs with a high level of 
homogeneity and provide fine control over size, shape and surface properties [25], [26]. 
The introduction of capping agents, such as proteins, enzymes, oligonucleotides, allows the 
introduction of molecular recognition properties to the surface of the metal NPs, responsible of 
their applications in specific fields of the biomedical research (diagnostic, drug delivery, etc.) [25]. 
1.3.1. Properties of metallic NPs 
The remarkable optical properties of metal NPs, are due to their unique interaction with light 
which causes the collective coherent oscillation of their free conduction band electrons, termed 
localized surface plasmon resonance. Oscillation of the free electron results in either radioactive 
decay with a strong visible scattering of light or nonradioactive decay, which causes the conversion 
of photon energy into thermal energy. These two decay mechanisms have been readily utilized in 
biodiagnostic and imaging and therapeutic applications. The plasmonic resonance of metallic NPs 
depends on several parameters, such as size, shape, the physical properties in which the NPs are 
dispersed and the nature of metallic NPs (Fig. 2) [25]–[27]. 
Metal NPs possess also electrical properties that are similar to those of the corresponding bulk 
metals. The electronic properties of metallic NPs have been used for many applications, such as 
electrical sensors using metal NPs, as a tag for recognizing a specific target molecule, and the 
development of new electronic chips [25]. 
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Fig.2. Scheme representing the plasmonic effect induced by white light on the absorbance of a 
silver nanoparticle. The plasmon is represented by the oscillation of an electron cloud along the 
surface of the nanoparticle[25]. 
1.3.2. Silver NPs (AgNPs) 
Silver (Ag) is a metallic element that is known to be used by humans since ancient times in a broad 
range of applications, including jewelry, utensils, monetary currency, dental alloy, photography and 
explosives. Nowadays, the main field of application is in the electronic industry, however Ag is 
better known as an effective antimicrobial agent in various products .In fact, Ag was perhaps the 
most important antimicrobial compound before the introduction of antibiotics in the 1940s and is 
still used today in a wide range of medical applications because of its antibacterial effects and low 
toxicity to human cells (Fig 3) [28]. 
Nano-silver particles (AgNPs) are generally smaller than 100 nm and contain 20–15,000 silver 
atoms and have unusual and enhanced physical, chemical and biological properties compared to 
their bulk parent materials[29].AgNPs have been shown to be effective biocides against bacteria 
(such as Escherichia coli, Staphylococcus aureus, Staphylococcus epidermis, Leuconostoc 
mesenteroides, Bacillus subtilis, Klebsiella mobilis, andKlebsiella pneumonia), fungi and yeasts (such 
as Aspergillus niger, Candida albicans, Saccharomyces cerevisiae, and Penicillium citrinum) and 
viruses (such as Hepatitis B, HIV-1, respiratory syncytial virus)[30]. 
Because of the reported antimicrobial activity, there is a widespread use of AgNPs in many 
consumer products (in bedding, washing machine, water purification, toothpaste, clothes, shoes, 
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detergents, fabrics, nursing bottle, deodorants, filters and humidifiers) including food packing 
materials, but also in food itself and dietary supplements [31]–[33]. 
Furthermore, the use of AgNPs is already established for some medical applications, including 
wound dressing (the antibacterial, antiviral and antifungal properties of AgNPs can facilitate 
healing), with many new potential application currently being investigated at preclinical level, 
including the applications as antiviral agents, photosensitizers and/or radiosensitizer, anticancer 
therapeutic agents in leukemia, breast cancer, hepatocellular carcinoma, lung carcinoma [26], [34]. 
Implantable medical devices, such as neurosurgical and venous catheters, have greatly benefited 
from the broad antibacterial activity of AgNPs by reducing patient infection and dependence on 
the antibiotic use [35]. 
Additionally AgNPs prevent the occurrence of resistance to microorganisms, so they are considered 
as a potential additive to animal feed or alternatives to growth-promoting antibiotics in animal 
agriculture [36], [37]. 
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Fig.3. Uses of silver (right-hand side) and silver NPs (left-hand side) in medicine. Traditionally, silver 
nitrate is used in a number of clinical contexts: to stem the flow of blood from nosebleeds, to 
induce the pleurodesis when closing chest tube wounds and cauterization of granulomas. AgNPs is 
emerging as a next-generation antibacterial agent, augmenting antibiotics and disinfectants for 
coating of medical devices. AgNPs-based wound dressings are already commercially available (e.g. 
ActicoatTM) and in current clinical use. NS is used as an antibacterial additive or coating in a range 
of catheters and in bone cement. NS can also be used in hand gels and paints as a prolonged 
antibacterial disinfectant[35]. 
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Mechanism of AgNPs antimicrobial activity 
Although the mechanisms behind the activity of nano-scaled silver on bacteria are not yet fully 
elucidated, the three most common mechanisms of toxicity proposed to date are: (1) uptake of 
free silver ions followed by disruption of ATP production and DNA replication, (2) silver 
nanoparticles and silver ions generation of ROS, and (3) silver nanoparticles direct damage to cell 
membranes (Fig. 4)[30], [38]. 
The detailed mechanism by which silver nanoparticles interact with cytoplasmic membranes and 
are able to penetrate inside the cells is not fully clarified. One hypothesis is that the interaction 
between nanoparticles and bacterial cells are due to electrostatic attraction between negatively 
charged cell membranes and positively charged nanoparticles[30].Morphological changes become 
evident upon such interaction and can be characterized by shrinkage of the cytoplasm and 
membrane detachment ﬁnally leading to rupture of the cell wall. Besides electrostatic attraction, 
the interaction of AgNPs with the sulfur-containing proteins present in the cell wall causes changes 
in the cell wall structure that result in its disruption. This, in turn, aﬀects the integrity of the lipid 
bilayer and of the permeability of the cell membrane [38]. After adhesion to the cell membrane, 
the AgNPs may also penetrate inside the cells and aﬀect their vital cellular functions, in fact, Ag (+) 
ions can affect the functionality of the respiratory electron transport chain by uncoupling it from 
oxidative phosphorylation through the inhibition of the respiratory chain enzymes[39]. The 
excessive amount of generated free radical directly damages the mitochondrial membrane through 
the hyperoxidation of lipids, proteins and DNA [38], [40]. 
Several studies suggest that the toxicity of AgNPs is affected by their size, which is responsible for 
their speciﬁc physiochemical characteristics[41]–[43]. The smaller the nanoparticles are, the larger 
the surface available for interaction is, resulting in a higher speciﬁc activity. In addition, compared 
to larger AgNPs, small AgNPs release more Ag ions and consequently exhibit stronger antimicrobial 
activities[28].Moreover the bactericidal properties of the AgNPs are strongly inﬂuenced by their 
shape and concentration. AgNPs interacts with bacteria, fungi and viruses in a shape-dependent 
manner. As compared to the spherical or rod-shaped AgNPs, truncated triangular shaped AgNPs 
demonstrate enhanced antibacterial action. AgNPs with the same surface areas, but, diﬀerent 
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shapes show diﬀerential bactericidal activity, which can be attributed to the variations in the 
eﬀective surface areas and active facets of AgNPs[38]. The antibacterial eﬀect is also 
concentration-dependent. Interestingly, the Gram-positive bacteria, such as S. aureus, are less 
susceptible than Gram-negative bacteria, such as E. coli and Salmonella typhi; however, both 
classes of bacteria display complete growth inhibition at higher AgNPs concentrations[44]. 
 
Fig.4. Nano-scaled silver may (1) release silver ions and generate ROS; (2) interact with membrane 
proteins affecting their correct function; (3) accumulate in the cell membrane affecting membrane 
permeability; and (4) enter into the cell where it can generate ROS, release silver ions, and affect 
DNA. [30].  
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1.3.3. Iron oxide NPs 
Iron is the most current transition metal that chemically combines with oxygen to form iron oxides 
compounds, such as magnetite (Fe3O4), maghemite (ƴ-Fe2O3), and hematite (α-Fe2O3) as the most 
common. Iron oxides are prevalent, widely used as they are inexpensive, and play an imperative 
role in many biological processes. They are also extensively used by humans, in catalysts, durable 
pigments (coatings, paints, and colored concretes) [45]. 
Iron oxide NPs (IONP) are a specific type of metallic NPs that exhibit magnetic properties and are 
becoming the popular magnetic core composite for metallic NPs due to their excellent relaxivity 
and biocompatibility [46]. 
Iron oxide magnetic NPs with appropriate surface chemistry are prepared by various methods, 
such as wet chemical, dry processes, or microbiological techniques and several synthesis routes to 
achieve shape, size, crystallinity, dispersity, and magnetic behavior have been developed [47]. 
Once synthesized, the iron oxide core is coated with a biocompatible coating, such as a 
carbohydrate or polymer. Biocompatible coatings are imperative for stability of NPs in a biological 
environment, to protect the NPs from biodegradation. The choice of the coating material to be 
utilized makes a substantial difference in cellular response material and applications [46]. 
Due to their super-paramagnetic properties IONP have attracted much attention and are especially 
interesting in biomedical applications for protein immobilization, such as diagnostic magnetic 
resonance imaging (MRI), thermal therapy, and drug delivery. The ability of IONP to bind with a 
range of substances like antibodies, dyes, chemotherapeutic agents, and nucleic acid, enables 
them to have multiple functions (Fig. 5) [48]. 
As therapeutic applications, the majority of IONP FDA-approved materials are indicated as iron 
replacement therapies. There are several approved compounds (Venofer®, Ferrlecit®, INFed®, 
Dexferrum® and Feraheme®), which are employed to treat anemia related to chronic kidney 
disease (CKD). Each of these are composed of an iron oxide core, coated with hydrophilic polymers 
(e.g. dextran, sucrose), which provide slow dissolution of the iron following intravenous injection. 
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This allows rapid administration of large doses without increasing free iron in the blood to a level 
which causes toxicity [14]. 
In the area of cancer therapy, the aminosilane-coated super-paramagnetic IONP designed for 
tumor therapy (glioblastoma) by using local tissue hyperthermia (Nanotherm™),was approved by 
European regulatory. Here, the magnetic fluid is injected directly into the tumor, and an 
alternating magnetic field applicator is used to selectively heat the particles, resulting in local 
heating of the tumor environment (temperatures reach 40–45°C), leading to programmed 
(apoptosis) and not programmed (necrosis) cell death. In a recent clinical trial, the treatment of 59 
patients with recurrent glioblastoma with thermotherapy using magnetic iron-oxide nanoparticles 
in conjunction with fractionated stereotactic radiotherapy, was associated with a remarkable 
increase in overall patient survival, comparing to the median survival for patients treated with 
chemotherapy following glioblastoma recurrence [14], [49]. 
IONP is applied for their used in enhancing MRI contrast and parameters such as surface coating, 
shape and composition are all factors in determining the magnetic and biological behavior of IONP. 
Coating is important to prevent opsonization and rapid blood clearance while size is important in 
MR signal-enhancing effect [50], [51]. As example, ferumoxytol (Feraheme®) is under investigation 
as an imaging agent [52]. 
Moreover, the outer coating on the metal-based core ensures that the NPs can be utilized in 
diagnostic procedures. In a multifunctional system, metallic NPs may be further incorporated with 
therapeutic payloads (chemotherapeutics or biotherapeutics), serving as both an imaging agent 
and a therapeutic carrier, and the ability of cellular tracking in MRI can be improved by linking 
antibodies or gene expressing cells to the NPs’ surfaces [46]. 
However, despite the increasing production of new tools based on metallic NPs for potential 
applications in therapeutic and diagnostic area, to date only few of them have reached the clinics. 
Yet, some formulations based on gold and iron oxide NPs have already been approved or are in 
phase 3 of clinical trials. One of the most challenging technical difficulties that NMs are facing in 
biomedicine, is to successfully cross biological barriers and specifically recognize their targets while 
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they circulate through the body. Moreover, the use of NMs may pose unknown risks to patients, 
until now poorly investigated [53]. 
 
Fig.5. Schematic illustration of a full-suite theranostic NP. The magnetic core serve as a MRI 
contrast agent and heat source for magnetic hyperthermia, and  a polymer coating increases 
biocompatibility, mitigates mononuclear phagocytes system uptake, and allows for facile 
functionalization with chemotherapeutic and targeting moieties [50]. 
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1.4. General mechanisms of metallic NPs toxicity and routes of exposure 
The widespread applications of NPs raise concerns about the potentially unpredictable and adverse 
consequences of human exposure. In this contest, nanotoxicology refers to the study of 
interactions of NPs with biological systems with an emphasis on elucidating the relationship 
between the physical and chemical properties with induction of toxic biological responses[54].The 
unusual properties of NMs (which are due to their small particle sizes, large surface to volume 
ratios, and material differences) could lead to a modified distribution model and different 
biokinetic behavior, thereby producing different, unexpected effects [55]. Even though it became 
clear that cellular responses were strongly dependent on specific NM physicochemical properties, 
the elucidation of these unique correlations has presented a major challenge. The need for 
advanced assessment tools which are accurate at lower concentrations and in a physiologically 
relevant fluid, and the complete characterization of manufactured NM (as it produced by a 
manufactures, as it actual used in products, as to which consumers may be exposed) are two main 
aspects to be fulfilled in order to obtain comparable results not affected by NM behavioral 
patterns (e.g. insoluble nature, ability to agglomerate, particle sedimentation) [7], [56]. 
The assessment of NPs toxicity has largely been determined in vitro. Typical end points measured 
include mortality, growth, respiration, oxidative stress, and gene expression. Generation of 
reactive oxygen species (ROS) and free radicals causes oxidative stress (activation or inhibition of 
the antioxidant defense system), lipid peroxidation, and DNA damage are recognized as some of 
mechanisms by which NPs might induce toxicity [57]–[60]. 
In vitro tests do not consider the complexity of in vivo interactions. Factors that might influence in 
vivo NPs toxicity include particle-related properties, the administered dose, the route of 
administration and extent of tissue distribution. Additionally, the toxicity of these materials 
depends on their persistence or clearance from the different organs due to the immune response 
of the host [16], [61], [62]. For these reasons, in vivo studies are important in elucidating potential 
health hazards associated with NMs exposure in a physiological environment. 
The diverse routes of human exposure include inhalation, dermal uptake, ingestion, and injection 
(for drug delivery system). 
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Inhalation is the most common route of exposure to NPs in the workplaces. Once inhaled, these 
materials are carried by electrostatic force of the air from the upper to the lower respiratory tract. 
The NPs are absorbed across the lung epithelium and enter the blood and lymph depending on the 
nanomaterial size. When the NPs are deposited in the alveolar, they are usually attacked by the 
process of phagocytosis. This also leads to chemotactic activities which trigger the inflammatory 
cell response [61]. 
Oral is another route whereby NPs may enter the body. NPs can reach the gastrointestinal tract 
through the food, water, cosmetics, drugs, and drug delivery devices. Furthermore, exposure can 
occur during handling of the materials that contain the NPs. NPs administered orally are usually 
absorbed, through the epithelial cells of the Peyer’s patches in the gut-associated lymphoid tissue 
(GALT) and also through the gut enterocytes and can translocate to other organs [54], [61]. 
However most of the effects observed after oral dosing in experimental animals are low and most 
of the NPs are excreted [63]. 
The intravenous administration of NPs is a very important route for the conduction of toxicological 
assessment in experimental animals. After i.v. injections, NPs have a rapid systemic distribution 
and most substances are subject to first-pass metabolism within the liver where they may 
accumulate or distribute via the vasculature to end organs including the brain. The blood—brain-
barrier (BBB) protects the brain from external chemical insults, but the potential for 
nanoparticulate matter to pass through tight junctions makes the brain vulnerable to particle-
mediated toxicity [16]. 
Upon inhalation, ingestion, or injection of pristine NPs, they encounter various complex 
physiological environments, leading to the covering of NPs with various biomolecules. Of particular 
importance is the adsorption of proteins on the nanoparticle surface. The formation of 
nanoparticle-protein complexes is commonly referred to as the nanoparticle-protein corona (NP-
PC). Upon the formation of such a corona of biomolecules, the in vivo transformation of pristine 
NPs is rapidly initiated [53]. Serum/plasma and cellular proteins represent complex biological 
system that may cause the NP to undergo a complex sequence of modifications, so far not fully 
understood. Even within one environment the NP-protein interactions are constantly changing. For 
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example, when exposed to blood plasma, the nano-bio interface has been reported to change with 
time due to constant adsorption and desorption of proteins. NPs uptake could be influenced by 
protein adsorption, physical characteristics of the NPs, and the their properties to interact with 
cells [64], [65].  
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1.4.1. AgNPs in vivo toxicity  
Biodistribution and toxicity of AgNPs were assessed in rodents by inhalation, intravenous, or oral 
exposure. An update of studies performed were revised by the Scientific Committee on Emerging 
and Newly Identified Health Risks (SCENHIR) and concluded that data on absorption and internal 
systemic exposure of nanomaterials is limited and may vary depending on physicochemical 
properties of the individual particles and the local barriers present in different organs[66]. 
The most common route of pulmonary exposure to AgNPs is via the occupational inhalation of 
airborne particles during manufacturing. Some studies have demonstrated in a rat model that 
inhaled NPs can translocate from their original site of deposition (e.g. lungs) to other tissues[67]. In 
the acute setting, no significant body weight changes or clinical changes were observed. 
Furthermore, lung function tests did not reveal any statistical differences between exposed and 
control groups. The subchronic inhalation induced a time- and dose-dependent inflammatory 
response in the alveoli and granulomatous changes as well as decreased lung function[68], [69]. 
In most AgNPs studies in rodents, the liver has been described as the primary organ for Ag 
distribution, followed by the spleen, kidneys, lung and brain. The results of i.v. injection suggested 
that tissue distribution of AgNPs was size-dependent and further suggest the potential size-
dependent toxicity and health risks[70]. Adverse effects were generally recognized through 
changes in the blood biochemical parameters of liver function (such as ALT, AST, ALP, and 
cholesterol), while only occasionally mild histopathological changes were reported, such as biliary 
hyperplasia, fibrosis, hepatocellular vacuolar degeneration, and rarely necrosis [69], [71], [72]. 
Orally administered ionic and nanoparticulate silver have been described to be deposited in a wide 
range of organs. Some studies mainly performed in rats using different doses of AgNPs and 
different particle size, found the majority of the silver in the stomach and intestine followed by 
liver, spleen, testis, kidneys, brain and lungs [73], [74]. 
Adverse effects reported in AgNPs oral dosing studies were mild and only evident at doses of 125 
mg/kg and above. n a range of oral investigations, no effects on body weight were reported [31], 
[73], [75], [76]. At that dose, an elevate cholesterol and cholestatic enzymes (alkaline phosphatase) 
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was observed and was accompanied by biliary hyperplasia [77]. This suggests that the biliary 
system may be a target for Ag accumulation [63]. Only one study evaluated adverse effects at a 
lower, more physiologically relevant dose [31]. In mice was found mild, dose-dependent increases 
in both serum pro-inflammatory (IL-1, IL-6, IL-12) and anti-inflammatory (IL-10, TGFß) cytokines. 
Among the different studies performed, no evidence of genotoxicity was detected [31], [78]. 
In the gastrointestinal tract some pathological findings were reported. AgNPs(5–20 nm) damaged 
the epithelial cell microvilli and intestinal glands [79]with an increased number of goblet cells [77]. 
In the brain, it was shown that exposure to AgNPs induces destruction of the BBB[80], astrocyte 
swelling, and causes neuronal degeneration [81]. Orally administered AgNPs affected also 
neurotransmitters (5-HT and dopamine) concentration in rat brain [82]. AgNP-treated rats, further 
subjected to heat stress, showed greater BBB disruption leading to edema formation, impairment 
of cognitive and motor functions and brain damage [83]. Moreover both AgNPs and Ag ions 
induced considerable synaptic damage, mainly in the hippocampus and to a lesser extent in the 
cerebral cortex of exposed rats [84]. 
Overall, data suggest that both tissue distribution and bioavailability of ingested AgNP are low and 
there is indirect evidence that AgNP may have lower bioavailability than ionic Ag. Moreover, 
evidence suggests that the likelihood for adverse effects on host tissues caused by acute or 
subchronic oral administration of AgNP is low [63]. 
Released of Ag ions from NPs surface is considered to be an important font for nanosilver toxicity. 
However studies are controversial, it was concluded that the toxicity of AgNPs is due to both the 
particulate form and the ionic silver released. In specific environmental conditions silver can be 
oxidized and dissolved to silver ions, which are the main active and reactive species of silver. Due 
to the limited specific surface area of bulk silver the amount of ionic species available is usually 
quite limited. As the particle size decreases towards nanoscale this situation is reversed, with a 
much higher proportion of the atoms being at the surface and consequently greater propensity for 
dissolution, or reaction [85]. Due to the ion release, the comparison of silver in nano and ionic form 
seems to be important in assessing AgNPs biodistribution and toxicity. 
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The best-described adverse effects in humans of chronic exposure to silver are a permanent bluish-
gray discoloration (argyria/argyrosis) of the skin or eyes. Inhalation of soluble silver compounds has 
been reported to cause both upper (nose and throat) and lower (lungs) respiratory tract irritation, 
although irritation is most likely caused by the corrosive effect of nitrate in some silver compounds 
rather than by silver itself. Silver ions possess a high affinity for the thiol groups in the liver and 
have been shown to bind to reduced glutathione and be transported into the bile, thus depleting 
the amount of reduced glutathione available for biochemical pathways. Reduced glutathione plays 
an important role in maintaining proper structure and function of red blood cells, as well as 
eliminating organic peroxides [86]. 
1.4.2. IONP toxicity 
Iron is considered one of the most inert materials used in nanotechnology. Overall the IONP do not 
seem to induce oxidative stress mediated toxicological effects, nor altered physiological process or 
behavior changes or visible pathological lesions. 
Size of IONP may not be of much significance except for its magnetic characteristics that are 
usually found to be safe. Coating is the parameters that may pose different toxicity issues, and 
results clearly revealed dependence of toxicity on surface ligation. It was established that the 
surface of IONP could be manipulated to alter the endocytosis of nanoparticles and their 
subsequent toxicity. Similarly, coating of IONP nanoparticles with three very closely related 
carbohydrates i.e. glucose, lactose and maltose resulted in very different behavior in human cell 
line suggesting that the effect of surface coating will markedly affect nanoparticles fate in vivo.  In 
vitro studies gave insight into the relationship between NP-coating material and cell viability. It was 
discovered that positively charged coatings induced a decrease in cell viability, due to DNA 
damage. Also, it is critical to understand the mechanism and interactions in which the NPs are 
involved in the body, to alleviate any possible side effects. It was found that, at high concentrations 
(above 400ppm), cell viability decreased. From this observation, so it was proposed that iron 
concentration is the critical factor for cell viability [46]. 
The cytotoxicity assays (WST-8, DCF, and LDH) performed by Hong et al., tested increasing 
concentrations of each modified SPION for cell viability, oxidative stress, and cell membrane 
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integrity. When considering IONP for clinical application, we should also consider the factor of iron 
overload, the metal may dissolve inside the body and lead to hemosiderosis i.e. accumulation of 
iron in various body organs, especially in the liver [87]. 
The main important conclusion about NPs toxicity is that because of the wide differences in 
properties among NMs, each of these types of NPs can elicit its own unique biological responses. 
As a result, different types of NPs must be categorized, characterized, and studied separately, 
although certain concepts of nanotoxicology based on the small size and coating, could likely be 
applied to all NMs [67]. 
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2. AIMS 
The constant increase in the applications of NPs in multiple fields, and the consequent concern for 
the human exposure, impel for an in-depth investigation of their potential toxic effects. A definitive 
conclusion on toxicological properties of NPs cannot be drawn so far due to high variability of 
tested NPs in terms of source of NPs (generated in the laboratory vs commercially available 
materials products), size, coating, route of exposure, dose administered, and the length of 
treatment during the conduction of the in-vivo experiments. 
Moreover, since the physicochemical properties strongly affect the behavior of different NPs, a 
comprehensive physicochemical characterization of tested NPs is required. The lack of sufficient 
characterization of the nanoparticles used in the various experiments makes any correlation 
unlikely and hinders the comparison between different experiments. 
The in vivo studies undertaken during my PhD were aimed at investigating two main aspects 
related to the exposure to nanoparticles:  
 The role of physicochemical properties, in particular the size and coating, in the 
biodistribution (and potential toxicity) of fully characterized NPs. To this purpose, AgNPs 
and newly synthesized IONP were selected and administered by intravenous route. 
 The in vivo effects following repeated oral exposure to low doses of AgNPs, in the attempt 
of investigating the potential effects that may arise in humans after repeated ingestion of 
very low doses of AgNPs that represents the most likely route of human exposure to these 
NPs. 
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3. MATERIAL AND METHODS 
3.1. Physicochemical characterization of NPs 
3.1.1. AgNPs 
In order to reduce variability in term of source of silver nanoparticles (AgNPs), commercially 
available AgNPs were used (NanoComposix, San Diego, USA).All the suspensions were supplied at a 
concentration of about 1.0 mg/ml. BioPure™ AgNPs were chosen because they were guaranteed to 
be sterile and with an endotoxin level lower or equal to 2.5 EU/ml. The suspending solvents of CT- 
and PVP-coated AgNPs were 2.0 mM sodium citrate and Milli-Q water (Millipore), respectively. 
Since NPs toxicity is related to the corresponding physicochemical properties, a rigorous approach 
is essential to have a reliable characterization of NPs [5]. For this reason, before the administration, 
a quality control was performed to ensure manufacture’s physicochemical properties; particularly 
to describe the size of the primary particles and to assess the presence of agglomerates and/or 
aggregates. 
AgNPs were characterized by using three different techniques, namely Dynamic Light Scattering 
(DLS), UV-visible (UV–Vis) spectroscopy, and Transmission Electron Microscopy (TEM). The 
following parameters were reported: 
 The hydrodynamic diameter of the particles and their possible aggregation when suspended in 
the testing medium were evaluated by DLS. 
 UV–Vis spectroscopy measurements were performed to further investigate the intrinsic 
features of the putative aggregates detected in 10 nm AgNPs. AgNPs exhibit a characteristic 
absorbance maximum in the visible range due to the surface plasmon resonance (SPR) effect 
[37]. Notably, optical properties of AgNPs are closely related to their morphology, therefore 
UV–Vis spectroscopy can detect any change in size/shape as well as the presence of 
aggregates. 
 Additionally, TEM analysis was performed to assess the shape and primary size distribution of 
tested AgNPs. 
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Dynamic Light Scattering (DLS) 
The actual size of AgNPs in dispersion was measured by DLS. Measurements were performed with 
a Malvern Zetasizer Nano ZS90 instrument operating with a light source wavelength of 532 nm and 
a fixed scattering angle of 90°. All the nanoparticles were diluted 1:100 except for 10 nm-sized 
AgNPs. Indeed, due to their small size, the 10 nm AgNPs presented increased absorption and lower 
scattering intensity compared to 40 nm and 100 nm AgNPs. Accordingly, the 10 nm AgNPs were 
diluted 1:50. All measurements were run at room temperature for at least three times. 
UV-Visible (UV–Vis) Spectrophotometry 
The UV–Vis spectra were acquired in the 300–800 nm range using a DU730 Beckman Coulter 
Spectrophotometer. All the nanoparticles were diluted 1:100 except for 10 nm AgNPs, which were 
diluted 1:200 because of their increased UV–Vis absorbance with respect to larger nanoparticles. 
All measurements were run at room temperature for at least three times. 
Transmission Electron Microscopy (TEM) 
Formvar coated copper TEM grids (cod. PE1GC300, Pelco) were pre-treated with 20 μl of poly-L-
lysine 0.01 % (w/v) (Sigma Aldrich) for 15 min. After washing twice with MilliQ water, 3 μl of AgNPs 
suspensions were deposited onto the grid for 5 min and then rinsed with 3 μl of 2-propanol (Sigma 
Aldrich). According to the manufacturer’s advice, 100 nm and 40 nm AgNPs were used at the 
concentration of 1.0 mg/ml, while 10 nm AgNPs were diluted up to 0.1 mg/ml before use. The grids 
dried overnight at room temperature in a covered crystallizing dish. TEM (FEI Tecnai G2, 
Eindhoven) images were analyzed with the ImageJ software (http:// imagej.nih.gov/ij/) to obtain 
the nanoparticles dimensional distribution. Small objects due to background and overlapping 
nanoparticles were omitted by using proper cut-off filters and Feret diameter (intended as the 
larger diameter of the NP projection) was used to evaluate the size of the particles. For each 
sample, a minimum of about 250 nanoparticles were considered. 
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3.1.2. IONP 
The synthesis of an NP-enzyme system for cancer therapy was performed according to the paper of 
Cappellini et al (Appendix B). The NP-enzyme system was based on iron oxide magnetic NPs (IONP) 
conjugated to the ROS producing enzyme D-amino acid oxidase from Rhodotorula gracilis (Fe3O4-
APTES-DAAO). 
IONP were characterized by using Dynamic Light Scattering (DLS) and infra-red (IR) spectroscopy. 
IR spectroscopy allows the detection of functional groups and adsorbed molecules at the surface of 
NPs, as well as monitoring changes of the surface chemistry. 
Dynamic Light Scattering (DLS) 
Fe3O4-APTES-DAAO NPs were analyzed at concentrations of 250, 25 and 2.5 μg/ ml in water. 
Samples dilutions were done in order to analyze the effect of concentration on NP aggregation. 
Each measurement was preceded by an equilibration time of 90 s. Analyses were performed with 
Zetasizer Nano ZS90 (Malvern, UK) instrument. Measures were reported as scattering intensity in 
function to diameter. 
Infra-red (IR) spectroscopy 
Fe3O4NP-APTES-DAAO NPs were characterized by IR analysis in different conditions. Samples (disks 
of 2 cm2 area) were placed in a quartz cell equipped with KBr windows. A movable quartz sample 
holder allows to adjust the pellet in the infrared beam for spectra recording and to displace it into 
a furnace at the top of the cell for thermal treatment. The cell was connected to a vacuum line for 
evacuation (Presidual = ∼10–6 torr) and for the introduction of gases into the infrared cell. Spectra 
were recorded at room temperature. The addition of well-known doses of gas in the cell was 
possible via a pressure gauge for the control of the gas pressure. A Nicolet Nexus spectrometer 
equipped witha Mercury Cadmium Telluride (MCT) cryodetector and an extended KBr beam 
splitter was used for the acquisition of spectra in the 600–5500 cm-1 range. IR spectra are 
absorption spectra and the notation used is a.u. for absorption units. The resolution of the spectra 
was 4 cm-1, and 256 scans were accumulated for each spectrum. Three different experiments were 
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performed: first the samples have been dispersed in the KBr, then on the surface of a silica pellet; 
finally on a silicon disk. In details: a wafer containing 98 mg of KBr has been pressed at 4 tons/cm2, 
together with ∼2 mg of the targeted sample; a wafer of 20 mg silica has been casted mixing in its 
center ∼6–7 mg of sample, then pressed to 2 tons /cm2 and ∼2 mg of powder was dispersed on 
the surface of a 2 cm2 silicon disk by the help of a spot of ethanol. 
3.2. Dissolution study for AgNPs 
CT-coated particles were selected for this investigation given the higher stability and lower 
dissolution generally showed by PVP-coated AgNPs [88]. Dissolution of CT-coated AgNPs of 10, 40 
and 100 nm was ascertained by ultrafiltration, using a PES spin filter membrane (Vivaspin 500, 3 
kDa MWCO, Sartorius, Göttingen, Germany) and centrifugation at 15000 g for 20 min, followed by 
quantification of silver in the filtrates. The concentration of ionic silver was measured both in the 
AgNPs stock suspensions and in conditions simulating AgNPs interaction with biological fluids. For 
the latter purpose, each stock suspension was spiked to mouse serum (Euroclone, Milan, Italy) to 
provide the mass concentration of AgNPs of a single dose of 10 mg/ kg bw, which approximately 
corresponded to a 1:5 dilution (v/v) of the original AgNPs suspension. Spiked samples and serum 
blank were prepared in triplicate and incubated at 37 °C under agitation for 5, 10, 60 min and 24 h. 
Ionic silver was assessed for each time point. For ICP-MS determination of ionic silver, filtrates 
(prepared in triplicate) were vigorously shaken before further dilution and analysis as described in 
the section “Determination of silver”. In addition to ionic silver, each stock suspension of CT-coated 
AgNPs was characterized in terms of total silver concentration and the results for ionic silver were 
expressed as percentages of total silver (AgNPs+Ag+). Samples for total silver determinations were 
prepared in triplicate by dilution with acidified (HNO3) water as necessary. In order to establish 
possible sources of bias from the filtration membrane, procedural blanks were run in parallel and 
the recovery of ionic silver (10 μg/L) from the filtration unit was assessed. No silver was detected in 
the procedural blanks and the average recovery of ionic silver was found to be 102.6± 3.8 %, 
showing absence of silver release/adsorption during filtration. 
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3.3. In vivo Studies 
The following studies were described in this thesis: 
 Single intravenous administration of AgNPs: effect of size and coating on biodistribution 
and toxicity. 
 Single intravenous administration of AgNPs: batch dependent toxicity. 
 5 days repeated oral administration of AgNPs: effect of coating on biodistribution  
 28 days repeated oral administration of AgNPs: effect of repeated administration of low 
doses on accumulation and toxicity 
 Single intravenous administration of IONPs: effect of dose and vehicle on distribution and 
toxicity 
The detailed experimental designs are reported for each study in chapter 4, while common 
material and methods applied are described in the following sections. 
3.3.1. Animals 
Male CD-1(ICR) mice of 4–5 weeks were purchased from Charles River (Calco, Italy). They were 
acclimated to the environment for a week prior to the initiation of the study, with free access to 
water and a standard pellet diet ad libitum. The environmental conditions were set at a 
temperature of 22±2 °C, relative humidity of 55± 10 % and a 12 h light/dark cycle. Animals were 
euthanized by carbon dioxide inhalation. 
All the experiments were approved by an independent Ethical Committee on Animal 
Experimentation (Ethical Committee of the University of Milan, Opinion no. 81/14 and 5/15)and 
were performed in accordance with the Italian Laws (D.L.vo 116/92 or D.L.vo 26/2014), which 
enforce EU 86/609 or2010/63 Directive. 
3.3.2. Irwin test 
The Irwin observation test is commonly used to evaluate the effects of a new substance on 
behavior and physiological function. The Irwin test can also be used in a safety approach for 
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detecting untoward effects of a new compound on general behavior and for evaluating its acute 
neurotoxicity. 
Behavioral modifications, physiological and neurotoxicity symptoms are recorded according to a 
standardized observation grid. Irwin’s rating scale for the mouse consists of three major categories 
with which the behavioral, neurological and autonomic profiles are graded. All the measurable 
effects are scored on an arbitrary scale from 0 to 9. Four is assigned to a characteristic which is 
usually present under normal circumstances. The degree to which this characteristic is altered is 
scored from 4 to 8, if it is increased and 4 to 0 if it is decreased. Observations are performed 15, 30, 
60, 120 and 180 minutes after administration of the test substance and 24 and 48 hours later. 
3.3.3. Body and organ weight 
The body weight of each mouse was measured before the treatment and the sacrifice. In the 28 
days repeated oral administration study, body weight was measured each day, immediately before 
treatment. During the recovery period mice were weighted two days a week. 
The organ weight was measured after the sacrifice and relative organ weights (%) were calculated 
as wet organ weight/total body weight. 
3.3.4. Sampling 
At the end of the studies mice were euthanized by carbon dioxide inhalation and mice underwent 
complete necropsy. Blood and tissues were sampled for different analyses (total silver 
determination, histology, special stains, immunohistochemistry, immunofluorescence, TEM) as 
detailed in this and following chapters. 
3.3.5. Hematology and clinical chemistry 
Blood was counted on a laser based counter (Sysmex-XT 2000iV) with species-specific software. A 
blood smear was prepared, samples were centrifuged, and plasma (300 to 750 µLs) was 
transferred in another tube and frozen at -20°. WBC differential, cell morphology, and platelet 
estimate were determined on May Grünwald-Giemsa stained smears. Clinical chemistry was 
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performed on thawed plasma with an automated spectrophotometer (ILAB-300, Instrumentation 
Lab). 
3.4. Determination of silver in the organs (inductively coupled plasma mass spectrometry: 
ICP-MS) 
Total silver content was determined in organs and in the whole blood by means of a triple 
quadrupole inductively coupled plasma mass spectrometer (ICP-MS) at the Department of Food 
Safety and Veterinary Public Health, National Health Institute-Roma. A 8800 ICPQQQ spectrometer 
(Agilent Technologies, Japan, Tokio) equipped with an autosampler, a peristaltic pump, a Micro-
Mist glass concentric nebuliser, and operated at a RF power of 1550 W, was used. All sample 
manipulations were carried out in clean room conditions under a laminar flow box. Before ICP-MS 
measurements, whole organs and blood were placed in Falcon tubes and pre-digested for 5 h at 
room temperature with 2–4 ml HNO3, depending on the organ weight. After adding 1 ml H2O2, 
samples were digested in a microwave system at 90 °C for 8 h, maximum power 800 W. After 
cooling, the digests were diluted by adding HCl (final concentration 3.0 M) to promote the 
formation of soluble silver complexes and prevent the precipitation of insoluble Ag+ salts. Prior to 
analysis the digests were highly diluted with 0.1 % HNO3 and the appropriate amount of HCl to 
maintain silver in complexed form. Measurements were carried out on 107Ag and 103Rh, as 
internal standard, by the method of external calibration. The method detection limit ranged from 
0.4 to 0.7 μg/kg, depending on the tissue, and was 0.09 μg/l for blood. Truthfulness of ICP-MS 
measurements was assessed by analyzing the certified reference material SRM 1577c Bovine Liver 
(NIST, Gaithersburg, MD, USA), with a certified value for silver of 5.9 ± 1.6 μg/kg and the control 
material Seronorm™ Trace Elements Whole Blood L-1 (SERO AS, Billingstad, Norway) with an 
indicative value for silver of 185 ± 10 ng/l, both included in every analytical batch. The average 
determined silver concentrations were 6.0 ±0.5 μg/kg (n = 6) and 179 ± 2 ng/l (n = 6) for the 
liverbased and the blood-based materials, respectively, in good agreement with the reference 
values. The truthfulness of determinations was also assessed through spikes of known amounts of 
silver in tissues and blood before sample dissolution, giving recoveries within the range of 90-100 
% with no appreciable differences between sample types. 
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3.5. Histopathological examination 
For histological examination organs were fixed in formalin solution, 10% neutral-buffered (pH 7.2, 
Bio-optica, Milan) for at least 48h at room temperature, routinely processed for paraffin 
embedding by using an automated tissue processor (Leica Microsystems). Formalin fixed paraffin 
embedded (FFPE) tissues were sectioned at 4 μm thickness, stained with hematoxylin-eosin 
according to standardized protocol 
(http://www.ihcworld.com/_protocols/special_stains/HE_Mayer.htm), and blindly evaluated 
under a light microscope. 
The trimming procedures for sampled organs are here reported: 
Liver: median lobe including the gall bladder, spleen: apical portion, kidney: half of the right kidney, 
lung: the left lobe, brain: half brain, for intravenous administration studies; after oral repeated 
administration, transversal sections were obtained after the fixation by using a brain matrix (Adult 
Mouse Brain Slicer Matrix BSMAS005-1, Zivic Instruments, USA), heart, small intestine (proximal 
and distal), colon and caecum. 
Grading of histopathological lesions in the examined organs was performed as follows: 0 = absence 
of lesions; 1 = minimal lesions; 2 = mild lesions; 3 = moderate lesions; 4 = severe lesions. 
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3.6. Special histological stains  
To visualize silver and iron in tissue sections, the following special stains were applied: 
Autometallography (AMG) 
According to Danscher [113], this method visualizes trace amounts of silver in paraffin sections 
from biological tissue. After exposure to light, which ensures reduction of silver ions that are not 
bound to sulphide, histological sections from animals treated with silver compounds are exposed 
to a photographic developer containing silver ions. 
After AMG staining, sections were counterstained with safranin O and evaluated under a light 
microscope for the identification of tissue and cellular localization of silver, visible as black granular 
pigment. 
Perls’ iron stain 
The stain aims to visualized iron deposits within tissues.The technique is based on the conversion 
of ferrocyanide to insoluble crystals of Prussian blue in the presence of Fe3+ under acidic 
conditions. Protocol applied according to Prophet et al. [114]. 
3.7. Immunohistochemistry and immunofluorescence 
Four µm sections of FFPE tissues were simultaneously deparaffinized and heat induced epitope 
retrieval (HIER) was performed by immersion in a Buffer H solution according to the datasheet 
procedure (Dewax and HIER Buffer H, Thermo Scientific). Than the following primary antibodies 
were applied: 
Antibody Clonality Marker of 
GFAP (Glial FibrillaryAcidic 
Protein) 
Rabbit polyclonal Astrocyte 
IBA1 (Ionized calcium binding 
adaptor molecule 1) 
Rabbit polyclonal Pan-macrophage/histiocyteand 
microglia 
Albumin Rabbit polyclonal Blood Brain Barrier damage 
Cleaved-caspase 3 Rabbit polyclonal Apoptotic cells 
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Sections were then incubated with biotinylated secondary antibody, labelled by the avidin-biotin-
peroxidase procedure. The immunoreaction was visualized with 3,3’-diaminobenzidine substrate 
and sections were counterstained with Mayer’s haematoxylin. Known positive control sections 
were included in each immunolabeling assay. 
For immunofluorescence (IF), following secondary antibody was applied: AlexaFluor555 F(ab′ )2 
Fragment of Goat Anti-Rabbit IgG (H + L) (Molecular Probes, Life Technologies Europe BV, Monza, 
Italy). Immunofluorescent labeled sections were acquired with the Leica TCS SP5 confocal 
microscope (Leica Microsystems). The fluorophore was excited with the 532 nm laser line and the 
emitted fluorescence acquired in sequential scan mode with ACS APO 63x/1.15 Oil CS objective. 
Nuclei were visualized by DAPI staining (405nm laser line excitation). Silver aggregates were 
visualized by reflection of light at 561 nm. 
3.8. Digital Image Analysis (DIA) 
Images were acquired using a 20x or 40x objective and analyzed using the ImageJ analysis program 
(http://rsb.info.nih.gov/ij/). 
DIA for Perls stain 
Three 200x microscopic fields in liver, spleen, lung, kidney, brain, heart were randomly acquired 
and the area of Perls staining was measured in each field. The percentage of Perls positive area per 
field was then calculated. 
DIA for IBA1 and GFAP IHC 
Area of Iba1 and GFAP immonostaining was measured in three 400x/microscopic fields randomly 
selected in the hippocampus (CA1- CA2 and CA3 regions). The percentage of immunostained 
positive area per field was then calculated. Additionally, the number of IBA1 positive cells per 400x 
field was then counted. 
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3.9. TEM 
Hippocampus and small intestine samples were reduced and fixed with 4% paraformaldehyde 
(PFA) and 2% glutaraldehyde in phosphate buffer 0.12 mol/l pH 7.4 for 6 hours, followed by 
incubation at room temperature for 2 h in 1% OsO4. After dehydration in a graded series of ethanol 
preparations, tissue samples were cleared in propylene oxide, embedded in epoxy medium (Epoxy 
Embedding Medium kit; Sigma-Aldrich, St. Louis, MO 63103 USA) and polymerized at 60°C for 72 h. 
From each sample, one semi-thin (1 μm) section was cut with a Leica EM UC6 ultramicrotome 
(Leica Microsystems, Vienna, Austria), stained with Toluidine Blue and mounted on glass slides to 
identify the areas of interest. Ultra-thin (60 nm thick) sections were then obtained, counterstained 
with uranyl acetate and lead citrate, and examined with an energy filter transmission electron 
microscope (Libra120, Carl Zeiss NTS GmbH, Oberkochen, Germany) equipped with a yttrium 
aluminum garnet (YAG) scintillator slow-scan charge-coupled device (CCD) camera (Sharp eye, TRS, 
Moorenweis, Germany). 
3.10. Statistical analysis 
Data were analyzed using Graph Pad Prism version 5.0 (GraphPad Software, San Diego, CA). Since 
the numbers of data obtained from in vivo experiments and from digital image analyses do not 
assume normal distribution, nonparametric tests (Kruskal-Wallis and Mann-Whitney U test) were 
used to compare the different groups of treatment. 
List of abbreviation: 
DLS: Dynamic Light Scattering 
TEM: transmission Electron Microscopy 
AgNPs: Silver Nanoparticles 
IONP: Iron Oxide Nanoparticles 
AgAc: Silver Acetate 
H&E: Haematoxylin and Eosin 
AMG: Autometallography 
IHC: Immunohistochemistry 
IF: Immunofluorescence 
DIA: Digital Image Analysis 
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4. RESULTS 
4.1. BIODISTRIBUTION AND TOXICITY OF AgNPs 
4.1.1. Single intravenous administration: effect of size and coating on biodistribution and 
toxicity  
(published paper: Recordati-De Maglie et al, 2016) 
In order to assess the impact of the physicochemical properties of AgNPs on the mice behavior in 
vivo, a preliminary study was conducted to investigate the effect of the size and coating of AgNP on 
tissue distribution and toxicity after single intravenous administration. The results obtained were 
compared with those obtained after administration of silver ions. In comparison to the studies 
selected from the literature, lower doses were administered. 
Physicochemical characterization 
AgNPs of 10, 40 and 100 nm in size, coated either with citrate(CT) or polyvinylpyrrolidone (PVP) 
were checked according to methods described in chapter 3 (3.1). Following methods was applied: 
 DLS 
 UV-vis spectroscopy 
 TEM 
A dissolution study was performed in mouse serum in conditions simulatingAgNPs interaction with 
biological fluids. 
Study design 
Mice were randomly assigned to8 groups of treatments (n=3 per group) (Tab.1).Mice were 
intravenously injected with AgNPs of different size (10 nm, 40 nm and 100 nm), either CT or PVP-
coated, at a single dose of 10 mg/kg, and with AgAc (silver acetate) at a single dose of 15.5 mg/kg, 
corresponding to 10 mg Ag/kg bw (n=3 animals per group). The dosing volume was 10 ml/kg bw. 
Animals belonging to the control group were treated with deionized water. Immediately after the 
treatment and the following hours, the general health and behavior of mice was monitored (Irwin 
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test). The body weight of each mouse was measured before treatment and at sacrifice which 
occurred 24 hours after the treatment. 
Tab. 1. Experimental Groups: 
Treatment Dose Time of sacrifice 
CTR (vehicle) 10 ml/kg 
T +24h 
CT-AgNPs 10nm 10 mg/kg 
CT-AgNPs 40nm 10 mg/kg 
CT-AgNPs 100nm 10 mg/kg 
PVP-AgNPs 10nm 10 mg/kg 
PVP-AgNPs40nm 10 mg/kg 
PVP-AgNPs 100nm 10 mg/kg 
AgAc 15.5 mg/kg 
 
According to the procedures described in chapter 3, organs (liver, spleen, kidney, lung, brain, 
heart) were sampled and the following determinations were done: 
 Determination of silver content in tissues: ICP-MS; 
 Visualization of silver in tissues: AMG 
 Identification of cells containing silver aggregates: immunofluorescence for IBA1. 
 Histopathological examination. 
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Results and discussion 
(Additional details in the published paper Recordati.De Maglie et al 2016, Annex B and additional 
data in Annex A) 
Physicochemical characterization 
The particles were thoroughly characterized before the investigation of their toxicological effects in 
vivo and theiraccordance to manufacturer’s specifications assessed. 
 DLS 
The hydrodynamic diameter of the particles and their possible aggregation when suspended in the 
testing medium were evaluated by DLS. The results are summarized in Table 2. Monomodal 
distributions were observed for 40 nm and 100 nm AgNPs, coated with both CT and PVP. The 10 
nm AgNP-CT and 10 nm AgNP-PVP suspensions showed multimodal distributions. The peaks at 
18.1 and 19.6 nm were indicative of isolated nanoparticles in 10 nm AgNP-CT and 10 nm AgNP-
PVP, respectively, while larger peaks in both samples suggested the possible presence of 
aggregates with variable dimensions. However, these large peaks were still detected b yDLS even 
after filtration (0.22 μm pore size), thus indicating their dynamic nature. 
 UV-vis spectroscopy 
To further investigate the intrinsic features of theputative aggregates detected in 10 nm AgNPs, 
UV–Vis. spectroscopy measurements were performed. AgNPs exhibit a characteristic absorbance 
maximum in the visible range due to the surface plasmon resonance (SPR) effect[89]. Notably, 
optical properties of AgNPs are closely related to their morphology, therefore UV–Vis spectroscopy 
can detect any change in size/shape as well as the presence of aggregates. The UV–Vis results are 
shown in Table 2. The correspondence between the optical properties given by the manufacturer 
and those measured in our laboratory appeared satisfactory. In particular, we did not observe any 
decrease inthe maximum absorbance value (Hmax), indicating absence of aggregates. Then, full 
absorbance spectra of all samples were considered (Fig. 6). In 10 nm AgNP-CT and 10 nm AgNP-
PVP the optical density in the 600–800 nm range, which is typical for aggregate absorption, was 
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not detected, further demonstrating that the presence of stable aggregates in these samples could 
be excluded. 
Tab. 2. Physicochemical characterization of tested AgNPs. 
BiopureTM Silver NPs DLS UV-Vis TEM 
 
Mean 
hydrodynamic 
diameter (nm) 
Max intensity peaks pdI λ max (nm) Hmax (a.u.) Diameter 
(mean±SD, 
nm) 
10 nm AgNP-CT np 18-4646 0,258 392 163,5 8,4±1,5 
10 nm AgNP-PVP np 19,6-11-4292 0,343 389 163,6 10,8±2,6 
40 nm AgNP-CT 40,1 49,8 0,213 412 125,6 39,3±4,8 
40 nm AgNP-PVP 51,8 97,6 0,251 410 145,7 40,3±5,6 
100 nm AgNP-PVP 87,6 102,9 0,148 490 45,1 107,7±5,6 
100 nm AgNP-PVP 104,1 119,4 0,124 491 46,8 105,5±10,9 
 
 
Fig.6.Particle characterization by UV–Vis spectroscopy: full absorbance spectra of the tested silver 
nanoparticles. The optical density in the 600–800 nm range, which is typical for aggregate 
absorption, was not detected in any of tested AgNPs, indicating the absence of stable aggregates in 
these samples. 
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 TEM 
Eventually, TEM analysis was performed to assess the shape and primary size distribution of tested 
AgNPs. All the tested AgNPs were spherical in shape (Fig.7), and their Feret diameter distributions 
were in good accordance with data reported by the manufacturer (p > 0.05 in all cases). 
 
Fig. 7. TEM of tested silver nanoparticles. Representative transmission electron micrographs of 10, 
40, and 100 nm AgNPs, CT- and PVP-coated. All purchased particles were spherical in shape, and no 
stable aggregates were visible (scale bar = 100 nm). 
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Dissolution study 
The presence of ionic silver in the stock suspensions of CT-coated AgNPs as well as AgNPs 
dissolution upon interaction with mouse serum was investigated by filtration on membranes with a 
pore size allowing discrimination of ionic silver from AgNPs. The percentage of ionic silver in the 
original stock suspensions was found to be negligible (0.002 %, 0.001 %, 0.001 % of total silver for 
10, 40 and 100 nm AgNPs, respectively). Time dependent dissolution of AgNPs in simulated 
biological conditions is shown in Table 3. As expected, the dissolution was greater for smaller 
particles and increased with time; however even for 10 nm-sized particles at 24 h, the percentage 
of ionic silver was found to be exceedingly low (0.005 %).The low dissolution of AgNPs when 
incubated in mouse serum is in accordance with other studies, which suggest that when AgNP are 
introduced in a physiological environment, their ability to release Ag+ is inhibited. This could be 
probably due to the formation of the protein corona [39]. Interaction of protein thiol groups with 
the charged surface of AgNPs in a medium with a high ionic strength is at the basis of the 
sulfidation process that leads to an extensive decrease of the dissolution rate in vitro, causing also 
the formation of nanobridges between particles, and has the potential to stabilize them in vivo. 
The formation of the protein corona decreases the extracellular dissolution of AgNPs. This leads to 
the cellular uptake of particles, which may lose the corona after the internalization resulting in an 
exacerbated release of Ag ions and toxicity [39].Dissolved silver ions likely react with chlorine in 
serum to form AgCl[90]. On the other hand, it cannot be ruled out that a minor part of the released 
silver ions might have been complexed with high affinity S-containing proteins and thus has been 
excluded by the membrane used, leading to a possible underestimation of the level of Ag+ 
released [91].However, even if the method used for the study of particles dissolution may have not 
provided an entirely accurate measure of ionic silver formation in physiological conditions – all 
available methods have some limitations in this respect [92] – it clearly shows that the extracellular 
dissolution of the AgNPs used in this study is very limited, and animals dosed with AgNPs were 
internally exposed to particulate and not ionic silver. 
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Tab. 3. Time dependent dissolution of AgNPs in simulated biological conditions. Results for ionic 
silver are expressed as percentage of total silver measured in the stock suspensions 
BiopureTM Silver NPs 5 min 10 min 60 min 24 h 
10 nm AgNP-CT 0,377*10-3 0,510*10-3 0,937*10-3 5,010*10-3 
40 nm AgNP-CT 0,049*10-3 0,075*10-3 0,176*10-3 1,235*10-3 
100 nm AgNP-PVP 0,005*10-3 0,016*10-3 0,038*10-3 0,366*10-3 
 
Clinical signs 
Immediately after the administration of AgNPs and AgAc, and during the following hours, all mice 
appeared healthy and no abnormal behavior was observed (see Irwin test for 10 nm AgNPs, 
Appendix A). However,24 h after the treatment, two mice (one mouse treated with 10 nm AgNP-CT 
and another one treated with 10 nm AgNP-PVP) were found dead. Complications related to the 
injection procedure or formation of large aggregates after administration were reasonably ruled 
out given the delayed onset of mortality and the results of the subsequent histopathological 
evaluation (i.e. absence of thromboembolic lesions associated with silver aggregates).At sacrifice, 
no significant differences in bodyweight gain and organ weights were recorded between CT- and 
PVP-coated AgNPs of the same size. In mice treated with 10 nm AgNPs, a significant difference in 
weight loss and relative spleen to body weight were observed when compared to controls, and 40 
and 100 nm AgNP-treated mice (Tables 4-5).No other significant differences were observed in the 
relative organ weights between treated and control mice. 
  
44 
 
Tab. 4. Mean of body weight and body weight gain in all groups of treatment. 
Treatment Weight (gr) Weight gain  
CTR pre-treatment sacrifice  (g) weight (%) 
mean 28,73 27,82 -0,91 -3,31 
SD 1,34 2,67 1,35 4,95 
CT-coated Ag-NPs 10 nm         
mean 27,82 24,34 -4,25 -14,84 
SD 1,47 0,56 0,37 0,83 
CT-coated Ag-NPs 40 nm         
mean 27,66 27,65 -0,01 0,04 
SD 1,82 1,42 0,84 2,98 
CT-coated Ag-NPs 100 nm         
mean 28,50 28,08 -0,42 -1,39 
SD 1,86 1,38 0,48 1,57 
PVP-coated Ag-NPs 10 nm         
mean 28,31 24,73 -2,48 -9,32 
SD 2,30 3,34 1,53 6,23 
PVP-coated Ag-NPs 40 nm         
mean 27,56 26,84 -0,72 -2,61 
SD 1,61 1,64 0,62 2,28 
PVP-coated Ag-NPs 100 nm         
mean 27,73 28,06 0,33 1,21 
SD 0,56 2,06 2,07 7,49 
AgAc         
mean 28,2 26,4 -1,8 -6,3 
SD 2,6 2,5 0,9 3,3 
 
  
45 
 
Tab. 5.Total and Relative organ weights. 
 
 
TOTAL WEIGHT  
 
RELATIVE WEIGHT 
CTR spleen liver kidney Brain lung 
 
spleen liver kidney Brain lung 
mean 0,13 1,84 0,50 0,49 0,18 
 
0,45 6,61 1,80 1,77 0,66 
SD 0,05 0,32 0,09 0,01 0,03 
 
0,14 0,75 0,16 0,14 0,05 
CT-coated Ag-NPs 10 nm           
 
          
mean 0,15 1,85 0,41 0,45 0,17 
 
0,64 7,26 1,68 1,75 0,62 
SD 0,01 0,16 0,05 0,04 0,05 
 
0,04 0,31 0,25 0,01 0,10 
CT-coated Ag-NPs 40 nm           
 
          
mean 0,12 1,81 0,45 0,48 0,18 
 
0,43 6,53 1,64 1,73 0,65 
SD 0,03 0,24 0,07 0,01 0,05 
 
0,10 0,58 0,24 0,11 0,16 
CT-coated Ag-NPs 100 nm           
 
          
mean 0,11 1,97 0,52 0,47 0,17 
 
0,39 7,01 1,86 1,66 0,61 
SD 0,01 0,05 0,07 0,02 0,02 
 
0,03 0,29 0,15 0,11 0,09 
PVP-coated Ag-NPs 10 nm           
 
          
mean 0,17 1,70 0,44 0,44 0,13 
 
0,65 6,18 1,64 1,81 0,76 
SD 0,03 0,32 0,07 0,02 0,10 
 
0,03 0,49 0,08 0,16 0,07 
PVP-coated Ag-NPs 40 nm           
 
          
mean 0,12 1,93 0,52 0,49 0,18 
 
0,45 7,21 1,95 1,83 0,66 
SD 0,02 0,17 0,05 0,02 0,01 
 
0,08 0,61 0,27 0,14 0,04 
PVP-coated Ag-NPs 100 nm           
 
          
mean 0,11 1,94 0,49 0,46 0,18 
 
0,40 6,92 1,73 1,64 0,65 
SD 0,03 0,17 0,04 0,03 0,02 
 
0,09 0,20 0,03 0,15 0,03 
AgAc           
 
          
media 0,12 1,85 0,51   0,21 
 
0,47 6,99 1,92 0,00 0,80 
SD 0,02 0,31 0,07   0,01 
 
0,03 0,49 0,22 0,00 0,08 
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Biodistribution (ICP-MS, AMG, IF) 
Distribution and localization of silver in the different organs 24 hours after IV administration of the 
different AgNPs were evaluated using two distinct, but complementary approaches: ICP-MS and 
autometallography (AMG) staining. ICP-MS was used to quantitatively measure the silver 
concentration in blood, spleen, liver, lung, kidney, and brain; while AMG was used to qualitatively 
assess its localization within the sampled organs. After 24 hours, the silver concentration in blood 
was severely reduced in all groups. 
For all particle sizes, regardless their coating, the highest silver concentration was found in the 
spleen and liver, followed by lung, kidney and brain. These results are in line with previous studies 
that investigated tissue distribution of AgNPs 24 h after IV administration [72], [93].When 
considering the percentage of the administered silver dose recovered after administration, for all 
tested AgNPs, approximately 40 % of the administered dose was found in the liver, which resulted 
to be the main target organ of silver distribution, followed by spleen, lung, kidney, and brain. Most 
of the silver that reaches the blood is filtered by the liver and excreted into the bile [50], while the 
remaining circulating particles are distributed to organs containing a large number of phagocytic 
cells. Concentrations of silver in the lung, kidney, and brain were higher in mice treated with 10 
nm-AgNPs (CT- and PVP-coated) than in mice treated with larger particles (40 nm and 100 nm). In 
addition, silver concentration in the brain of mice treated with 10 nm-AgNPs was higher than in 
mice treated with larger particles. Regarding the effect of coating on tissue distribution of AgNPs, 
coating of AgNPs did not have any relevant effect on biodistribution, in line with previous studies 
[73](Fig. 6). 
The tissue localization of silver was further evaluated after AMG staining that allows enhancing the 
silver present within the tissues, thus providing a rapid and more sensitive histochemical approach 
for the detection of the distribution of silver within the organs. Tissues from control mice were 
negative for the specific staining. In the liver of AgNPs treated mice, most of silver was found 
within Kupffer cells. Also sinusoidal endothelial cells and hepatocytes were occasionally stained. In 
the spleen, regardless the size and coating, silver was localized within the cytoplasm of 
macrophages in the marginal zone of the white pulp and in the red pulp, and occasionally within 
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splenic endothelial cells. In the lung, scattered silver containing cells were found in the alveolar 
septa, either within the capillaries or the interstitium. AMG is not able to identify particles and thus 
to assess localization of silver in the brain and kidney (Fig.7). In AgAc treated mice, silver was found 
in renal tubule (Fig. 8). 
Immunostaining of sections with IBA1 (a pan-macrophage marker) confirmed that the majority of 
the silver-containing particle aggregates were accumulated within the cytoplasm of Kupffer cells in 
the liver in all the examined groups(Fig. 9).The amount and size of silver containing aggregates 
within macrophages decreased with the reduction in size of AgNPs. In 10 nm AgNPs treated mice, 
only scattered and very small aggregates were found throughout the liver, while no visible silver-
containing aggregates were found in the liver of AgAc treated mice. 
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Fig. 6.Silver tissue concentration after IV administration of AgNPs (Ct and PVP-coated) and AgAc in 
mice. Data are expressed as means±SD. Statistical significance: a=p<0.05; b=p<0.01vs10nm. 
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Fig.7. AMG staining, 1000x (scale bar 20 µm). Treated animals: Silver localized in liver Kupffer cells, 
marginal zone macrophages in the spleen and in the alveolar septa in the lungs. No silver was 
detected in tissues of control group (left panel). 
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Fig.8. AMG staining. 1000x (scale bar 20 µm). In AgAc treated mice, silver was found in renal 
tubules (left panel).Silver accumulation was not observed in AgNPs treated amice.  
 
 
 
 
Fig.9. Immunufluorescence for Iba1 (red) and co-localization with AgNPs (green) in the liver 
(magnification, 400x, scale bar 20 µm). 
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Histopathological examination 
Histological AgNP-related lesions were observed in the spleen, liver, and gall bladder of AgNP-
treated mice. No relevant differences were found between CT- and PVP-coated particles of the 
same size. Overall, the prevalence and severity of lesions (in particular those involving liver and gall 
bladder) were size-dependent, and most frequently observed in mice treated with 10 nm AgNPs, 
that are more severely affected compared to 40 nm and 100 nmA gNP-treated mice, that 
respectively show milder or negligible lesions (Table 7). Splenic hyperemia was present in all mice 
treated with AgNPs, but it was particularly pronounced only in mice treated with 10 nm-sized 
particles. They might be responsible for the splenomegaly observed, as well as the increased 
relative spleen weight measured in this group. Mice treated with 10 nm AgNPs were affected by 
diffuse and severe midzonal hepatocellular necrosis and hemorrhage, multifocal peribiliary 
microhemorrhages, occasional portal vein endothelial damage (i.e. endothelial sloughing, 
subendothelial hemorrhages, intraluminal fibrin thrombi), and diffuse mural and intraluminal 
hemorrhage of the gall bladder. Among mice treated with 40 nm AgNPs, only one out of six had 
early peri-portal coagulative necrosis, scattered hepatic single cell necrosis, and gall bladder severe 
mural and intraluminalgall bladder hemorrhage. In the other mice treated with40 nm AgNPs, the 
hepatic lesions were not observed and gall bladder lesions were milder, usually consistent with 
mural hyperemia and/or edema. Mice treated with100 nm AgNPs had only occasional and mild gall 
bladder mural hyperemia and/or edema. No relevant pathological changes were observed in the 
lung, kidneys, and brain of AgNP-treated mice, and in all the examined organs of control mice (Fig. 
10). A completely different pathological scenario was observed after administration of AgAc. 
Hepatobiliary lesions were not observed, whereas a marked acute renal tubular necrosis and 
apoptosis with intraluminal accumulation of hyaline casts was found in all treated mice. Presence 
of renal lesions, associated with the identification of silver in the affected renal tubules and 
relevant silver concentrations in the kidney of AgAc-treated mice indicates that, dissolved silver 
ions resulted in an increased renal silver distribution compared to AgNPs, and that renal lesions 
were linked to the renal excretion of silver (Fig. 11). 
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Tab. 7. Prevalence of histopathological lesions in mice following IV exposure to 10 mg/kg of AgNPs. 
Data are expressed as number of mice with lesions/total number of examined mice per group (%).  
Group Spleen Liver Gall bladder Lung Kidneys Brain 
Control 1/3 (33%) 0/3 (0%) 0/3 (0%) 0/3 (0%) 0/3 (0%) 0/3 (0%) 
10 nm AgNP-CT 3/3 (100%) 3/3 (100%) 3/3 (100%) 0/3 (0%) 0/3 (0%) 0/3 (0%) 
10 nm AgNP-PVP 3/3 (100%) 3/3 (100%) 3/3 (100%) 0/3 (0%) 0/3 (0%) 0/3 (0%) 
40 nm AgNP-CT 3/3 (100%) 1/3 (33%) 2/3 (67%) 1/3 (33%) 0/3 (0%) 0/3 (0%) 
40 nm AgNP-PVP 2/3 (67%) 0/3 (0%) 1/3 (33%) 1/3 (33%) 0/3 (0%) 0/3 (0%) 
100 nm AgNP-CT 1/3 (33%) 0/3 (0%) 2/3 (67%) 0/3 (0%) 0/3 (0%) 0/3 (0%) 
100 nm AgNP-PVP 1/3 (33%) 0/3 (0%) 0/3 (0%) 0/3 (0%) 0/3 (0%) 0/3 (0%) 
AgAc 0/3 (0%) 0/3 (0%) 0/3 (0%) 0/3 (0%) 3/3 (100%) 0/3 (0%) 
 
 
 
Fig. 10.Hematoxylin&Eosin.Liver, 200x (scale bar 50 µm): in 10 nm AgNP, treated mice showed a 
marked midzonal hepatocellular necrosis (*) and hemorrhage(arrow), while in 40 nm treated mice 
only occasional single cell necrosis (arrow) was occasionally found. Gall bladder, 100x (scale bar 
500 µm): intraluminal (*) and mural (arrow) hemorrhage in 10 nm and 40 nm AgNPs treated mice. 
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Fig. 11.Hematoxylin&eosin, 400x (scale bar 50 µm). Midzonal hepatocellular necrosis (upper panel) 
was found in liver of mice treated with AgNPs, while renal tubular necrosis with intraluminal 
accumulation of hyaline casts was observed in mice treated with AgAc. 
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Conclusions 
 The physicochemical characterization ensured that the AgNPs used in the experimental 
conditions were suitable for in vivo studies and no stable aggregates were detected.  
 The dissolution study of AgNPs performed in mouse serum indicated that the tested AgNPs 
underwent a very low dissolution and animals dosed with AgNPs were thus internally exposed 
to particulate and not ionic silver.  
 After IV administration, we concluded that the organs most affected by Ag accumulation were 
the spleen and the liver, followed by the lungs. These results are in line with other in vivo 
studies conducted in rodents [71], [72], [93]. Some authors suggested that tissues with a 
fenestrated or incomplete endothelial lining, such as liver and spleen, respectively, contribute 
to a significant uptake of nanoparticles[93]. The accumulation occurred in tissues containing 
large numbers of phagocytic cells involved in clearing foreign body particles and xenobiotic NPs 
from the blood stream.  
In the liver, those cells residing within the portal tract region exhibit increased levels of 
scavenger receptors, phagocytosis and lysosomal enzyme activity compared to centrally 
located cells, which have increased cytokine activities. Splenic macrophages that reside within 
the red pulp, white lymphatic pulp and marginal regions significantly differ in the levels of 
endocytosis, with marginal zone macrophages exhibiting significant increases in MARCO 
(macrophage receptor with collagenous structure) receptors. These receptors were also used 
by the alveolar macrophages for the uptake and processing of NPs [94]. 
 The biodistribution of Ag was size dependent, confirming the results of other studies [93] which 
demonstrated that particles smaller than the pore size of liver fenestrae (∼100 nm)undergo to 
an enhanced liver uptake. 
 The toxicity of AgNP was size dependent. The smallest AgNPs induce the more severe effects. 
This might be due to their greater surface area; a much higher proportion of the atoms being at 
the surface and consequently greater propensity for dissolution, or reaction [85]. 
 Concerning the observed histopathological changes, the hepatocellular midzonal necrosis is the 
least common histopathological pattern of hepatocellular necrosis following exposure to 
hepatotoxicants. The gall bladder mural hemorrhage, as well as the portal peribiliary 
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hemorrhages, could result from the endothelial damage consequent to the massive elimination 
of AgNPs in the bile, which is considered the main route of silver excretion following IV 
administration of AgNPs [95]. 
 The toxicity was different between AgNPs and Ag ions, and this is because of the different 
excretion routes. Dissolved silver ions resulted in an increased renal silver distribution 
compared to AgNPs, and renal changes were likely consequent to the renal excretion of silver. 
 The different coating of AgNPs did not have any relevant effect on toxicity, likely because of the 
protein corona formation after injection. 
 Due to the severe toxicity and the higher distribution showed by the smallest AgNPs, the 10 nm 
were selected to conduct oral studies. 
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4.1.3. Single intravenous administration of AgNPs: batch dependent biodistribution and 
toxicity  
To confirm the lesions occurred after administration of 10 nm AgNPs, additional three different 
batches of AgNPs of the same size were tested. Eventually, to assess the hypothesis that very small 
NPs determine the most severe toxic effects, 5 nm AgNPs was administered. 
Physicochemical characterization 
Three batches of 10 nm AgNPs, CT coated, were checked according to the methods described in 
chapter 3 (3.1). Specifically the following methods were applied: 
 DLS 
 UV-vis spectroscopy 
 TEM 
Study design 
Mice were randomly assigned to 7 groups of treatments (n=3 per group). Mice were intravenously 
injected with 10 nm AgNPs from three different batches (A, used in study 4.1.1, B, C) at two 
different doses (5 mg/kg and 10 mg/kg). Additionally a group of mice (n=3) was treated with 5 nm 
AgNPs at a single dose of 10 mg/kg. The dosing volume was 10 ml/kg bw. Immediately after the 
treatment and the following hours up to 24 hours, the general health and behavior of mice were 
monitored. The body weight of each mouse was measured before treatment and at sacrifice, 
which occurred 24 hours after the treatment. 
Tab. 8. Experimental Groups: 
Treatment Dose Time of sacrifice 
CTR (vehicle) 10 ml/kg 
T +24h 
AgNPs 10nm Batch A 5- 10 mg/kg 
AgNPs 10nm Batch B 5- 10 mg/kg 
AgNPs 10nm Batch C 5- 10 mg/kg 
AgNPs 5nm 10 mg/kg 
 
According to procedure described in chapter 3, organs (liver,spleen, kidney, lung, brain, heart) 
were sampled and the histopathological examination was done.  
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Results 
Physicochemical characterization 
 DLS 
Monomodal distributions were observed for tested batches indicating the absence of aggregates, 
as showed in table 9. 
 UV-vis spectroscopy 
The correspondence between the optical properties given by the manufacturer and those 
measured in our laboratory appeared satisfactory; in particular, it is worth to point out, that it was 
not observed any decrease in the maximum absorbance value (Hmax), indicating the absence of 
aggregates (Tab. 9). Then, full absorbance spectra of all samples were analyzed (Fig. 12). The 
optical density in the 600–800 nm range, which is typical for aggregates absorption, was not 
detected in 10 nm AgNP-CT and 10 nm AgNP-PVP, further demonstrating that the presence of 
stable aggregates in these samples could be excluded. 
Tab. 9. Physicochemical characterization of tested AgNPs. 
BiopureTM Silver NPs DLS UV-Vis 
  
Mean hydrodynamic diameter 
(nm) 
Max intensity peaks pdI λ max (nm) Hmax (a.u.) 
Batch A np 18-4646 0,258 392 1635 
Batch B np 18,17 – 122,4 0,680 392 145,5 
Batch C 16,31 16,53 – 569,4 0,253 392 169,5 
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Fig.11. Particle characterization by UV–Vis spectroscopy: full absorbance spectra of the tested 
silver nanoparticles. The optical density in the 600–800 nm range, which is typical for aggregates 
absorption, was not detected in any of tested AgNPs, indicating the absence of stable aggregates in 
these samples 
 TEM 
All the tested AgNPs were spherical in shape, as represented in TEM images (Fig. 13). 
 
Fig. 13. TEM of tested silver nanoparticles. All purchased particles were spherical in shape, and no 
stable aggregates were visible (scale bar = 100 nm). 
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Histopathological examination 
All batches induced liver changes and hemorrhages in the gall bladder, confirming the effects 
observed in the previous study. As demonstrated in table 9, the severity of the lesions was dose 
and batch dependent, with batch A inducing the most severe effects (Fig. 14). Some in vitro studies 
reported that the toxicity of AgNP suspensions varied between batches, and hypothesized to be 
related to some differences occurring in the physicochemical properties [96]. 
Comparing the particle size distribution of tested batches (as reported in the datasheet) we noted 
that there was a difference in the percentage of very small AgNPs. The percentage of AgNPs<8nm 
was about 30%, 23% and 17% in batch A, B, and C, respectively, suggesting that at least part of the 
observed changes (in particular the hemorrhages) could be related to the very small AgNPs (Fig. 
15).  
In order to test this hypothesis, a single dose (10 mg/Kg) of 5 nm AgNPs was administered i.v., 
resulting in moderate to severe hepatobiliary lesions. Gall bladder hemorrhages were particularly 
severe in this group, as compared to those observed after administration of 10 nm AgNPs. This 
could be due to a more specific endothelial damage induced by very small AgNPs consequent to 
their massive elimination in the bile, as discussed in previous study. 
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AgNPs Batch 
n.  
AgNPs 
size 
Dose   
Histopathological grading (median scores)  
Hepatocellular 
necrosis/hemorrhage  
Gall bladder 
hemorrhage  
Total score  
A 10 nm 
5 mg/kg  1 2.5 3.5 
10 mg/kg  4 2 6 
B 10 nm 
5 mg/kg  1 1 2 
10 mg/kg  2 2 4 
C 10 nm 
5 mg/kg  2  0  2   
10 mg/kg  4 0.5    4.5  
  5 nm 10 mg/kg  3 4 7 
 
Tab.9. Histopathological grading. Mice treated with 10nm CT-coated AgNPs at different doses and 
with 3 different AgNPs batches (score: 0 = absence of lesions; 1 = minimal lesions; 2 = mild lesions; 
3 = moderate lesions; 4 = severe lesions). 
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Fig. 14. Hematoxylin&Eosin, Upper panel, Liver, 400x (scale bar 50 µm). Lower panel: gall bladder, 
50x (scale bar 500 µm). Mild to severe hepathocellular necrosis and gall bladder hemorrhages in 
mice treated with two different doses (Batch A). 
 
 
 
Fig.15. Size distribution of the three analyzed batches (datasheets of the manufacture).Variable 
presence of very small particles (less than 10 nm in diameter) in batches A and B that could have 
affected thetoxicityobserved. 
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Conclusions 
 The toxicity of 10 nm AgNPs observed in the study 4.1.1 was confirmed after testing 2 
additional batches of 10 nm AgNPs.  
 The toxicity of 10 nm AgNPs was dose-dependent. 
 The very small AgNPs (5nm) induced the most severe hepatobiliary lesions.  
 Among the AgNPs with same size, it seems that the size distribution is relevant to predict the in 
vivo outcomes. 
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4.1.3. 5 days repeated oral administration of AgNPs: effect of coating on biodistribution 
after oral exposure  
The aim of this study was to compare the effect of two different coating (Ct or PVP)on the 
biodistribution of silver after oral administration of 10 nm AgNPs in order to select the coating for 
the 28 days repeated oral administration study. 
Physicochemical characterization 
10 nm AgNPs coated with either citrate(CT) or polyvinylpyrrolidone (PVP)from the same batches 
used in the study 4.1 were tested according to methods described in chapter 3 (3.1).  
Study design 
Three groups of mice received AgNPs 10 nm CT-coated, AgNPs 10 nm PVP-coated and an aqueous 
solution of deionized water (vehicle control) respectively by oral gavage once a day for 5 days at a 
dose of 5 mg/kg bw (n=3 per group). The dosing volume was 10 ml/kg bw. The body weight of each 
mouse was measured before treatment and at sacrifice which occurred 24 hours after the 
treatment. 
According to the procedure described in chapter 3, organs (liver, spleen, kidney, lung, brain, heart, 
small intestine) were collected and the following determinations were done: 
 Determination of silver content in tissues (liver, spleen, small intestine): ICP-MS; 
 Visualization of silver in tissues: AMG 
 Histopathological examination. 
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Results and discussion 
Physicochemical characterization 
See results of the study 4.1.1 
 
Biodistribution (ICP-MS, AMG) 
Administration of the CT coated AgNPs resulted in a higher accumulation of Ag in spleen and liver 
compared to PVP-coated ones. In the liver silver concentration detected after CT coated AgNPs 
administration was twofold higher than that observed after administration of PVP-coated AgNPs 
(Fig. 16). Although there was no significant difference in Ag content in the intestine, the Ag 
concentration was slightly higher after administration of PVP-coated AgNPs. 
Silver aggregates were not detected by AMG staining in any of the analyzed organs (intestine, liver, 
spleen). 
 
Histopathological examination 
No treatment related histopathological changes were observed in any of the treated groups. 
 
 
Fig.16.Silver concentration in liver, spleen and small intestine of mice after repeated oral 
administration of 10 nm-CT and PVP coated AgNPs at 5 mg/kg bw/day. 
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Conclusion 
 After ingestion, spleen and liver were the organs where the accumulation of silver was 
more evident, while only small amount of silver was detected in the intestine suggesting 
that AgNPs were already absorbed or excreted. 
 Following oral administration a coating-dependent tissue distribution was observed, with 
increased accumulation of the CT-coated NPs in the spleen and liver, , suggesting a different 
mechanism of absorption, likely resulting from interaction with the biological membrane or 
fluids. 
 Due to the higher silver accumulation in the analyzed organs, the CT-coated AgNPs were 
selected for the 28 days repeated oral administration. 
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4.1.3. 28 days repeated oral administration of AgNPs: effect of repeated administration 
of low doses on accumulation and toxicity 
The aim of this study was to assess the biodistribution and effect of repeated oral administration of 
small AgNPs. An additional period of recovery to assess Ag persistence in organs was considered. 
Since no data about exposure are available, the two doses were selected as the lowest tested in 
literature studies. 
Physicochemical characterization 
10 nm AgNPs CT- coated were tested according to methods described in chapter 3 (3.1). 
Specifically, the following methods were applied: 
 DLS 
 UV-vis spectroscopy 
 TEM 
Study design 
Mice were randomly assigned to four groups of treatments (n=6 animals per group) plus a vehicle 
control group .Mice received AgNPs10 nm CT-coated at two doses of 0.25 and 1 mg/kg body 
weight (bw). For comparison, a group was treated with silver acetate (AgAc), used as source of 
silver ions, at a dose of 1.55 mg/kg bw, containing the equivalent dose of 1 mg Ag/kg bw. An 
aqueous solution of deionized water was administrated as vehicle control. Mice were treated by 
oral gavage once a day for 28 days. For each group, 6 mice were sacrificed at the end of treatment 
while 6animals were kept untreated, monitored and sacrificed after 28 days recovery period. At 
the sacrifice blood were collected by cardiac puncture for haematology and serum chemistry. 
According to procedure described in chapter 3, organs (brain, liver, spleen, kidney, lung, brain, 
heart, small intestine) were sampled and the following determination was done: 
 Haematology and serum chemistry 
 Determination of silver content in tissues (liver, spleen, small intestine, testis, brain): ICP-
MS; 
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 Visualization of silver in tissues: AMG 
 Histopathological examination. 
 Immunohistochemistry: Iba1 (microglial cells), GFAP (astrocytes), Albumin, Cleaved 
caspase-3 
 TEM analysis of brain and intestine 
Results and discussion 
Physicochemical characterization 
The physicochemical properties of AgNPs were monitored and evaluated during the treatment. 
Quality control was performed before the first administration and weekly (day 7, 14, 21), to ensure 
the adequate dispersion and absence of aggregation over the time (Tab. 10).  
The correspondence between the optical properties given by the manufacturer and those 
measured in our laboratory appeared satisfactory; DLS and UV-vis spectroscopy as well as TEM 
indicated absence of aggregates and ensure the spherical shape of tested AgNPs (Fig.17) 
  
68 
 
Time 
(days) 
DLS UV-Vis 
 Mean size (nm) peak (nm) PdI λmax (nm) Hmax (A.U.) 
0 14.17±0.23 15.30±0.46 0.103±0.047 391.89±0.33 163.69±0.60 
7 14.46±0.42 15.42±0.66 0.129±0.063 391.89±0.33 161.35±1.68 
14 19.42±7.42 15.21±1.27 0.242±0.063 391.00±0.00 173.51±4.62 
21 14.59±0.14 15.44±0.96 0.159±0.67 391.00±0.00 161.31±4.18 
Tab. 10. Quality control of AgNPs in the as-received conditions (day 0) and at three other time 
points (day 7, 14, 21). For DLS analyses, the mean size of AgNPs is expressed in terms of 
hydrodynamic diameter. The maximum intensity peak is also reported to describe more 
comprehensively samples having multimodal distributions (for example, in the presence of AgNPs 
aggregates). The pdI provides a measure of particles uniformity. For UV-Vis analyses, the maximum 
wavelength (λmax, i.e. the wavelength corresponding to the highest absorbance of AgNPs) and the 
maximum absorbance value (Hmax) are reported. The λmax and Hmax values were expressed as 
nanometer (nm) and arbitrary units (a.u.), respectively. 
 
 
Fig.17. TEM of tested silver nanoparticles. All purchased particles were spherical in shape, and no 
stable aggregates were visible (scale bar = 50 nm). 
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Hematology and serum chemistry 
The hematological mean values of all the other groups were within reference intervals; however 
the group treated with AgNPs at a dose of 1 mg/kg showed a lymphocyte values slightly higher 
than the upper limit of the reference interval. The few hematological changes observed are 
consistent with a slight activation of inflammatory/immune response in individual mice (Tab. 11). 
Concerning the clinical chemistry values, the group treated with AgNPs at a dose of 1 mg/kg has an 
increased in GLDH (glutamate dehydrogenase) suggesting an acute hepatocyte damage possibly 
associated with a slight impairment of liver function (Tab. 12). 
When the results of hematology and clinical chemistry are evaluated together, it seems that 
treatment did not induce severe hematological or biochemical changes.   
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Tab. 11. Hematological values after oral exposure. Data expressed as median value. 
  WBC x RBC Hb Ht MCV MCH MCHC Plt  Neutr  Lymph  Mono  Eos  
Group 10³/µL 10
6
/µL g/dL % fL pg % 10³/µL 10³/µL x10³/µL 10³/µL 10³/µL 
Ctrl                         
Mean  8,8 8,1 11,3 44,8 55,3 13,8 25 1586 1,15 7,34 0,27 0,03 
± SD ± 1,7 ± 0,7 ± 1,1 ± 3,0 ± 2,2 ± 0,3 ± 1,0 ± 318 ± 0,61 ± 1,41 ± 0,14 ± 0,05 
AgNPs 0,25 mg/kg                         
Mean  8,3 8,4 11,5 46,2 54,9 13,7 24,9 1448 1,19 6,4 0,58 0,14 
± SD ± 1,6 ± 0,3 ± 0,5 ± 2,4 ± 0,8 ± 0,1 ± 0,3 ± 605 ± 0,38 ± 0,88 ± 0,54 ± 0,23 
AgNPs 1 mg/kg                         
Mean  10 8,8 12,2 48,9 55,6 13,9 25 1480 0,88 8,76 0,33 0,08 
± SD ± 2,9 ± 0,3 ± 0,5 ± 2,1 ± 1,3 ± 0,4 ± 0,4 ± 306 ± 0,35 ± 2,97 ± 0,23 ± 0,11 
AgAc                         
Mean  9,3 8,2 11,6 46,6 56,7 14,2 25 1409 1,9 6,77 0,54 0,15 
± SD ± 2,6 ± 0,7 ± 0,9 ± 3,3 ± 1,3 ± 0,2 ± 0,2 ± 360 ± 2,53 ± 3,11 ± 0,47 ± 0,13 
Ref. Int. 3.8-13.8 6.2-
11.6 
10.3-
19.0 
34.9-
65.0 
47.1-
65.1 
14.5-
18.3 
24.1-34.9 744-2314 0.00-3.15 2.87-
10.31 
0.12-0.86 0.00-
0.46 
 
Tab. 12. Clinical chemistry values after oral exposure. Data expressed as median value. 
    GLDH Urea Creatinine Triglycerides ALT Albumin Total protein 
Group   (U/L) (mg/dL) (mg/dL) (mg/dL) (U/L) (mg/dL) (mg/dL) 
Ctrl                 
Mean ± SD   8,0 ± 3,5 39 ± 3 0,32 ± 0,03 155 ± 48 37 ± 28 2,31 ± 0,24 5,27 ± 0,79 
AgNPs 0,25 mg/kg                 
Mean ± SD   4,5 ± 2,4 34 ± 5 0,28 ± 0,01 93 ± 35 18 ± 6 2,40 ± 0,22 4,60 ± 0,29 
AgNPs 1 mg/kg                 
Mean ± SD   11,3 ± 3,7 44 ± 5 0,35 ± 0,11 157 ± 36 18 ± 5 2,45 ± 0,29 5,34 ± 0,42 
AgAc                 
Mean  ± SD   13,3 ± 11,5 35 ± 4 0,30 ± 0,04 126 ± 101 24 ± 23 2,14 ± 0,55 4,54 ± 0,47 
Ref. Int. 6.5-14.5 32 ± 8 0.40 ± 0.12 192 ± 67 45 ± 16 2.99 ± 0.62 5.38 ± 0.95 
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Clinical signs 
No changes in body weight were observed across the treated groups, control included. The body 
weight increased both during the treatment and the recovery period (Fig. 18). This is in line with 
most of the data reported by others investigators [97]. 
 
Fig. 18. Mean body weight gain (%) during PO administration and the recovery period. Data are 
expressed as means ± SD 
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Biodistribution 
After 28 days of treatment the distribution pattern of silver was similar between the nano and the 
ionic form of silver. ICP-MS analysis demonstrated the highest silver concentration in the brain and 
in the liver, followed by spleen and small intestine. A very low concentration of silver was found in 
the kidney. The accumulation of silver in the organs was dose-dependent for the AgNPs, and was 
lower in comparison to the corresponding organs of mice exposed to AgAc treatment. Statistically 
significant differences were found in the brain and in the liver of mice treated with the high dose of 
AgNPs and in the brain, liver and spleen of mice treated with the high dose of AgAc in comparison 
to the tissues from control animals (Fig. 19).  
The accumulation of Ag was dose-dependent and the ion form was present in a larger amount than 
AgNPs. This is possibly due to the lower bioavailability of the AgNPs compared to Ag ions[97]. 
After recovery period, Ag was still detected in the brain in all treated group (Fig. 20), however at 
lower amount, indicating that a time dependent clearance occurred. 
Histopathological examination 
No histopathological changes were identified in control and treated groups. This supports the 
evidence reported by other authors that adverse effects on host tissues caused by oral 
administration of AgNP are inconsistent [63]. 
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Fig. 19. Silver concentration in tissues after 28 days oral administration. Data are expressed as 
means ± SD. Statistical significance: *= p<0.05; **= p<0.01; **=p<0.001 vs control group. 
 
 
 
Fig. 20. Silver concentration in the brain 28 days after oral administration and after the recovery 
period. Data are expressed as means ± SD. Statistical significance: *= p<0.05; **= p<0.01; 
**=p<0.001 vs control group.  
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Immunohistochemical evaluation 
Since the brain was the organ with the highest Ag accumulation, immunohistochemical 
investigation was performed to evaluate changes in the cells involved in brain homeostasis and 
response to injury (astrocytes and microglia). In the hippocampus, an increase of GFAP (astrocytes 
marker) and Iba1 (microglia marker) immunostaining was observed in all treated groups in 
comparison to control animals; this was significantly higher for astrocytes in mice treated with 
AgNPs at 1 mg/kg and AgAc. After 28 days of treatment, an increase in the microglia positive area 
was detected in the same treated groups. After the recovery period, no differences in the 
morphology and density of astrocytes were observed however, a decrease of about 20% in Iba1 
positive area was detected in the animals treated with the higher dose of AgNPs and of AgAc (Figs. 
21-22). This decrease could correspond with the resolution phase of microglial activation; 
however, no morphological changes in glial cells were distinguished at histological magnification 
(Fig. 23). 
The number of Iba1 positive cells in each filed was also considered to relate the changes detected 
by digital image analysis to an increase or decrease in the number of cells. However, no changes in 
the cells number was observed in any treated groups. This suggests that the changes observed 
were possibly related to an increase/decrease of cell area. Additionally, no apoptotic glial cells 
were detected (Fig 24). 
Albumin immunohistochemistry were performed to detect any BBB damage. 
Immunohistochemical staining did not reveal any signs of albumin extravasation from brain 
microvasculature in all controls and treated mice. 
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Fig. 21. Quantification of GFAP (astrocyte) positive cells after 28 days of AgNPs oral administration 
and at the end of the recovery period in the hippocampus. Data are expressed as means ± SEM. 
Statistical significance: ** = p<0.01 vs control group. 
 
 
 
Fig. 22. Quantification of Iba1 (microglia) positive cells after 28 days of AgNPs oral administration 
and the end of the recovery period in the hippocampus. Data are expressed as means ± SEM.  
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Fig. 23. IHC for GFAP and Iba1, 400x (scale bar 50 µm). Hippocampus, glial cells after 28 days of oral 
administration. 
 
 
 
Fig. 24. IHC for Albumin, 400x (scale bar 50 µm). No sign of albumin extravasations was observed. 
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TEM analysis 
TEM analysis of the hippocampus showed splitting of the basement membrane of the capillaries, 
and swelling of the perivascular end-feet of astrocytes in both AgNPs- and AgAc-treated mice (Fig. 
25). These morphological changes were not observed at the end of the recovery period, suggesting 
that the change was reversible. 
TEM analysis of the small intestine of control and treated mice showed no changes in the intestinal 
mucosa. Neither AgNPs nor Ag was detected. 
 
 
Fig. 25. Representative TEM images of the hippocampal capillary. Swelling of perivascular end-feet 
of astrocytes (asterisk) in AgNPs and AgAc treated mice. Splitting of capillary basement membrane 
in three and two different branches (arrows) in AgNPs and AgAc treated mouse. 
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Conclusions 
 Our study shows that the organ with the highest amount of Ag accumulation is the brain; 
differently from other the studies where it is reported that the main target organs for silver 
accumulation after repeated dose of orally administered NPs are liver, spleen and intestine 
[31], [32]. This evidence leads to hypothesize that the brain Ag accumulation could be due to 
the low clearance activity of this tissue, possibly indicating that the blood–brain barrier 
prevents the back  transfer of Ag into the blood [84], [98].  
 Ag persists in the brain also after the recovery period, even if a gradual reduction was 
observed. These data are in agreement with the results of few reported studies showing that 
Ag was still present in brain and testis 8 weeks after oral dosing (28 days oral exposure of 90 
mg/kg bw of AgNPs < 15 nm in rats) [73].The persistence of AgNPs in the brain can lead to the 
release of Ag ions from the particle surface, triggering ROS production and oxidative stress in 
the cells[32]. 
 In all the organs analyzed, the higher Ag concentration was found in animal treated with AgAc, 
suggesting a different mechanism in cellular uptake and fate between Ag ionic and 
nanoparticulate form. 
 We were not able to observe any cellular localization of AgNPs by TEM and to clarify if AgNPs 
were able to cross the blood–brain barrier (BBB).Recent studies showed that metallic and 
AgNPs can penetrate the BBB without affecting its permeability or conversely by inducing its 
destruction [80], [83], [99]. In our study, immunohistochemical staining for albumin did not 
reveal any sign of albumin extravasation (sign of blood brain barrier damage) from brain 
microvasculature in both control and treated animals. 
 At the low doses, no histophatological findings were detected in most of the tissues evaluated 
supporting the evidences from other authors that adverse effects in the host tissues caused by 
oral administration of AgNP are low[63]. 
 The evaluation of glial cells showed the involvement of astrocytes and microglial cells in 
response to Ag; possibly in terms of activation of the cells protecting the brain from oxidative 
stress and metal toxicity. 
 TEM analysis of the BBB showed ultrastructural morphological changes in astrocytes end-feet 
and capillary basement membrane. Swelling of astrocytic perivascular end-feet was observed 
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also in a study of a 2-week oral exposure to 1 mg/kg or 10 mg/kg of Ag-NPS in rats[100].It was 
hypothesized that extracellular potassium homeostasis and pH dysregulation play an important 
role in astrocytes swelling [101], [102]that could suggest a local increase in BBB permeability 
[103]. The splitting of capillary basement membrane was never reported before and this could 
be related to the Ag ions uptake. 
 Ultrasctructural changes and immunohistochemical investigations were similar in nano and 
ionic form of Ag, supporting the evidence that the effects induced by nano form of Ag are 
mediated by silver ions released from the particle surface[97]. 
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4.2. BIODISTRIBUTION AND TOXICITY OF IRON OXIDE NPs (IONP) 
4.2..1. Single intravenous administration of IONPs: effect of dose and vehicle on 
distribution and toxicity  
(published paper Cappellini at al 2015) 
The aim of the study was to assess the biodistribution and toxicity of newly synthesized IONP after 
single intravenous administration in mice. 
The synthesis method of IONPs was fully described in the paper. 
Physicochemical characterization 
IONP were checked according to methods described in chapter 3 (3.1). The Following methods 
were applied: 
 DLS 
 Infra-red (IR) spectroscopy 
Study design 
Mice were intravenously injected with a single dose of IONP (Fe3O4-APTES-DAAO, 100 mg/kg 
bodyweight (bw) of NPs in NaCl 0.9%, and 20 mg/kg bw of NPs in NaPPi buffer at pH 7.4) (n= 3 per 
group) and sacrificed 24 h after the treatment. The control groups were treated with the 
corresponding vehicle (NaCl 0.9% or NaPPi buffer). Immediately after the treatment and the 
following hours, the general health and behavior of mice was monitored (Irwin test). The body 
weight of each mouse was measured before treatment and at sacrifice.  
According to procedure described in chapter 3, organs (liver, spleen, kidney, lung, brain, heart) 
were sampled and the following determinations were done: 
 Visualization of silver in tissues: Perls iron staining 
 Identification of cells containing iron aggregates: immunofluorescence for IBA1. 
 Histopathological examination. 
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Results and discussion 
(Additional details in the published paper Cappellini et al 2015, Appendix B and additional data 
in Appendix A) 
Physicochemical characterization 
DLS 
DLS analyses showed that the population of Fe3O4-APTES-DAAO is stable around a dimension of 1 
μm indicating that the enzyme conjugation process induces aggregation of NPs. However, more 
information on the hydrodynamic diameter of the iron core, the magnetization capabilities and the 
iron content would allow us to better compare these newly created particles and allow a 
comparison to others. 
Infra-red (IR) spectroscopy 
Fe3O4NP-APTES-DAAO were characterized by IR analysis to assess the functionalization of ligands in 
the newly synthetized system. All conjugation sites of Fe3O4 NPs are saturated, obtaining an 
absolute APTES functionalization. 
Clinical signs 
Immediately after the administration of NPs, and during the following hours, all mice appeared 
healthy and no relevant behavioral alterations were observed (data on Irwin test, appendix A). No 
significant differences in body weight gain and relative organ weights of liver, spleen and kidney 
were observed between control and Fe3O4-APTES-DAAO treated group (Tab. 13). 
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Group   TOTAL WEIGHT    
 
RELATIVE WEIGHT 
  Body weight liver spleen kydneys 
 
liver spleen kidneys 
CTR         
 
      
mean 30,14 1,99 0,15 0,58 
 
6,55 0,48 1,91 
SD 1,99 0,50 0,05 0,04 
 
1,23 0,13 0,01 
IONP 100 mg/kg         
 
      
mean 29,46 2,11 0,17 0,48 
 
7,18 0,57 1,63 
SD 2,35 0,07 0,03 0,02 
 
0,35 0,06 0,09 
CTR (NaPPi pH7,4)         
 
      
mean 28,9 1,93 0,15 0,51 
 
6,66 0,50 1,75 
SD 0,5 0,0 0,0 0,0 
 
0,1 0,1 0,1 
IONP 20 mg/kg         
 
      
 
28,6 2,0 0,2 0,5 
 
6,90 0,54 1,59 
  1,4 0,1 0,0 0,0 
 
0,2 0,1 0,2 
Tab. 13. Total and relative weight 
Biodistribution 
In treated group, intracytoplasmic brown granular material (consistent with iron pigment, as 
confirmed by Perls iron staining) was found in HE stained sections of the liver, spleen and lungs, 
and only occasionally in the kidney (at level of blood vessels). In the liver the iron pigments was 
found mainly in the cytoplasm of Kupffer cells (immunostained with Iba1)(Fig. 26). In the lungs, 
there were moderate numbers of cells (monocytes/macrophages) with intracytoplasmic iron 
pigments infiltrating the alveolar septa, throughout the pulmonary parenchyma. In the spleen, 
large numbers of histiocytes with intracytoplasmic iron pigment were found in the red pulp, 
marginal zone, and PALS/germinal center (Fig. 25). No iron deposits were observed in the heart, 
testis and brain. Reduced amount of iron-containing deposits were detected in liver and spleen of 
mice treated with 20 mg/kg compared with those found in mice treated with 100 mg NP/kg. 
Mainly, iron deposits were found in the cytoplasm of monocytes/macrophages/histiocytes, 
indicating that most of injected particles were removed from blood circulation by phagocytic cells. 
The results of the quantitative evaluation of the iron deposits detected in Perls iron stained 
sections of examined organs is reported in Table 14. 
 
83 
 
Group Liver Spleen Lung Kidney Brain Heart 
Vehicle 0,02 ±0,02 0,02 ±0,00 0,05 ±0,02 0,04 ±0,01 0,00 ±0,00 0,00 ±0,00 
IONP 100 mg/kg 2,98 ±1,11 1,40 ±0,55 0,51 ±0,13 0,09 ±0,05 0,00 ±0,00 0,00 ±0,00 
IONP 20 mg/kg 0,23 ±0,07 0,17 ±0,06 0,13 ±0,08 0,04 ±0,02 0,00 ±0,00 0,00 ±0,00 
Tab 14.Quantitative evaluation of iron deposits detected in Perls iron stained sections 
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Fig. 25.Histology of liver, spleen, lung, and kidney of mice treated with vehicle (A, control), 20 
mg/kg (B, EXP 1), and 100 mg/kg (C, EXP 2) of NPs (upper pannel: H&E; lower pannel: Perls stain; 
scale bar = 25 µm). Brown granular material is evident in H&E stained sections (arrowheads) of NP 
treated mice, consistent with iron aggregates, as confirmed by Perls stain (blue). 
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Fig. 26. IF stain, 400x (scale bar 20 µm). Iron-containing NPs (green) are mainly found in the 
cytoplasm of Iba1+ Kupffer cells (red) of liver. Nuclei stained with DAPI (cyan). 
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Histopathological evaluation 
In lungs of mice treated with the highest dose, multifocally, intravascular up to 100 μm in diameter 
iron aggregates (emboli) surrounded by granulocytes, were found in association with interstitial 
infiltrates of histiocytes expanding the alveolar septa after higher dose administration (Fig. 27).The 
presence of pulmonary embolization of iron aggregates is due to the nanoparticles aggregation. 
The presence of intravascular iron deposits associated with interstitial inflammation indicated that 
pulmonary embolization occurred after intravenous administration of aggregated NPs, as 
confirmed by the results of DLS analysis. The white pulp was affected by mild-to-moderate 
follicular reactive hyperplasia. This finding may be interpreted as an antigenic response, likely 
directed against the enzymatic portion of the NP system. 
Any adverse effect was observed after intravenous administration of a lower dose of NPs, 
containing a different vehicle (NaPPi buffer instead of 0.9% NaCl) that prevents NPs aggregation. 
H&E    Perls 
 
Fig. 27.Histology and Perls stain (400x). Alveolar septa infiltrated by macrophages and neutrophils 
surrounding a brown-black aggregate of iron-containing nanoparticles. 
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Conclusions 
 The physicochemical properties of NPs as well as of the vehicle used during synthesis processes 
and inoculation strongly influence their fate, organ/cellular distribution and toxicity. 
 Particularly for nanoparticles designed for clinical applications, the structure-property relations 
are critical to achieve long circulation time, efficient extravasation and site accumulation. 
Furthermore in NPs based drug-delivery platforms an additional concerns to be considered is 
the potential toxicity of the component of the platform other than the drug [53].  
 Finally, the potential toxic effects due to the chronic persistence of NPs in MPS and the likely 
transformation of NPs in vivo remains to be determined and should be further investigated. 
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5. DISCUSSION 
The effects of engineered nanoparticle (NPs) and nanomaterials (NMs) need to be thoroughly 
investigated to ensure a better understanding of nanoparticle toxicology, of their fate and behavior 
and of the life cycle of nanomaterial-embedded products. With a better knowledge of all these 
aspects, the potential hazards can be minimized for consumers, workers and the environment and 
proper risk management be developed[7]. 
One of the main limitations in the risk assessment of NMs is the general lack of high quality 
exposure and dosimetry data for humans. A strategy to identify the proper metrics that can best 
relate exposure levels to human health effects has not yet identified. Indeed, there are no health-
based recommendations for evaluating occupational exposures to NMs. One of the issues is the 
difficulty to determine the presence on NMs and properly measure them [104]. 
Another issue is the difficulty to compare different studies in terms of NPs type, source dosing and 
exposure methodologies. Since there is a general need for harmonization of the methodologies 
used for the characterization of NMs, the OECD working Party on Manufactured NMs aims to 
provide appropriate testing methods to assess physical chemicals properties, environmental fate 
and behaviour, and toxicity of NMs. 
As a starting point, the detailed description of the NMs is very important to assess the physical-
chemical properties of the NMs with regard to their potential adverse effects [7]. Moreover 
selected doses of administered NMs should ensure adequate exposure, they need to be 
scientifically justified and they must reflect possible exposure scenarios in human toxicology[105]. 
In our studies, the physicochemical properties of NPs were fully characterized in order to correlate 
any observed effects to the nanoparticles’ properties. Moreover, the dissolution study performed 
for AgNPs ensured an adequate internal exposure to AgNPs, as it is demonstrated that NMs may 
change form during and after release [105]. 
The dosing for i.v. exposure was based on the literature data. Comparing to them, very low doses 
and doses that previously demonstrated mild or low adverse effects were chosen. Despite the low 
doses administered the main findings observed were the marked hepatotoxicity and pulmonary 
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embolization of iron aggregates after AgNPs and IONP administration respectively. Both 
biodistribution and toxicity were related to size and size distribution as well as the vehicle used for 
the synthesis. Of note, the pulmonary embolization observed is due to the aggregation of IONPs 
and not related to the NPs itself. The use of a vehicle capable to prevent NPs aggregation is 
fundamental for a proper evaluation of adverse effects that may occur. 
Even if it is well known that the relationship of size and/or shape to NPs toxicity or nano medicine 
efficacy should be investigated on a case by case basis, because of the wide differences in the 
behavior of different NPs, the identification of physicochemical parameters that most affect NPs 
toxicity could help in the prediction of the in vivo behaviour of NPs. 
Another limit of current literature studies is the lack of long term exposure studies, useful to mimic 
the human exposure scenario[7]. In our preliminary study of 28 days repeated oral administration 
of AgNPs, we demonstrated that NPs accumulate in the brain and some morphological changes 
occurred in astrocytes and basement membrane of capillaries and in glial cells, specifically involved 
in brain homeostasis and response to injury. Since it was demonstrated an induction of 
inﬂammation and oxidative stress in brain after NPs exposure, and since oxidative stress is involved 
in the pathogenesis of many neurodegenerative diseases, such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD), or Huntington’s disease, the effects of NPs in neural cells should be 
carefully analyzed [106], [107]. It was also demonstrated the role of trace metals in development 
of neurodegenerative diseases. Increased iron levels have been reported to be elevated in the PD 
midbrain, leading to subsequent neurodegeneration. Moreover the central tenet of amyloid beta 
toxicity in AD is linked with the presence of redox metals, mainly copper and non-redox 
zinc[107].Based on these observations the effects of metal NPs on the development of 
neurodegenerative disease should be further studied. 
In nanomedicine the application of NPs (especially IONP) in brain imaging, brain-targeted drug or 
gene delivery is a promising field, however little is known about the accumulation, retention, and 
adverse effects of NPs in the brain. Also in that case, it should be considered the metal release 
resulting in an accumulation of free metals in brain and other organs that may lead to an increase 
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in ROS production and oxidative stress, subsequently leading to mitochondrial damage and 
cytotoxicity. [108]. 
The association of NPs with various brain diseases or their translocation using models that express 
a compromised BBB should also be investigated. 
Another important issue associated to the use of NPs is their persistence in tissues. The few studies 
performed indicate brain and testis as organs where Ag is still present after a recovery period. For 
bulk materials, it has already been known for a long time that certain elements such as silver have 
a prolonged half-life in the CNS compared with other organs [75]. Concerning other tissues, very 
little is known about the cellular elimination of NPs and bulk materials. The cellular retention of 
NPs may cause adverse effects and it is a relevant issue considering that NPs localized in the cells 
of the mononuclear phagocyte system (MPS), the professional macrophages involved in the 
clearance and processing of larger NPs from the blood flow. In general, liver, spleen and lung are 
usually the dominant organs for clearance of the NPs from the bloodstream where specialized 
tissue-resident macrophages (Kupﬀer cells in liver, marginal zones macrophages in spleen and 
alveolar macrophages in lungs) are localized [109]. NPs, unlike small molecular weight, soluble 
therapeutics, approximate the same size scale as biologics, do not permeate epithelial membranes 
efﬁciently and often are decorated with diverse non-speciﬁcally adsorbed host proteins, increasing 
their non-speciﬁc cellular interactions. Both size and physical properties increase cellular 
recognition that prompts host recognition, NPs clearance and associated inﬂammatory 
effects[110]. In vivo recognition of NPs by phagocytes is a complex phenomenon depending on the 
combination of the various physicochemical parameters, i.e. size, shape, charge and the nature 
and density of coating molecules. Uptake of the NPs by the macrophages of liver and spleen is 
usually preceded by opsonization, recognition by the macrophages and phagocytosis. Among these 
processes, the adsorbed protein coating, referred to as “corona” in the NPs influence the 
presentation of NPs to phagocytes and is increasingly important to understand as a determinant of 
their clearance[110].Many in vitro studies investigated the role of macrophages in uptake of 
NPs.They show that the cytokines release can accurately predict the in vivo outcomes, but it was 
difficult to study the mechanisms of NPs elimination  [110], [111]. Lysosomes play a central role in 
the cellular elimination of NPs either by dissolution or degradation or by exocytosis. Lysosomes are 
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able to degrade not only biodegradable polymers, but also metal oxide NPs such as iron oxide NPs 
[111].  
The investigations of the uptake and retention of NPs in MPS should be taken in consideration in 
nanomedicine during the design of NPs that should avoid MPS uptake to maximize NPs 
accumulation in the delivery sites, such as tumors. Modification of the surface with polyethylene 
glycol (PEG) is commonly used for this purpose and to induce a longer circulation time [112]. On 
the other hand, for some other imaging applications such as evaluation of brain lesions, 
assessment of rejection of the transplants or grafts, higher uptake rates of the injected NPs (i.e. 
IONP) by specific macrophages (other than the Kupffer cells) or circulating monocytes and their 
subsequent homing to specific tissues is desired. Recent reports also demonstrate that either NPs 
or monocyte–macrophages can be selectively manipulated to facilitate their phagocytosis and 
targeting abilities. For instance, by either specific coating of NPs or by pretreating phagocytic cells 
with specific cytokines the phagocytic and tissue or lesion homing capabilities of particle containing 
phagocytes can be influenced. It is important to note that macrophage uptake can have either 
beneficial or detrimental eﬀects, based on the desired application [109].  
Developing correlations between NPs physicochemical characteristics and NPs uptake, processing 
and clearance mechanisms in macrophages would provide a basis to overcome particle systemic 
delivery and targeting, and facilitate design of new, more efficacious and safer nanomaterial 
platforms. 
In conclusion, comparing to other literature studies, unusual findings concerning the toxic effects 
after NPs i.v. and PO exposure and at low doses were highlighted in our experiments. These 
findings were strictly related to the physicochemical properties of NPs and strongly confirmed that 
a complete NPs characterization is fundamental to ensure the NPs changes before the 
administration that could affect the in vivo outcomes. The brain was the organ most involved in Ag 
accumulation after repeated oral exposure due to a low clearance, confirming previous results. 
Moreover, the involvement of glial cells and changes at the BBB level observed, added new 
knowledge about brain changes occurred. Finally, the involvement of MPs in NPs biodistribution 
and toxic effects due to the persistence of NPs in MPS was considered. 
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One of the limits of the studies reported was the low number of animal used in each experiment. 
However, these studies should be considered as preliminary investigative studies and based on the 
observation obtained, more specific studies to confirm the evidences described should be planned. 
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Appendix A: ADDITIONAL DATA 
4.1.1 Single intravenous administration: effect of size and coating on biodistribution and toxicity 
 
Behavioural observation: Irwin test 
No relevant behavioral alterations were observed. 
Time: + 5 min   CTR  AgNPs 10 nm Ct-coated 
Undisturbed animal Ref 
value 
C3 C4 C1 C2 C5 
1) Body position   4 4 4 4 4 4 
2) Mobility 4 0 0 4 0 4 
3) Eye prominence - - - - - - 
4) Respiration 4 4 4 4 4 4 
5) Tremors 0 0 0 0 0 0 
6) Convulsions - - - - - - 
7) Grooming 4 0 0 0 0 0 
8) Stereotypies  0 0 0 0 0 0 
9) Piloerection 0 0 0 0 0 0 
Disturbed animal       
1) Touch response 4 4 4 4 4 4 
2) Positional passivity 0 0 0 0 0 0 
3) Catatonia 0 0 0 0 0 0 
4) Grip strenght 4 4 4 4 4 2 
5) Abdomen tone 4 4 4 4 4 4 
6) Corneal reflex 4 4 4 4 4 4 
7) Pinna reflex 4 4 4 4 4 4 
8) Tail pinch response 4 4 4 4 4 4 
9) Righting reflex  0 0 0 0 0 0 
Neurovegetative 
profile 
      
1) Skin color 4 4 4 4 4 4 
2) Stools       
3) Urines - - - - - - 
4) Lacrimation  0 0 0 0 0 0 
5) Salivation 0 0 0 0 0 0 
6) Rhinorrhea 0 0 0 0 0 0 
7) Temperature / / / / / / 
 
Time: + 5 min   CTR  AgNPs 10 nm Ct-coated 
Undisturbed animal Ref 
value 
C3 C4 C1 C2 C5 
1) Body position   4 4 4 4 4 4 
2) Mobility 0 0 0 0 0 0 
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3) Eye prominence - - - - - - 
4) Respiration 4 4 4 4 4 4 
5) Tremors 0 0 0 0 0 0 
6) Convulsions - - - - - - 
7) Grooming 4 0 0 0 0 0 
8) Stereotypies  0 0 0 0 0 0 
9) Piloerection 0 0 0 0 0 0 
Disturbed animal       
1) Touch response 4 4 4 2 4 4 
2)Positional passivity 0 0 0 0 0 0 
3) Catatonia 0 0 0 0 0 0 
4) Grip strenght 4 4 4 4 4 4 
5) Abdomen tone 4 4 4 4 4 4 
6) Corneal reflex 4 4 4 4 4 4 
7) Pinna reflex 4 4 4 4 4 4 
8) Tail pinch response 4 4 4 4 4 0 
9) Righting reflex  0 0 0 0 0 0 
Neurovegetative 
profile 
      
1) Skin color 4 4 4 4 4 4 
2) Stools       
3) Urines - - - - - - 
4) Lacrimation  0 0 0 0 0 0 
5) Salivation 0 0 0 0 0 0 
6) Rhinorrhea 0 0 0 0 0 0 
7) Temperature / / / / / / 
 
 
Time: +30 min   CTR  AgNPs 10 nm Ct-coated 
Undisturbed animal Ref 
value 
C3 C4 C1 C2 C5 
1) Body position   4 6 4 4 4 4 
2) Mobility 4 0 0 0 0 0 
3) Eye prominence - - - - - - 
4) Respiration 4 4 4 4 4 4 
5) Tremors 0 0 0 0 0 0 
6) Convulsions - - - - - - 
7) Grooming 4 0 0 4 0 0 
8) Stereotypies  0 0 0 0 0 0 
9) Piloerection 0 0 0 0 0 0 
Disturbed animal       
1) Touch response 4 4 4 2 4 4 
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2) Positional passivity 0 0 0 0 0 0 
3) Catatonia 0 0 0 0 0 0 
4) Grip strenght 4 4 4 4 2 4 
5) Abdomen tone 4 4 4 4 4 4 
6) Corneal reflex 4 4 4 4 4 4 
7) Pinna reflex 4 4 4 4 4 4 
8) Tail pinch response 4 4 4 4 4 4 
9) Righting reflex  0 0 0 0 0 0 
Neurovegetative 
profile 
      
1) Skin color 4 4 4 4 4 4 
2) Stools       
3) Urines - + - - - - 
4) Lacrimation  0 0 0 0 0 0 
5) Salivation 0 0 0 0 0 0 
6) Rhinorrhea 0 0 0 0 0 0 
7) Temperature / / / / / / 
 
 
Time: +60 min   CTR  AgNPs 10 nm Ct-coated 
Undisturbed animal Ref 
value 
C3 C4 C1 C2 C5 
1) Body position   4 6 4 4 4 4 
2) Mobility 4 0 0 0 0 0 
3) Eye prominence - - - - - - 
4) Respiration 4 4 4 4 4 4 
5) Tremors 0 0 0 0 0 0 
6) Convulsions - - - - - - 
7) Grooming 4 0 0 0 0 0 
8) Stereotypies  0 0 0 0 0 0 
9) Piloerection 0 0 0 0 0 0 
Disturbed animal       
1) Touch response 4 6 4 2 2 4 
2) Positional passivity 0 0 0 0 0 0 
3) Catatonia 0 0 0 0 0 0 
4) Grip strenght 4 4 4 4 4 4 
5) Abdomen tone 4 4 4 4 4 4 
6) Corneal reflex 4 4 4 4 4 4 
7) Pinna reflex 4 4 4 4 4 4 
8) Tail pinch response 4 4 4 4 4 4 
9) Righting reflex  0 0 0 0 0 0 
Neurovegetative       
105 
 
profile 
1) Skin color 4 4 4 4 4 4 
2) Stools  11 12 6 4 2 
3) Urines - - - - - - 
4) Lacrimation  0 0 0 0 0 0 
5) Salivation 0 0 0 0 0 0 
6) Rhinorrhea 0 0 0 0 0 0 
7) Temperature / / / / / / 
 
Histopathological examination 
Grading of most relevant histopathological lesions observed in mice following i.v. exposure to 10 
mg/kg of AgNPs, evaluated as follows: 0 = absence of lesions; 1 = minimal lesions; 2 = mild lesions; 
3 = moderate lesions; 4 = severe lesions. Results are expressed as median score per group (range).  
Group 
Hepatobiliary tract Spleen Kidney 
Hepatocellular 
necrosis and 
hemorrhage 
Peribiliary 
hemorrhage 
Portal vein 
endothelial 
damage 
Gall bladder 
hemorrhage 
Red pulp 
hyperemia 
Tubuar 
necrosis 
Control 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 1 (0-2) 0 (0-0) 
10 nm AgNP-CT 4 (3-4) 2 (1-4) 1 (0-4) 2 (2-4) 2 (2-3) 0 (0-0) 
10 nm AgNP-PVP 4 (2-4) 2 (1-4) 2 (0-4) 2 (1-4) 3 (3-4) 0 (0-0) 
40 nm AgNP-CT 0 (0-1) 0 (0-1) 0 (0-0) 1 (1-4) 2 (2-3) 0 (0-0) 
40 nm AgNP-PVP 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-1) 2 (1-2) 0 (0-0) 
100 nm AgNP-CT 0 (0-0) 0 (0-0) 0 (0-0) 1 (0-1) 0 (0-1) 0 (0-0) 
100 nm AgNP-
PVP 
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 1 (0-2) 0 (0-0) 
AgAc 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 1 (0-2) 4 (3-4) 
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ICP-MS 
Silver concentration (µg/g wet organ) determined by ICP-MS in blood and organs following i.v. 
exposure to 10 mg/kg bw of AgNPs in mice.  
Group Mouse ID 
Organ      
Spleen Liver Lung Kidney Brain Blood 
Control B1 0.002 0.004 0.039 0.005 0.001 0.000 
 
C2 0.006 0.005 0.017 0.002 0.001 0.000 
 
A3 0.002 0.002 0.002 0.001 0.003 0.000 
 
Mean  0.003 0.004 0.003 0.001 0.020 0.000 
  SD 0.002 0.001 0.001 0.000 0.018 0.000 
AgAc H4 11,8 55,2 3,3 16,5 0,36 n.a. 
 
H5 19,1 63,2 4,1 13,8 0,43 n.a. 
 
H6 10,6 78,6 4,3 10,2 0,36 n.a. 
 
Mean 13,9 65,7 3,9 13,5 0,38 n.a. 
 
SD 4,6 11,9 0,5 3,2 0,04 n.a. 
10 nm AgNP-CT A1 113.6 77.6 73.6 2.2 0.4 2.7 
 
B2 112.4 71.3 62.9 3.3 0.3 n.a. 
 
C3 139.1 85.7 66.1 4.0 0.3 2.4 
 
Mean  121.7 78.2 67.5 3.2 0.3 2.6 
  SD 15.1 7.2 5.5 0.9 0.1 0.3 
40 nm AgNP-CT E5 70.9 62.9 8.4 0.5 0.2 1.5 
 
G3 109.7 79.3 10.1 1.0 0.2 1.1 
 
H1 72.0 70.8 5.6 0.9 0.2 2.7 
 
Mean  84.2 71.0 8.0 0.8 0.2 1.8 
  SD 22.1 8.2 2.3 0.3 0.0 0.8 
100 nm AgNP-CT C5 67.6 51.4 7.6 0.4 0.2 0.8 
 
E6 61.9 56.9 10.9 0.5 0.2 0.7 
 
D4 78.2 51.5 5.9 0.6 0.2 0.7 
 
Mean  69.2 53.2 8.1 0.5 0.2 0.7 
  SD 8.3 3.1 2.5 0.1 0.0 0.0 
10 nm AgNP-PVP F1 81.6 63.8 34.8 3.0 0.2 n.a. 
 
G2 100.0 69.5 32.1 2.5 0.4 2.2 
 
H3 82.3 74.2 31.3 2.9 0.3 2.1 
 
Mean  88.0 69.2 32.8 2.8 0.3 2.2 
  SD 10.5 5.2 1.8 0.3 0.1 0.1 
40 nm AgNP-PVP A5 80.9 69.3 6.0 1.2 0.2 1.3 
 
A6 68.6 67.7 4.9 0.9 0.2 0.8 
 
E1 59.6 58.2 4.7 0.9 0.2 1.0 
 
Mean  69.7 65.0 5.2 1.0 0.2 1.0 
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  SD 10.7 6.0 0.7 0.2 0.0 0.2 
100 nm AgNP-PVP D3 60.5 61.6 1.9 0.9 0.2 0.6 
 
F4 54.8 62.7 2.8 0.7 0.2 0.7 
 
G5 68.3 71.9 2.9 0.6 0.2 0.6 
 
Mean  61.2 65.4 2.5 0.7 0.2 0.6 
  SD 6.8 5.7 0.5 0.1 0.0 0.0 
 
 
4.1.2 Single intravenous administration of AgNPs: batch dependent biodistribution and toxicity 
 
 
Histopathological examination 
Summary of histopathological examination. 
  
          
Histopathological grading  
  
Size Lot. ID Administration Dose Mouse ID 
Hepaocellular 
necrosis/hemorrhage 
Median 
Gall bladder 
hemorrhage 
Median 
10 nm A IV 24h 5 mg/kg E2 4 1 4 2,5 
        F5 0   1   
        G1 1   0   
      10 mg/kg A1 3 4 2 2 
        B2 4   4   
        C3 4   2   
10 nm B IV 24h 5 mg/kg A2 1 1 0 1 
        C4 1   1   
        C5 0   1   
      10 mg/kg B4 3 2 3 2 
        B5 1   2   
        B6 2   1   
10 nm C IV 24h 5 mg/kg B1 3 2 np 0 
        B2 2   0   
        B3 2   1   
      10 mg/kg B4 3 4 0 0 
        B5 4   np   
        B6 4   0   
5 nm \ IV 24h 10 mg/kg A1 4 4 4 3 
        A3 4   2   
        A4 3   3   
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4.2.1 Single intravenous administration of IONPs: effect of dose and vehicle on distribution and 
toxicity 
 
Behavioural observation: Irwin test 
No relevant behavioral alterations were observed. 
Time: + 5 min   CTR  Fe3O4-DAAO 100mg/kg 
Undisturbed animal Ref 
value 
C3 C4 C1 C2 C5 
1) Body position   4 4 4 4 4 4 
2) Mobility 4 0 0 4 0 4 
3) Eye prominence - - - - - - 
4) Respiration 4 4 4 4 4 4 
5) Tremors 0 0 0 0 0 0 
6) Convulsions - - - - - - 
7) Grooming 4 0 0 0 0 0 
8) Stereotypies  0 0 0 0 0 0 
9) Piloerection 0 0 0 0 0 0 
Disturbed animal       
1) Touch response 4 4 4 4 4 4 
2) Positional passivity 0 0 0 0 0 0 
3) Catatonia 0 0 0 0 0 0 
4) Grip strenght 4 4 4 4 4 2 
5) Abdomen tone 4 4 4 4 4 4 
6) Corneal reflex 4 4 4 4 4 4 
7) Pinna reflex 4 4 4 4 4 4 
8) Tail pinch response 4 4 4 4 4 4 
9) Righting reflex  0 0 0 0 0 0 
Neurovegetative 
profile 
      
1) Skin color 4 4 4 4 4 4 
2) Stools       
3) Urines - - - - - - 
4) Lacrimation  0 0 0 0 0 0 
5) Salivation 0 0 0 0 0 0 
6) Rhinorrhea 0 0 0 0 0 0 
7) Temperature / / / / / / 
 
Time: +15 min   CTR  Fe3O4-DAAO 100mg/kg 
Undisturbed animal Ref 
value 
C3 C4 C1 C2 C5 
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1) Body position   4 4 4 4 4 4 
2) Mobility 0 0 0 0 0 0 
3) Eye prominence - - - - - - 
4) Respiration 4 4 4 4 4 4 
5) Tremors 0 0 0 0 0 0 
6) Convulsions - - - - - - 
7) Grooming 4 0 0 0 0 0 
8) Stereotypies  0 0 0 0 0 0 
9) Piloerection 0 0 0 0 0 0 
Disturbed animal       
1) Touch response 4 4 4 2 4 4 
2) Positional passivity 0 0 0 0 0 0 
3) Catatonia 0 0 0 0 0 0 
4) Grip strenght 4 4 4 4 4 4 
5) Abdomen tone 4 4 4 4 4 4 
6) Corneal reflex 4 4 4 4 4 4 
7) Pinna reflex 4 4 4 4 4 4 
8) Tail pinch response 4 4 4 4 4 0 
9) Righting reflex  0 0 0 0 0 0 
Neurovegetative 
profile 
      
1) Skin color 4 4 4 4 4 4 
2) Stools       
3) Urines - - - - - - 
4) Lacrimation  0 0 0 0 0 0 
5) Salivation 0 0 0 0 0 0 
6) Rhinorrhea 0 0 0 0 0 0 
7) Temperature / / / / / / 
 
Time: +30 min   CTR  Fe3O4-DAAO 100mg/kg 
Undisturbed animal Ref 
value 
C3 C4 C1 C2 C5 
1) Body position   4 6 4 4 4 4 
2) Mobility 4 0 0 0 0 0 
3) Eye prominence - - - - - - 
4) Respiration 4 4 4 4 4 4 
5) Tremors 0 0 0 0 0 0 
6) Convulsions - - - - - - 
7) Grooming 4 0 0 4 0 0 
8) Stereotypies  0 0 0 0 0 0 
9) Piloerection 0 0 0 0 0 0 
Disturbed animal       
110 
 
1) Touch response 4 8 4 2 4 4 
2) Positional passivity 0 0 0 0 0 0 
3) Catatonia 0 0 0 0 0 0 
4) Grip strenght 4 4 4 4 2 4 
5) Abdomen tone 4 4 4 4 4 4 
6) Corneal reflex 4 4 4 4 4 4 
7) Pinna reflex 4 4 4 4 4 4 
8) Tail pinch response 4 4 4 4 4 4 
9) Righting reflex  0 0 0 0 0 0 
Neurovegetative 
profile 
      
1) Skin color 4 4 4 4 4 4 
2) Stools       
3) Urines - + - - - - 
4) Lacrimation  0 0 0 0 0 0 
5) Salivation 0 0 0 0 0 0 
6) Rhinorrhea 0 0 0 0 0 0 
7) Temperature / / / / / / 
 
Time: +60 min   CTR  Fe3O4-DAAO 100mg/kg 
Undisturbed animal Ref 
value 
C3 C4 C1 C2 C5 
1) Body position   4 6 4 4 4 4 
2) Mobility 4 0 0 0 0 0 
3) Eye prominence - - - - - - 
4) Respiration 4 4 4 4 4 4 
5) Tremors 0 0 0 0 0 0 
6) Convulsions - - - - - - 
7) Grooming 4 0 0 0 0 0 
8) Stereotypies  0 0 0 0 0 0 
9) Piloerection 0 0 0 0 0 0 
Disturbed animal       
1) Touch response 4 8 4 2 2 4 
2) Positional passivity 0 0 0 0 0 0 
3) Catatonia 0 0 0 0 0 0 
4) Grip strenght 4 4 4 4 4 4 
5) Abdomen tone 4 4 4 4 4 4 
6) Corneal reflex 4 4 4 4 4 4 
7) Pinna reflex 4 4 4 4 4 4 
8) Tail pinch response 4 4 4 4 4 4 
9) Righting reflex  0 0 0 0 0 0 
Neurovegetative       
111 
 
profile 
1) Skin color 4 4 4 4 4 4 
2) Stools  11 12 6 4 2 
3) Urines - - - - - - 
4) Lacrimation  0 0 0 0 0 0 
5) Salivation 0 0 0 0 0 0 
6) Rhinorrhea 0 0 0 0 0 0 
7) Temperature / / / / / / 
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Tissue distribution and acute toxicity of
silver after single intravenous
administration in mice: nano-specific and
size-dependent effects
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Abstract
Background: Silver nanoparticles (AgNPs) are an important class of nanomaterials used as antimicrobial agents for
a wide range of medical and industrial applications. However toxicity of AgNPs and impact of their physicochemical
characteristics in in vivo models still need to be comprehensively characterized. The aim of this study was to
investigate the effect of size and coating on tissue distribution and toxicity of AgNPs after intravenous
administration in mice, and compare the results with those obtained after silver acetate administration.
Methods: Male CD-1(ICR) mice were intravenously injected with AgNPs of different sizes (10 nm, 40 nm, 100 nm),
citrate-or polyvinylpyrrolidone-coated, at a single dose of 10 mg/kg bw. An equivalent dose of silver ions was
administered as silver acetate. Mice were euthanized 24 h after the treatment, and silver quantification by ICP-MS
and histopathology were performed on spleen, liver, lungs, kidneys, brain, and blood.
Results: For all particle sizes, regardless of their coating, the highest silver concentrations were found in the spleen
and liver, followed by lung, kidney, and brain. Silver concentrations were significantly higher in the spleen, lung,
kidney, brain, and blood of mice treated with 10 nm AgNPs than those treated with larger particles. Relevant toxic
effects (midzonal hepatocellular necrosis, gall bladder hemorrhage) were found in mice treated with 10 nm AgNPs,
while in mice treated with 40 nm and 100 nm AgNPs lesions were milder or negligible, respectively. In mice
treated with silver acetate, silver concentrations were significantly lower in the spleen and lung, and higher in the
kidney than in mice treated with 10 nm AgNPs, and a different target organ of toxicity was identified (kidney).
Conclusions: Administration of the smallest (10 nm) nanoparticles resulted in enhanced silver tissue distribution
and overt hepatobiliary toxicity compared to larger ones (40 and 100 nm), while coating had no relevant impact.
Distinct patterns of tissue distribution and toxicity were observed after silver acetate administration. It is concluded
that if AgNPs become systemically available, they behave differently from ionic silver, exerting distinct and size-
dependent effects, strictly related to the nanoparticulate form.
Keywords: Silver nanoparticles, Silver acetate, Dissolution, In vivo study, Mouse, Intravenous route, Tissue
distribution, Toxicity, Hepatocellular necrosis, Hemorrhage
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Background
Silver nanoparticles (AgNPs) are an important class of
nanomaterials characterized by sizes ranging approxi-
mately from 1 to 100 nm: these small dimensions result in
a high surface area to volume ratio determining unique
chemical, physical and biological properties different from
those of bulk material with the same composition [1].
Nowadays, AgNPs are the most common nanomaterial
found in consumer products (including cosmetics, textiles,
food boxes, sprays), appliances (refrigerators, washing
machines) and medical applications (wound dressings,
medical devices, drug-delivery systems, bio-sensing and
imaging methods) [2–5]. The widespread application of
AgNPs is mainly related to the renowned antimicrobial
activity of silver, whether ionic or nanoparticulate [6, 7].
However, extensive use of AgNPs may lead to environ-
mental contamination and human exposure by inhalation,
dermal and oral routes, raising concerns about their po-
tential environmental impact and toxicity [4].
The majority of toxicity studies on AgNPs have been per-
formed on bacteria, cell lines, and non-mammalian animal
species, with still comparatively limited information avail-
able from in vivo studies [1, 8]. In vitro studies revealed dis-
tinct (but not necessarily mutually exclusive) mechanisms
of toxicity of AgNPs, including 1) ROS generation, with
subsequent oxidative stress; 2) interaction with cellular pro-
teins and enzymes by binding to free thiol groups; and 3)
mimicry of endogenous ions (e.g. calcium, sodium, or
potassium) leading to ionoregulatory disturbances [1].
These mechanisms lead to cytokine production, cellular
damage, and eventually apoptosis or necrosis. Numerous
in vitro studies have demonstrated that the cytotoxic and
genotoxic effects of AgNPs are size- and dose-dependent,
as well as coating- and cell type-dependent [9–14].
In vivo studies in rodents (rats, mice, guinea pigs) and
occasionally in non-rodents species (pigs) have been
carried out, using different routes of exposure, in the at-
tempt to characterize kinetics, tissue distribution and
toxicity of AgNPs [15–26]. Compared to the general
consensus of in vitro studies, the results of the in vivo
studies are controversial regarding the onset of adverse
effects after AgNPs administration. Some of these stud-
ies indicate that AgNPs may have toxic effects on liver,
lung, intestine, nervous and immune systems, either
after single or repeated administration, and following
different routes of exposure [15–17, 22, 23, 26]. How-
ever, other studies found no relevant adverse effects
[19–21, 24]. These contradictory results may depend on
the high variability of the tested AgNPs, in terms of
source (generated in the laboratory or commercially
available materials), size, dispersion state, coating, and
concentration (i.e. number of particles and silver mass).
Also, the animal species, strain, sex, age, and the overall
experimental design (dose, exposure time, end points for
sampling) may have an impact on the outcome of the
study [21].
With the effort to standardize and compare in vivo
experiments, as well as to properly correlate nanoparticles’
properties with their in vivo effects, a prior and rigorous
physicochemical characterization of AgNPs is required
[27]. In particular, the assessment of size, monodispersity,
and aggregation is fundamental for a comprehensive un-
derstanding of their biological effects. However such mea-
surements, albeit fundamental, are not sufficient for fully
predicting nanotoxicological effects, likely because of ef-
fects related to the still poorly understood behavior of
nanoparticles in the biological milieu. Indeed, AgNPs after
injection readily interact with blood components (pro-
teins, lipids, etc.), forming on their surface a biomolecular
corona that influences the biological interactions of nano-
particles and cellular uptake [28]. In vivo toxicological
studies are thus considered critical for correlating the
physicochemical properties of nanoparticles with their
effects in living systems [29]. However, only very few
in vivo studies have been performed so far to evaluate the
role of size and coating of AgNPs, and based on these
studies tissue distribution and toxicity appeared to be con-
sistently size-dependent, whereas the effect of coating was
less obvious and only observed in the lung [21, 30–33]. In
addition to influencing the formation of the biomolecular
corona, size and coating are critical factors affecting the
release of silver ions from AgNPs. There has been much
debate in the literature regarding whether the adverse
effects caused by AgNPs are mediated by the release of sil-
ver ions [34]. Although it is generally accepted that dissol-
ution of AgNPs does account for at least a degree of
toxicity observed under AgNP exposure, it appears that ef-
fects cannot be fully attributed to the measured dissolved
fraction of silver especially for the smaller particles
(≤10 nm), which proved to be more toxic than predicted
on the basis of silver ion release [35, 36].
In view of the need to improve the understanding of
the impact of physicochemical characteristics of AgNPs
in in vivo models, the aim of this study was to investi-
gate the effect of the size and coating on tissue distribu-
tion and toxicity of AgNPs and compare the results with
those obtained after administration of silver ions, in the
form of silver acetate. Since this study was not intended
to mimic human exposure scenarios, to avoid limited
systemic exposure due to the cellular barriers present in
the skin, gastrointestinal tract and lungs, we used intra-
venous (IV) administration of AgNPs and ionic silver to
evaluate their potential systemic toxicity. The study
design included a thorough characterization of AgNPs
suspensions before use, assessment of tissue distribution
by measuring silver concentrations in blood and main
organs, and histopathological examination to evaluate
the presence of adverse effects and silver localization.
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Results and discussion
Physicochemical characterization of silver nanoparticles
Commercial AgNPs with a nominal size of 10, 40 and
100 nm were tested in this study. Citrate (CT)- and poly-
vinylpyrrolidone (PVP)-coated AgNPs were investigated
to probe the effect of surface stabilizing agents. Details
provided by the manufacturer on the physico-chemical
properties of the studied AgNPs are reported in Table 1.
The particles were thoroughly characterized before the in-
vestigation of their toxicological effects in vivo and their
accordance to manufacturer’s specifications assessed. A
rigorous characterization of the test dispersions is pre-
requisite to produce data that can help provide scientific
answers to regulatory issues, which are impelling for a
widely used nanomaterial type such as AgNPs.
Three different techniques were employed, namely
Dynamic Light Scattering (DLS), UV-visible (UV–Vis)
spectroscopy, and Transmission Electron Microscopy
(TEM). First, the hydrodynamic diameter of the particles
and their possible aggregation when suspended in the
testing medium were evaluated by DLS. The results are
summarized in Table 2. Monomodal distributions were ob-
served for 40 nm and 100 nm AgNPs, coated with both CT
and PVP. The 10 nm AgNP-CT and 10 nm AgNP-PVP
suspensions showed multimodal distributions. In particular,
the peaks at 18.1 and 19.6 nm were indicative of isolated
nanoparticles in 10 nm AgNP-CT and 10 nm AgNP-PVP,
respectively, while larger peaks in both samples suggested
the possible presence of aggregates with variable dimen-
sions. However, these large peaks were still detected by
DLS even after filtration (0.22 μm pore size), thus indicating
their dynamic nature.
To further investigate the intrinsic features of the
putative aggregates detected in 10 nm AgNPs, UV–Vis
spectroscopy measurements were performed. AgNPs
exhibit a characteristic absorbance maximum in the visible
range due to the surface plasmon resonance (SPR) effect
[37]. Notably, optical properties of AgNPs are closely re-
lated to their morphology, therefore UV–Vis spectroscopy
is able to detect any change in size/shape as well as the
presence of aggregates. The UV–Vis results are shown in
Table 2. The correspondence between the optical properties
given by the manufacturer and those measured in our la-
boratory appeared satisfactory; in particular, no decrease in
the maximum absorbance value (Hmax) was observed, indi-
cating absence of aggregates. Then, full absorbance spectra
of all samples were considered (Fig. 1). The optical density
in the 600–800 nm range, which is typical for aggregate ab-
sorption, was not detected in 10 nm AgNP-CT and 10 nm
AgNP-PVP, further demonstrating that the presence of
stable aggregates in these samples could be excluded [38].
Eventually, TEM analysis was performed to assess the
shape and primary size distribution of tested AgNPs. All
the tested AgNPs were spherical in shape (Fig. 2), and
their Feret diameter distributions were in good accord-
ance with data reported by the manufacturer (p > 0.05 in
all cases) (Table 2).
According to these analyses, both the 10 nm AgNP-
CT and the 10 nm AgNP-PVP gave questionable DLS
results, since peaks by far larger than 10 nm were de-
tected. Similar findings were recently reported for
AgNPs with size lower than 20 nm and 15 nm [21].
Here, the absorbance spectra clearly confirmed the ab-
sence of any stable aggregate, since neither the Hmax de-
crease nor the absorbance in the 600–800 nm range
were visible. TEM analysis further confirmed the ab-
sence of aggregates. Therefore, the large peaks detected
in the DLS analyses of 10 nm AgNPs were ascribed to
Table 1 Main physicochemical properties of tested AgNPs provided by the manufacturer and reported in the datasheet
DLS UV–Vis TEM
BiopureTM Silver
nanoparticle
Lot N° Mean
hydrodynamic
diameter
λmax Hmax Diameter Variation
coefficient
Mass
concentration
Particle
concentration
Solvent pH of
solution
(nm) (nm) (a.u.) (mean ±
SD) (nm)
(%) (mg/ml) (n° of
particles/ml)
10 nm AgNP-CT DAG1542 na 388 164.9 8.8 ± 1.7 19.6 1.03 3.5*1014 2.0 mM
citrate
7.3
10 nm AgNP-PVP DAG1823A 21.3 389 160.2 9.5 ± 1.9 7.5 1.1 2.2*1014 MilliQ
water
6.9
40 nm AgNP-CT DAG1176 53.7 411 151.1 40.6 ± 3.0 7.0 1.12 2.7*1012 2.0 mM
citrate
7.6
40 nm AgNP-PVP DAG1391 49.3 411 148.2 40.7 ± 4.1 20.2 1.1 2.7*1012 MilliQ
water
6.7
100 nm AgNP-CT DAG1186 99.8 495 49.2 99.4 ± 7.0 10.0 1.0 1.9*1011 2.0 mM
citrate
7.3
100 nm AgNP-PVP DAG1189 117.0 492 48.2 99.0 ± 5.7 5.8 1.07 1.9*1011 MilliQ
water
5.9
CT sodium citrate, PVP polyvinylpyrrolidone, na not available (not reported in the datasheet)
Recordati et al. Particle and Fibre Toxicology  (2016) 13:12 Page 3 of 17
dynamic aggregates, which are unstable and do not rep-
resent a problem for in vivo experiments. In conclusion,
the characterization by DLS, UV–Vis spectroscopy, and
TEM of stock AgNPs suspensions confirmed the particle
size certified by the manufacturer and their suitability
for in vivo administration.
Dissolution of silver nanoparticles in mouse serum
The presence of ionic silver in the stock suspensions of
CT-coated AgNPs as well as AgNPs dissolution upon
interaction with mouse serum was investigated by filtra-
tion on membranes with a pore size allowing discrimin-
ation of ionic silver from AgNPs. The percentage of
ionic silver in the original stock suspensions was found
to be negligible (0.002 %, 0.001 %, 0.001 % of total silver
for 10, 40 and 100 nm AgNPs, respectively). Time-
dependent dissolution of AgNPs in simulated biological
conditions is shown in Table 3. As expected, dissolution
was greater for smaller particles and increased with time;
however even for 10 nm-sized particles at 24 h, the
Table 2 Physicochemical characterization of tested AgNPs. The main findings in AgNPs characterization are reported for each tested
sample. For DLS analyses, the mean size of AgNPs is expressed in terms of hydrodynamic diameter, however this parameter is fully
informative only for samples with monomodal distributions. Accordingly, the maximum intensity peaks were also reported to
describe more comprehensively samples having multimodal distributions (i.e. 10 nm AgNP-CT and 10 nm AgNP-PVP). The pdI
provides a measure of particles uniformity. For UV–Vis analyses, the maximum wavelength (λmax, i.e. the wavelength corresponding
to the highest absorbance of AgNPs) and the maximum absorbance value (Hmax) are reported. The λmax and Hmax values were
expressed in nanometer (nm) and arbitrary units (a.u.), respectively. Finally, AgNPs size distributions expressed as Feret diameter
(mean ± SD, nm) and variation coefficient (%) were obtained from TEM analysis
BiopureTM Silver
nanoparticle
Lot N° DLS UV–Vis TEM
Mean hydrodynamic diameter Max intensity peaks pdI λmax Hmax Diameter Variation coefficient
(nm) (nm) (nm) (a.u.) (mean ± SD, nm) (%)
10 nm AgNP-CT DAG1542 np 18.1– 4046 0.258 392 163.5 8.4 ± 1.5 25.4
10 nm AgNP-PVP DAG1823A np 19.6– 111– 4292 0.343 389 163.6 10.8 ± 2.6 24.0
40 nm AgNP-CT DAG1176 40.1 49.8 0.213 412 152.6 39.3 ± 4.8 12.3
40 nm AgNP-PVP DAG1391 51.8 67.6 0.251 410 145.7 40.3 ± 5.6 13.9
100 nm AgNP-CT DAG1186 87.6 102.9 0.148 490 45.1 107.7 ± 10.5 9.8
100 nm AgNP-PVP DAG1189 104.1 119.4 0.124 491 46.8 105.5 ± 10.9 10.4
Np not provided for samples with multimodal distributions
Fig. 1 Particle characterization by UV–Vis spectroscopy: full absorbance spectra of the tested silver nanoparticles. The optical density in the 600–800 nm
range, which is typical for aggregate absorption, was not detected in any of tested AgNPs, indicating the absence of stable aggregates in these samples
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percentage of ionic silver was found to be exceedingly
low (0.005 %).
The low dissolution of AgNPs when incubated in
mouse serum is in accordance with other studies,
which put forward that following introduction into a
physiological environment the ability of AgNPs to
release Ag+ is likely inhibited due to the formation
of the protein corona [39]. Interaction of protein
thiol groups with the charged surface of AgNPs in a
medium with a high ionic strength is at the basis of
the sulfidation process that leads to an extensive de-
crease of the dissolution rate in vitro, causing also
the formation of nanobridges between particles, and
has the potential to stabilize them in vivo [40]. For-
mation of the protein corona decreases the extracel-
lular dissolution of AgNPs leading to cellular uptake
of particles, which may lose the corona after intern-
alization resulting in an exacerbated release of Ag
ions and toxicity [39].
Dissolved silver ions are likely to immediately react
with chlorine in serum to form AgCl [41]. On the
other hand, it cannot be ruled out that a minor part
of the released silver ions might have been complexed
with high affinity S-containing proteins and thus been
excluded by the membrane used, leading to a possible
underestimation of the level of released Ag+ [42].
However, even though the method used for studying
particle dissolution may have not provided an entirely
accurate measure of ionic silver formation in physio-
logical conditions – all available methods have some
limitations in this respect [43] – it clearly shows that
extracellular dissolution of the AgNPs used in this
study is very limited and animals dosed with AgNPs
were internally exposed to particulate and not ionic
silver.
In vivo study
Mice were intravenously (IV) injected with CT- or PVP-
coated AgNPs of different sizes at a single dose of
10 mg/kg body weight (bw). For comparison, a group
was treated with silver acetate (AgAc), used as source of
silver ions, at a dose of 15.5 mg/kg bw, containing the
equivalent dose of 10 mg Ag/kg bw. The body weight of
each mouse was measured before treatment and at sacri-
fice. Mice were euthanized 24 h after the treatment, and
blood and organs were collected for silver quantification
and histological examination.
Fig. 2 TEM of tested silver nanoparticles. Representative transmission electron micrographs of 10, 40, and 100 nm AgNPs, CT- and PVP-coated. All
purchased particles were spherical in shape, and no stable aggregates were visible (scale bar = 100 nm)
Table 3 Time dependent dissolution of AgNPs in simulated biological conditions. Results for ionic silver are expressed as
percentage of total silver measured in the stock suspensions
BiopureTM Silver nanoparticle 5 min 10 min 60 min 24 h
10 nm AgNP-CT 0.377*10−3 0.510*10−3 0.937*10−3 5.010*10−3
40 nm AgNP-CT 0.049*10−3 0.075*10−3 0.176*10−3 1.235*10−3
100 nm AgNP-CT 0.005*10−3 0.016*10−3 0.038*10−3 0.366*10−3
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In this study, the IV route of administration was
selected in order to avoid the variability in absorption
from the different exposure sites and identify the poten-
tial target organs for distribution and toxicity of particles
of different size and coating as well as of ionic silver. Al-
though IV administration is not considered a relevant
route of exposure to AgNPs for the consumer, this route
of exposure can provide valuable information about the
in vivo behavior of AgNPs crossing the primary barriers
(skin, lung, gastrointestinal tract) and entering blood cir-
culation, or administered for clinical purposes (e.g. intra-
vascular medical devices, wound dressings, imaging,
drug delivery) [44–47]. In many studies silver was de-
tected in the main organs after exposure to AgNPs by
different routes [15, 16, 21, 25, 48, 49], but only few
studies investigated the presence of silver particles in tis-
sues after oral exposure in rats [21, 48]. Loeschner et al.
[48] found silver granules by using TEM in the same size
range of administered AgNPs in the intestine (basal lam-
ina, macrophages, connective tissue of submucosa), but
not in the liver, after oral administration of 14 nm
AgNPs and AgAc (9 mg/kg b.w. of silver. Another study
[21], by using single particle ICP-MS, revealed the pres-
ence of NPs in the examined organs (gastrointestinal
tract, liver, spleen, lungs) after oral administration of
15–20 nm AgNPs (90 mg/kg b.w) and AgNO3 (9 mg/
kg). In both studies, nanoparticles were found also in the
group treated with Ag+, indicating that nanoparticles
can be formed in vivo from soluble silver. Even though
there is still little information on the ability of AgNPs to
be absorbed, and distribute systemically after dermal
application, inhalation, or ingestion, a definite conclu-
sion about the complete dissolution of AgNPs before
reaching the blood circulation or within the blood can-
not be drawn as well, leaving open the question about
the potential effects of AgNPs in case they enter (even
partially) blood circulation.
A dose of 10 mg/kg bw was chosen since it was in
the range of doses used in previous IV studies without
eliciting relevant adverse effects in animals [22, 23, 30,
31, 50]. A dose of 10 mg/kg bw in mice is equivalent
to a human dose of 0.81 mg/kg bw, corresponding to
approximately 50 mg for a human of 60 kg, according
to guidelines for dose translation from animals to
humans [51].
Animal behavior, body and organ weights
Immediately after administration of AgNPs and AgAc
and during the following hours, all mice appeared
healthy and no abnormal behavior was observed. How-
ever, 24 h after the treatment two mice (one mouse
treated with 10 nm AgNP-CT and another one treated
with 10 nm AgNP-PVP) were found dead. Complica-
tions related to the injection procedure or formation of
large aggregates after administration were reasonably
ruled out given the delayed onset of mortality and re-
sults of later histopathological evaluation (i.e. absence of
thromboembolic lesions associated with silver aggre-
gates). At sacrifice, no significant differences in body
weight gain and organ weights were recorded between
CT- and PVP-coated AgNPs of the same size (Additional
file 1: Table S1). In mice treated with 10 nm AgNPs a
significant difference in percentage of weight loss and
relative spleen weight were observed compared to con-
trol and 40 and 100 nm AgNP-treated mice (Table 4).
No other significant differences were observed in relative
organ weights between treated and control mice.
Tissue distribution and localization of silver
Distribution and localization of silver in the different or-
gans 24 h after IV exposure to CT- and PVP-coated
AgNPs of three different sizes, and AgAc, were evaluated
using two distinct but complementary approaches, i.e.
inductively coupled plasma mass spectrometer (ICP-MS)
and autometallography (AMG) staining. ICP-MS was
used to quantitatively measure the total silver concentra-
tion in spleen, liver, lung, kidney, brain, and blood, while
AMG was used to qualitatively assess silver localization
within the sampled organs.
In the control group, silver was present at back-
ground levels as shown by ICP-MS data for the exam-
ined organs (Additional file 1: Table S2). In the treated
animals, at 24 h after administration the silver concen-
tration in blood was drastically reduced in all groups
compared to the peak concentrations expected on the
basis of the administered dose, in agreement with
Table 4 Body weight gain and relative organ weight (%) after IV administration of 10 mg silver/kg. Data are expressed as means ±
SD
Group n Body weight gain Spleen Liver Lung Kidney Brain
Control 3 −3.3 ± 5 0.45 ± 0.1 6.61 ± 0.8 0.66 ± 0.0 1.80 ± 0.2 1.77 ± 0.1
10 nm AgNP 6 −12.1 ± 4.1* 0.67 ± 0.0* 7.23 ± 1.1 0.76 ± 0.1 1.75 ± 0.1 1.81 ± 0.2
40 nm AgNP 6 −1.3 ± 2.8++ 0.54 ± 0.1++ 6.87 ± 0.6 0.65 ± 0.1 1.79 ± 0.3 1.78 ± 0.1
100 nm AgNP 6 −0.1 ± 5.0++ 0.40 ± 0.1++ 6.97 ± 0.2 0.63 ± 0.1 1.80 ± 0.1 1.65 ± 0.1
AgAc 3 −6.3 ± 3.3 0.47 ± 0.0+ 6.99 ± 0.0 0.80 ± 0.1 1.92 ± 0.2 1.78 ± 0.2
*p <0.05 vs Control; + p < 0.05 ++p < 0.01 vs 10 nm AgNP
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previous studies of kinetics performed after one single
IV administration of 120 mg/kg of 15 nm AgNPs [22]
and 0.8 mg/kg of 20, 80, and 110 nm AgNPs [30]. In
the blood of 10 nm AgNPs-treated mice silver was ap-
proximately 1.5 times and 3.5 times higher than in
mice treated with 40 nm and 100 nm AgNPs, respect-
ively (Additional file 1: Table S2). Since previous stud-
ies demonstrated a rapide decline (minutes to few
hours) of silver blood levels after IV injection of
AgNPs regardless of nanoparticle size [22, 30, 50], the
greater silver concentration of 10 nm AgNPs-treated
mice 24 h after exposure might indicate an increased
and earlier redistribution of silver from organs to
blood in the case of 10 nm AgNPs compared to larger
ones. The results obtained for 10 nm AgNPs are in
agreement with those of a IV study on CT-coated
AgNPs having a similar size (8 nm), administered to
rats at the same dose of the present study (10 mg/kg
bw); after an initial decrease (up to 4 h post injection)
blood silver levels increased again and did not de-
crease during the experimental period until 96 h [50].
For all particle sizes, regardless of their coating, the
highest silver concentrations were found in the spleen and
liver, followed by lung, kidney and brain (Fig. 3, and
Additional file 1: Figure S1). These results are in line with
previous studies that investigated tissue distribution of
AgNPs 24 h after IV administration [22, 30, 50]. When
considering the percentage of the administered silver dose
recovered after administration, for all tested AgNPs
approximately 40 % of the administered dose was found in
the liver, which resulted to be the main target organ of sil-
ver distribution, followed by spleen, lung, kidney, and
brain (Table 5). Most of the silver that reaches the blood is
filtered by the liver and excreted into the bile [50], while
the remaining circulating particles distributed to organs
containing large numbers of phagocytic cells, such as liver,
spleen, and lung, which are devoted to clearing foreign
body particles from the circulating blood. The role of
macrophages in general, and Kupffer cells in particular, in
clearance and accumulation of nanoparticles was the same
observed after intravenous administration of other metal-
lic nanoparticles (e.g. gold NPs) [52, 53].
With exception of the liver, where similar silver con-
centrations were identified regardless of the source of
administered silver (AgNP or silver ions), in the other
examined organs silver concentrations were higher in
mice treated with 10 nm AgNPs (including both CT-
and PVP-coated particles) than in mice treated with
larger particles (40 nm, 100 nm), and concentrations de-
creased with increasing size of AgNPs. Since the silver
concentrations found in the brain and kidney were com-
parable or lower than those found in the blood, silver
contribution of residual blood contained in these organs
cannot be completely ruled out.
As regards the role of coating on silver tissue dis-
tribution, no significant differences were found be-
tween CT- and PVP-coated AgNPs of the same size,
in line with previous studies [21]. However, Principal
Component Analysis (PCA) highlighted a trend of
CT-coated 10 nm AgNPs to cluster separately from
PVP-coated 10 nm AgNPs (right side of the first
Principal Component, PC1) likely due to the higher
silver concentrations of the 10 nm AgNP-CT in
spleen, lungs, liver, and, to a lesser extent, in kidneys
compared to 10 nm AgNP-PVP (Additional file 1:
Figure S2). PCA thus revealed that the coating might
have a potential effect of on tissue distribution at
least for the smallest (10 nm) AgNPs.
Silver localization within organs was evaluated his-
tologically. In H&E stained sections intracytoplasmic
Fig. 3 Silver tissue concentration after IV administration of AgNPs and AgAc in mice. Data are expressed as means ± SD. Statistical significance: a = p< 0.05;
b = p< 0.01 vs 10 nm
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black granular pigment was multifocally (and often
barely) visible in the liver (along the sinusoids), spleen
(marginal zone and red pulp), and lungs (alveolar
septa) of all AgNP-treated mice, but not in AgAc-
treated mice (Additional file 1: Figure S3).
The tissue localization of silver was better detailed
after AMG staining (Fig. 4), which enhances the silver
present within the tissues, providing a rapid, cost-
effective histochemical means of detecting the distribu-
tion of silver within organs [54]. In AgNP-treated mice,
Table 5 Percentage of recovered silver dose in mice after IV administration of 10 mg silver/kg. Data are expressed as means ± SD
Group n Spleen Liver Lung Kidney Brain
10 nm AgNP-CT 3 6.6 ± 1.2 52.0 ± 4.7 4.2 ± 1.1 0.5 ± 0.1 0.056 ± 0.015
10 nm AgNP-PVP 3 5.3 ± 1.0 41.1 ± 2.3 1.5 ± 1.2 0.4 ± 0.1 0.049 ± 0.016
40 nm AgNP-CT 3 3.6 ± 1.1 46.1 ± 2.5 0.5 ± 0.1 0.1 ± 0.1 0.037 ± 0.007
40 nm AgNP-PVP 3 3.1 ± 1.1 45.5 ± 1.9 0.3 ± 0.1 0.2 ± 0.0 0.035 ± 0.009
100 nm AgNP-CT 3 2.7 ± 0.4 36.7 ± 0,3 0.5 ± 0.1 0.1 ± 0.0 0.029 ± 0.004
100 nm AgNP-PVP 3 2.5 ± 0.6 45.7 ± 1.1 0.2 ± 0.0 0.1 ± 0.0 0.028 ± 0.003
AgAc 3 0.6 ± 0.2 42.6 ± 4.5 0.3 ± 0.1 2.4 ± 0.6 0.064 ± 0.011
Fig. 4 Histological evaluation of silver tissue localization by AMG. Representative images of spleen, liver, kidney, and lung (scale bar = 20 μm),
from vehicle- (control), AgNP (10 nm, 40 nm, 100 nm), and AgAc-treated mice. In the spleen, silver was localized within the cytoplasm of macrophages in
the marginal zone of the white pulp (WP) and in the red pulp (RP). In the liver, the cellular localization of silver varied depending on the size of the AgNPs.
In 10 nm AgNP-treated mice, silver was present in the cytoplasm of Kupffer cells (arrowhead), sinusoidal endothelial cells (arrow) and hepatocytes (*).
In 40 nm AgNPs-treated mice, silver was localized in the cytoplasm of portal endothelial cells (*), sinusoidal endothelial cells (arrow) and Kupffer cells
(arrowhead). In 100 nm AgNPs-treated mice, most of silver was concentrated in the cytoplasm of Kupffer cells (arrowhead). In AgAc-treated mice, silver
was present in the cytoplasm of hepatocytes (*), and Kupffer cells (arrowhead). In the kidney, occasional silver-containing cells were observed in the
renal interstitium of 10 nm AgNP treated-mice (arrowhead), and large amounts of silver were identified in necrotic tubules of AgAc-treated mice
(arrowhead). In the lung, scattered silver-containing cells were found in the alveolar septa of 10 nm and 40 nm AgNP-treated mice
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regardless of the particle size and coating, the organs
showing the greatest silver accumulation were the spleen
and liver in agreement with the results of total silver
quantification obtained by ICP-MS. Occasionally, en-
hanced silver clusters were found in the lung and occa-
sionally in the kidney (mainly in 10 nm AgNPs-treated
mice), and none in the brain. In the spleen, silver was lo-
calized within the cytoplasm of macrophages in the mar-
ginal zone of the white pulp and in the red pulp, and
occasionally within splenic endothelial cells. In the liver
most of the silver was found in the cytoplasm of Kupffer
cells along the sinusoids, and occasionally within sinus-
oidal and portal endothelial cells, and more rarely within
hepatocytes, in accordance with previous studies [23, 31,
55]. A sort of size-dependent pattern of silver distribu-
tion in the liver was observed, suggesting that silver
uptake by Kupffer cells is almost exclusive after adminis-
tration of 100 nm AgNPs, while administration of 10 nm
and 40 nm AgNPs resulted in silver uptake also by endo-
thelial cells, and hepatocytes, in addition to Kupffer cells.
Only occasionally, the silver was identified in the gall
bladder of 10 nm AgNP-treated mice (within gall blad-
der epithelial cells and endothelial cells of blood vessels).
In the lung, scattered silver containing cells were found
in the alveolar septa, either within the capillaries or the
interstitium. In the kidney, only in mice treated with
10 nm AgNPs there were occasional silver-containing
cells in the glomerular tufts, and renal interstitium,
morphologically consistent with circulating leukocytes
(monocytes) that were also occasionally observed in the
other examined organs. No enhanced silver clusters were
identified in the brain sections of treated mice. This lack
of histological identification of silver in the brain is con-
sistent with the very small concentrations of silver
detected in this organ by ICP-MS.
In mice treated with AgAc silver concentrations deter-
mined by ICP-MS were similar in the liver and brain,
but significantly lower in the spleen and lung, and higher
in the kidney compared to mice treated with 10 nm
AgNPs (Fig. 3). Differently from AgNP-treated mice, no
black granular deposits (reminiscent of silver) were
found throughout the examined tissues stained with
H&E. In AMG stained sections, silver enhanced clusters
were identified in the liver (within Kupffer cells and
hepatocytes), spleen (marginal zone and red pulp), and
kidney (at level of degenerated/necrotic tubules) (Fig. 4).
No silver was identified in the lung and brain. Organs
from AgAc-treated mice showed higher values than
those from the control and AgNP-treated mice on PC2,
due to the higher silver concentration in the kidney
(Additional file 1: Figure S2). Overall these results sug-
gest that silver ions have a different biodistribution pat-
tern, and likely also of cell uptake, and excretion (i.e.
enhanced role of renal excretion in addition to biliary
excretion) compared to nanoparticles. This difference in
kinetics was reflected also by the identification of dis-
tinct target organ of toxicity for silver ions and AgNPs,
as discussed below.
Immunostaining of sections with IBA1 (a pan-
macrophage marker) further confirmed that most of
silver-containing aggregates were present within the
cytoplasm of Kupffer cells in the liver, in all AgNP-
treated groups (Fig. 5). The amount and size of silver-
containing aggregates within macrophages decreased
with decreasing size of AgNPs. In 10 nm AgNPs-
treated mice only scattered and very small aggregates
were found throughout the liver, while no visible
silver-containing aggregates were found in the liver of
AgAc treated mice, despite the identification of silver
by AMG staining within Kupffer cells and hepatocytes.
This result may suggest a different intracellular behav-
ior of silver depending on its form and size.
Since ICP-MS does not provide information about the
soluble or particulate form of silver detected within the
tissue, it is not possible to know whether the silver-
containing aggregates identified histologically in this study
were composed of silver nanoparticles or silver salts
formed upon interaction of silver ions with sulphur and
selenium, as previously described in the intestine of rats
following oral administration of AgNPs and AgAc [48], or
in the skin of patients with argyria [56, 57]. Additional
analyses, e.g. employing TEM with energy dispersive x-ray
spectroscopy (EDX), and Single Particle ICP-MS (not for
the 10 nm AgNPs, which are below the size detection
limit of the technique) should be taken into consideration
in future studies, to assess the composition and subcellu-
lar localization of silver within tissues, allowing to better
understand the intracellular fate of AgNPs and/or silver
ions.
Toxicity
Two mice out of six were found dead 24 h after treat-
ment with 10 nm AgNPs. No relevant gross changes
were observed in the examined mice, except for a mod-
erate splenomegaly in mice treated with 10 nm AgNPs.
Histological AgNP-related lesions were observed in the
spleen, liver, and gall bladder of AgNP-treated mice
(Fig. 6). No relevant differences were found between
CT- and PVP-coated particles of the same size. Overall
the prevalence and severity of lesions (in particular those
involving liver and gall bladder) were size-dependent,
with mice treated with 10 nm AgNPs most frequently
and severely affected compared to 40 nm and 100 nm
AgNP-treated mice that had milder or negligible lesions,
respectively (Tables 6 and 7). Splenic hyperemia was
present in all mice treated with AgNPs, but only in mice
treated with 10 nm-sized particles it was particularly
pronounced, and thus likely responsible for inducing
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splenomegaly, as well as the increased relative spleen
weight observed in this group. Mice treated with 10 nm
AgNPs were affected by diffuse and severe midzonal
hepatocellular necrosis and hemorrhage, multifocal peri-
biliary microhemorrhages, occasional portal vein endo-
thelial damage (i.e. endothelial sloughing, subendothelial
hemorrhages, intraluminal fibrin thrombi) (Additional
file 1: Figure S4), and diffuse mural and intraluminal
hemorrhage of the gall bladder. Among mice treated
with 40 nm AgNPs only one out of six had early peripor-
tal coagulative necrosis, scattered hepatic single cell ne-
crosis, and gall bladder severe mural and intraluminal
gall bladder hemorrhage. In the other mice treated with
40 nm AgNPs, the hepatic lesions were not observed
and gall bladder lesions were milder, usually consistent
with mural hyperemia and/or edema. Mice treated with
100 nm AgNPs had only occasional and mild gall blad-
der mural hyperemia and/or edema. No relevant
pathological changes were observed in the lung, kidney
and brain of AgNP-treated mice, and in all the examined
organs of control mice.
A completely different pathological scenario was ob-
served after administration of AgAc. Hepatobiliary le-
sions were not observed, whereas a marked acute renal
tubular necrosis and apoptosis with intraluminal accu-
mulation of hyaline casts was found in all treated mice.
Presence of renal lesions, associated with identification
of silver in the affected renal tubules and relevant silver
concentrations in the kidney of AgAc-treated mice indi-
cates that dissolved silver ions resulted in an increased
renal silver distribution compared to AgNPs, and that
renal lesions were likely secondary to the renal excretion
of silver.
Although liver is considered one of the most important
target organs for AgNPs, given its capacity of AgNP accu-
mulation and its role in biliary excretion of AgNPs [49], so
Fig. 5 Localization of silver in the liver evaluated by confocal microscopy. Representative images of liver (scale bar = 20 μm), from vehicle- (control),
AgAc, and CT- and PVP-coated AgNP (10 nm, 40 nm, 100 nm)-treated mice. Aggregates of silver (green) are found within the cytoplasm of Iba-1+
Kupffer cells (red) (white arrows) only in AgNP-treated mice. Rarely, small numbers of silver aggregates are found outside Kupffer cells (yellow arrow),
most likely in the cytoplasm of endothelial cells or hepatocytes. Nuclei are counterstained with DAPI (cyan)
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Fig. 6 Histological evaluation of adverse effects after single IV administration of AgNPs and AgAc in mice. Representative images of spleen (scale bar =
500 μm), gall bladder (scale bar = 500 μm), liver (scale bar = 50 μm), and kidney (scale bar = 50 μm) from vehicle- (control), AgNP (10 nm, 40 nm, 100 nm),
and AgAc-treated mice. No relevant changes were present in the examined organs of control mice. In the spleen, a severe hyperemia of the red pulp was
present in 10 nm-treated mice (*). In the gall bladder, severe intraluminal (*) and mural (arrowhead) hemorrhages were found in 10 nm AgNPs-treated
mice, and in a single mouse treated with 40 nm AgNPs, while in 100 nm-treated mice only mild mural edema and hyperemia were occasionally evident.
In the liver, in 10 nm AgNP-treated mice marked midzonal hepatocellular necrosis (*) and hemorrhages (arrowhead) were present, while in 40 nm-treated
mice only occasional single cell necrosis (arrowhead, and inset) and early signs of coagulative periportal necrosis (*) were found (PV = portal vein). In the
kidney, in AgAc-treated mice marked tubular necrosis (arrowhead) with intraluminal hyaline casts (*) were present
Table 6 Prevalence of histopathological lesions in mice following IV exposure to 10 mg silver/kg. Data are expressed as number of
mice with lesions/total number of examined mice per group (%)
Group Spleen Liver Gall bladder Lung Kidney Brain
Control 1/3 (33 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
10 nm AgNP-CT 3/3 (100 %) 3/3 (100 %) 3/3 (100 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
10 nm AgNP-PVP 3/3 (100 %) 3/3 (100 %) 3/3 (100 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
40 nm AgNP-CT 3/3 (100 %) 1/3 (33 %) 2/3 (67 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
40 nm AgNP-PVP 2/3 (67 %) 0/3 (0 %) 1/3 (33 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
100 nm AgNP-CT 1/3 (33 %) 0/3 (0 %) 2/3 (67 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
100 nm AgNP-PVP 1/3 (33 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
AgAc 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 0/3 (0 %) 3/3 (100 %) 0/3 (0 %)
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far hepatotoxic effects of AgNPs have been inconstantly
demonstrated in in vivo studies, either after IV, oral, or in-
halation exposure to AgNPs. In particular, hepatotoxicity
was generally recognized through changes in the blood
biochemical parameters of liver function (such as ALT,
AST, ALP, and cholesterol) [16, 17, 23, 58], while only oc-
casionally mild histopathological changes were reported,
such as biliary hyperplasia, fibrosis, hepatocellular vacu-
olar degeneration, and rarely necrosis [15, 16, 22]. The
lack of overt hepatic histopathological lesions in previous
studies that used small-sized particles could be related to
a poor dispersion of AgNPs in the administered suspen-
sions [22], since agglomeration of particles can affect bio-
availability by reducing the rate of degradation or cell
uptake [8]. According to our characterization of AgNPs,
we administered well-dispersed 10 nm-sized particles. An-
other aspect is that most of earlier in vivo studies of distri-
bution and toxicity of AgNPs have been performed in rats
and not in mice. Further investigation should be per-
formed in order to assess whether there is a different sen-
sitivity between these two species.
In addition to the severity of the hepatic lesions found
in mice treated with 10 nm AgNPs, also the pattern of he-
patocellular necrosis observed is very unusual. Midzonal
necrosis is the least common histologic pattern of hepato-
cellular necrosis following exposure to hepatotoxicants
[59]. Because hepatocytes are extremely variable in their
metabolic capacity and oxygen tension, midzonal necrosis
of hepatocytes is presumably dictated by an unique sus-
ceptibility of these hepatocytes based on their location
within the hepatic lobule [60]. The hemorrhage observed
in the gall bladder of mice treated with 10 nm AgNPs and
occasionally in mice treated with 40 nm AgNPs is another
very unusual finding. We can speculate that gall bladder
mural hemorrhage, as well as portal peribiliary hemor-
rhages, could be the result of endothelial damage second-
ary to a massive elimination of AgNPs in the bile, which is
considered the main route of silver excretion following IV
administration of AgNPs [31, 50]. The hypothesis of
particle-induced endothelial damage is further corrobo-
rated by the presence of endothelial damage found in the
intrahepatic branches of portal veins that may have oc-
curred after intestinal re-absorption of AgNPs excreted in
the bile. Another concurrent factor in the pathogenesis of
gall bladder hemorrhage could be the anti-platelet proper-
ties of AgNPs that may have impaired a prompt clotting
response [61].
In this study relevant size-dependent adverse effects
were observed 24 h after IV administration of AgNPs in
mice. First of all, and differently from previous studies
where AgNPs were administered IV (up to a dose of
120 mg/kg bw) [22, 23, 30, 31, 50], mortality was observed
in 2 out of 6 mice treated with the smallest particles
(10 nm AgNPs), regardless of the coating. The most strik-
ing finding was the marked hepatotoxicity demonstrated
by 10 nm AgNPs (both CT and PVP-coated), associated
with a massive hemorrhage of the gall bladder. These le-
sions (in particular the hemorrhage) were especially severe
in the two mice found dead, and can thus be regarded as
the most likely cause of death. Of note, administration of
AgNPs of different sizes and silver acetate resulted in
similar liver content of total silver (as determined by ICP-
MS), indicating that hepatobiliary toxicity induced by
10 nm AgNPs was not related to the mass of silver con-
tained in the liver, but rather it was imputable to their
small size. Size-dependent toxicity of AgNP was previ-
ously demonstrated in in vitro [11, 13, 14, 36], as well as
in in vivo studies using the respiratory route of
Table 7 Grading of most relevant histopathological lesions in mice after IV administration of 10 mg silver/kg. Results are expressed
as median score per group (range) (n = 3)
Group Hepatobiliary tract Spleen Kidney
Hepatocellular necrosis and
hemorrhage
Peribiliary
hemorrhage
Portal vein endothelial
damage
Gall bladder
hemorrhage
Red pulp
hyperemia
Tubular
necrosis
Control 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 1 (0–2) 0 (0–0)
10 nm AgNP-
CT
4 (3–4) 2 (1–4) 1 (0–4) 2 (2–4) 2 (2–3) 0 (0–0)
10 nm AgNP-
PVP
4 (2–4) 2 (1–4) 2 (0–4) 2 (1–4) 3 (3–4) 0 (0–0)
40 nm AgNP-
CT
0 (0–1) 0 (0–1) 0 (0–0) 1 (1–4) 2 (2–3) 0 (0–0)
40 nm AgNP-
PVP
0 (0–0) 0 (0–0) 0 (0–0) 0 (0–1) 2 (1–2) 0 (0–0)
100 nm
AgNP-CT
0 (0–0) 0 (0–0) 0 (0–0) 1 (0–1) 0 (0–1) 0 (0–0)
100 nm
AgNP-PVP
0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 1 (0–2) 0 (0–0)
AgAc 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 4 (3–4)
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administration [32, 33]. Our results further support the
importance of nanoparticle size for AgNP toxicity in vivo.
Release of silver ions following oxidation of particle sur-
face after administration of AgNPs is believed to consti-
tute the major mechanism contributing to AgNP toxicity
and since dissolution increases with decreasing size of
AgNPs [33], this appears to be the determinant of the
enhanced toxicity of smaller AgNPs compared to larger
ones. The most obvious explanation for increased dissol-
ution of smaller particles, compared to an equivalent mass
concentrations of larger particles, is their higher number
(in this study, the number of administered 10 nm AgNPs
was about 100 fold greater compared to 40 nm AgNPs)
and consequent larger surface area per unit mass. The re-
sults of our study however demonstrated that systemic
availability of silver ions is not responsible for the in vivo
hepatobiliary toxicity observed in mice treated with 10 nm
AgNPs, because dissolution of 10 nm AgNPs in mouse
serum was very low (0.005 %) and administration of AgAc
resulted in a distinct target organ of toxicity (kidney
instead of hepatobiliary system). Cell-type-dependent tox-
icity of silver ions and AgNPs was previously demon-
strated in in vitro studies. Furthermore, recent in vitro
studies demonstrated that toxicity of AgNPs rather than
being caused by silver ions liberated in the culture
medium is actually dependent on their intracellular release
[35, 62, 63]. According to the recently proposed general
mechanism for toxicity of metal-containing nanoparticles,
the so-called “Lysosome-Enhanced Trojan Horse effect”,
toxicity of these particles occurs after cellular uptake by
endocytosis and it is mediated by enhanced intracellular
release of ions secondary to the acidic corrosion within
lysosomes [62]. Increased toxicity of smaller AgNPs is
then explained by their increased number and reactive
surface area, resulting in increased intracellular release of
silver ions. The fact that the entry of AgNPs into cells is
size-dependent contribute to further enhance the toxic
potential of small particles, owing to their higher bioavail-
ability to cells [11, 13, 14, 35].
In our study, coating of AgNPs with CT and PVP
did not have a detectable effect on toxicity indicating
that particle size is more important than coating to
predict potential adverse effects of silver nanoparti-
cles, at least for the coatings tested herein. Coating-
dependent toxic effects were demonstrated in vitro
[9, 10], and only in the lungs in vivo [32, 33]. It can
be speculated that in in vivo studies, including ours,
coating has a minor effect, if any, as a consequence
of the formation of a corona after the adsorption of
proteins (and other biomolecules) on the surface of
particles once they enter in contact with biological
fluids [28]. The protein corona might mask the ef-
fect of the different particle coatings that is evident
in in vitro studies. This is in agreement with the
recent view that to predict the biological behavior of
nanoparticles the fingerprinting of the protein cor-
ona is more accurate than the sole characterization
of their physicochemical properties, since the protein
corona confers to nanoparticles a ‘biological identity’
that is strongly dependent but distinct from its ‘syn-
thetic identity’ [64, 65].
Conclusions
With this study, the influence of two distinct nanoparti-
cle properties, size and coating, was comprehensively
investigated in an in vivo model. We observed that tissue
distribution and toxic effects of AgNPs in mice after IV
administration are strongly size-dependent, while coat-
ing (CT or PVP) did not have a sizeable impact on tissue
distribution and toxicity. Overall, the smallest (10 nm)
particles resulted in higher silver tissue distribution and
caused overt acute adverse effects (centered on the hepa-
tobiliary tract) compared to the larger ones (40 and
100 nm). Overall, these results suggest that in the safety
assessment of silver particles the effect of size has to be
carefully considered, with a focus on small particles
(≤10 nm). Comparison with AgAc revealed a distinct
pattern of tissue distribution and toxicity between AgNP
and silver ions, indicating that the in vivo effects of
AgNPs are not attributable merely to the in vivo release
of silver ions in circulating blood but are strictly related
to the nanoparticulate form.
Methods
Characterization of silver nanoparticles
Suspensions of BioPure™ Silver Nanoparticles (AgNPs)
of 10, 40 and 100 nm in size, coated with either citrate
(CT) or polyvinylpyrrolidone (PVP), were purchased
from NanoComposix (San Diego, USA). All the sus-
pensions were supplied at a concentration of about
1.0 mg/ml. BioPure™ AgNPs were chosen because they
were guaranteed to be sterile and with an endotoxin level
lower or equal to 2.5 EU/ml. The suspending solvents of
CT- and PVP-coated AgNPs were 2.0 mM sodium citrate
and Milli-Q water (Millipore), respectively. For particle
characterization, the CT and PVP-coated AgNPs were
diluted with 2.0 mM sodium citrate (cod. W302600,
Sigma-Aldrich) buffer and Milli-Q water, respectively.
When necessary, samples were sonicated (Elmasonic S
30 H) for up to 30 s, in accordance with the manufac-
turer’s instructions. In order to prevent contamination,
measurements were run using disposable plastic cuvettes.
The AgNPs were tested immediately after their delivery
and in vivo experiments were run in the following week.
In the meanwhile, the AgNPs were stored at +4 °C, ac-
cording to manufacturer’s instructions.
Recordati et al. Particle and Fibre Toxicology  (2016) 13:12 Page 13 of 17
Dynamic Light Scattering (DLS)
The actual size of AgNPs in dispersion was measured by
DLS. Measurements were performed with a Malvern
Zetasizer Nano ZS90 instrument operating with a light
source wavelength of 532 nm and a fixed scattering
angle of 90°. All the nanoparticles were diluted 1:100
with the exception of 10 nm-sized AgNPs. Indeed, due
to their small size, the 10 nm AgNPs presented in-
creased absorption and lower scattering intensity com-
pared to 40 nm and 100 nm AgNPs. Accordingly, the
10 nm AgNPs were diluted 1:50. All measurements were
run at room temperature for at least three times.
UV-Visible (UV–Vis) Spectrophotometry
The UV–Vis spectra were acquired in the 300–800 nm
range using a DU730 Beckman Coulter Spectrophotom-
eter. All the nanoparticles were diluted 1:100 with the
exception of 10 nm AgNPs, which were diluted 1:200
because of their increased UV–Vis absorbance with re-
spect to larger nanoparticles. All measurements were
run at room temperature for at least three times.
Transmission Electron Microscopy (TEM)
Formvar coated copper TEM grids (cod. PE1GC300,
Pelco) were pre-treated with 20 μl of poly-L-lysine
0.01 % (w/v) (Sigma Aldrich) for 15 min. After washing
twice with MilliQ water, 3 μl of AgNPs suspensions were
deposited onto the grid for 5 min and then rinsed with
3 μl of 2-propanol (Sigma Aldrich). According to the
manufacturer’s advice, 100 and 40 nm AgNPs were used
at the concentration of 1.0 mg/ml, while 10 nm AgNPs
were diluted up to 0.1 mg/ml before use. The grids were
allowed to dry overnight at room temperature in a cov-
ered crystallizing dish. TEM (FEI Tecnai G2, Eindhoven)
images were analyzed with the ImageJ software (http://
imagej.nih.gov/ij/) to obtain the nanoparticles dimen-
sional distribution. In particular, small objects due to
background and overlapping nanoparticles were omitted
by using proper cut-off filters and Feret diameter
(intended as the larger diameter of the NP projection)
was used to evaluate the size of the particles. For each
sample, a minimum of about 250 nanoparticles was
considered.
Dissolution study
CT-coated particles were selected for this investigation
given the higher stability and lower dissolution generally
showed by PVP-coated AgNPs [66, 67]. Dissolution of
CT-coated AgNPs of 10, 40 and 100 nm was ascertained
by ultrafiltration, using a PES spin filter membrane
(Vivaspin 500, 3 kDa MWCO, Sartorius, Göttingen,
Germany) and centrifugation at 15000 g for 20 min,
followed by quantification of silver in the filtrates. The
concentration of ionic silver was measured both in the
AgNPs stock suspensions and in conditions simulating
AgNPs interaction with biological fluids. For the latter
purpose, each stock suspension was spiked to mouse
serum (Euroclone, Milan, Italy) in order to provide the
mass concentration of AgNPs of a single dose of 10 mg/
kg bw, which approximately corresponded to a 1:5 dilu-
tion (v/v) of the original AgNPs suspension. Spiked sam-
ples and serum blank were prepared in triplicate and
incubated at 37 °C under agitation for 5, 10, 60 min and
24 h. Ionic silver was assessed for each timepoint. For
ICP-MS determination of ionic silver, filtrates (prepared
in triplicate) were vigorously shaken before further dilu-
tion and analysis as described in the section “Determin-
ation of silver”. In addition to ionic silver, each stock
suspension of CT-coated AgNPs was characterized in
terms of total silver concentration and the results for
ionic silver were expressed as percentages of total silver
(AgNPs + Ag+). Samples for total silver determinations
were prepared in triplicate by dilution with acidified
(HNO3) water as necessary. In order to establish possible
sources of bias from the filtration membrane, procedural
blanks were run in parallel and the recovery of ionic sil-
ver (10 μg/L) from the filtration unit was assessed. No
silver was detected in the procedural blanks and the
average recovery of ionic silver was found to be 102.6 ±
3.8 %, showing absence of silver release/adsorption dur-
ing filtration.
Animals
Male CD-1(ICR) mice of 4–5 weeks were purchased
from Charles River (Calco, Italy). They were acclimated
to the environment for a week prior to the initiation of
the study, with free access to water and a standard pellet
diet ad libitum. The environmental conditions were set
at a temperature of 22 ± 2 °C, relative humidity of 55 ±
10 % and a 12 h light/dark cycle.
Experimental design
Mice were randomly assigned to groups of treatments.
The mice were intravenously (IV) injected into the lateral
tail vein with AgNPs of different sizes (10 nm, 40 nm,
100 nm), either CT- or PVP-coated, at a single dose of
10 mg/kg body weight (bw), and with AgAc at a single
dose of 15.5 mg/kg, corresponding to 10 mg Ag/kg bw (3
mice per group). The AgNPs suspensions were adminis-
tered to animals without any dilution. The control group
was treated with sterile water for injection. Immediately
after the treatment and the following hours, the general
health and behavior of mice were monitored. The body
weight of each mouse was measured before treatment and
at sacrifice. Mice were euthanized 24 h after the treat-
ment. The experiment was approved by an independent
Ethical Committee on Animal Experimentation (Ethical
Committee of the University of Milan, Opinion no. 81/14)
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and was performed in accordance with the Italian Laws
(D.L.vo 116/92 and following additions), which enforce
EU 86/609 Directive.
Sampling
At 24 h after IV administration mice were euthanized by
carbon dioxide inhalation. After drawing blood from the
heart, mice underwent complete necropsy. Blood, liver,
spleen, kidneys, lungs, and brain were collected for silver
quantification and histopathological examination. The
organ weight was measured and relative organ weights
(%) were calculated as wet organ weight/total body
weight. For quantification of silver, blood and a portion
of the collected organs were stored at -80 °C for later
analysis.
Determination of silver
Chemicals
Ultrapure deionized water obtained by a Milli-Q Element
System (Millipore, Molsheim, France), ultrapure grade ni-
tric acid (67–69 % v/v) (Carlo Erba Reagenti, Rodano, Italy),
ultrapure grade hydrochloric acid (32-35 % v/v) (Romil Ltd,
Cambridge, UK) and ultrapure grade hydrogen peroxide
(30 % v/v) (Merck, Darmstadt, Germany) were used
throughout. For ICP-MS measurements, silver calibrants
and rhodium solutions used were obtained from standard
certified solutions of 1 mg/ml (High Purity Standard,
Charleston, SC) by dilution with acidified (HNO3 and HCl)
water, as necessary.
Determination of total silver content
Total silver concentrations were determined in organs and
whole blood by means of a triple quadrupole inductively
coupled plasma mass spectrometer (ICP-MS). A 8800 ICP-
QQQ spectrometer (Agilent Technologies, Japan, Tokio)
equipped with an autosampler, a peristaltic pump, a Micro-
Mist glass concentric nebuliser, and operated at a RF power
of 1550 W, was used. All sample manipulations were car-
ried out in clean room conditions under a laminar flow box
(Spetec GmbH, Erding, Germany). Before ICP-MS mea-
surements, whole organs and blood were placed in Falcon
tubes and pre-digested for 5 h at room temperature with
2–4 ml HNO3, depending on the organ weight. After add-
ing 1 ml H2O2, samples were digested in a microwave sys-
tem (Milestone Ethos E microwave labstation, FKV,
Bergamo, Italy) at 90 °C for 8 h, maximum power 800 W.
After cooling, the digests were diluted by adding HCl (final
concentration 3.0 M) to promote the formation of soluble
silver complexes and prevent the precipitation of insoluble
Ag+ salts. Prior to analysis the digests were highly diluted
with 0.1 % HNO3 and the appropriate amount of HCl so as
to maintain the silver in complexed form. Measurements
were carried out on 107Ag and 103Rh, as internal standard,
by the method of external calibration. The method
detection limit ranged from 0.4 to 0.7 μg/kg, depending on
the tissue, and was 0.09 μg/l for blood.
Analytical quality control
Trueness of ICP-MS measurements was assessed by ana-
lysing the certified reference material SRM 1577c Bovine
Liver (NIST, Gaithersburg, MD, USA), with a certified
value for silver of 5.9 ± 1.6 μg/kg and the control mater-
ial Seronorm™ Trace Elements Whole Blood L-1 (SERO
AS, Billingstad, Norway) with a indicative value for silver
of 185 ± 10 ng/l, both included in every analytical batch.
The average determined silver concentrations were 6.0 ±
0.5 μg/kg (n = 6) and 179 ± 2 ng/l (n = 6) for the liver-
based and the blood-based materials, respectively, in
good agreement with the reference values. The trueness
of determinations was also assessed through spikes of
known amounts of silver in tissues and blood before
sample dissolution, giving recoveries within the range of
90-100 % with no appreciable differences between sam-
ple types.
Histopathological examination
For histological examination, liver (median lobe includ-
ing the gall bladder), spleen (apical portion), kidney (half
of the right kidney), lung (left lobe), brain (half brain,
cut along the sagittal plane) were fixed in 10 % neutral
buffered formalin for at least 48 h at room temperature,
routinely processed for paraffin embedding, sectioned at
4 μm thickness, stained with hematoxylin-eosin (H&E),
and evaluated under a light microscope. Grading of
histopathological lesions in the examined organs was
performed as follows: 0 = absence of lesions; 1 = minimal
lesions; 2 =mild lesions; 3 =moderate lesions; 4 = severe
lesions.
To analyze the tissue distribution and localization of
silver, autometallography (AMG) [42] and immunofluor-
escence were performed on serial sections. After AMG
staining, sections were counterstained with safranin O
and evaluated under a light microscope for the identifica-
tion of tissue and cellular localization of silver, visible as
black granular pigment. For immunofluorescence, liver
sections were immunostained with rabbit monoclonal
anti-IBA1 antibody (Wako Chemicals Richmond, VA,
USA, cat. No. 019-19741), a pan-macrophage marker [68].
Secondary antibody, Alexa Fluor® 555 F(ab’)2 Fragment of
Goat Anti-Rabbit IgG (H + L) (Life Technologies Europe
BV, Monza, Italy, cat. No. A-21430) was then added.
Immunofluorescently labeled sections were acquired with
the Leica TCS SP5 confocal microscope (Leica Microsys-
tems GmbH, Wetzlar, Germany). The Alexa555 fluoro-
phore was excited with the 561 nm laser line and the
emitted fluorescence (570–700 nm) acquired with a 63x/
1.4 oil immersion objective (Leica Microsystems GmbH).
Nuclei were visualized by DAPI staining (405 nm laser line
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excitation, 415–500 nm acquisition window). Silver aggre-
gates were visualized by reflection of light at 561 nm [24].
Statistical analysis
Data were analyzed using Graph Pad Prism version 5.0
(GraphPad Software, San Diego, CA). For TEM, paired
samples t-test was performed. Since the number of data
(weights and silver concentrations) obtained from in vivo
experiments was small, nonparametric tests (Kruskal-Wallis
and Mann–Whitney U test) were used to detect differences
between groups. The P-values <0.05 were considered statis-
tically significant. Data were additionally explored by Princi-
pal Component Analysis, in order to understand the
relationships among variables and their effect on data
distribution.
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Abbreviations
AgAc: silver acetate; AgNP: silver nanoparticle; AMG: autometallography;
bw: body weight; CT: sodium citrate; DLS: dynamic light scattering;
H&E: hematoxylin and eosin; ICP-MS: inductively coupled plasma mass
spectroscopy; PVP: polyvinylpyrrolidone; TEM: transmission electron
microscopy; UV–Vis: UV-visible.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CR conceived and designed the study, performed the histopathological
analysis, analyzed and interpreted the data, and drafted the manuscript.
MDM participated in the design of the study, conducted the animal
exposures, performed the histochemical stainings, participated in the data
analysis, and drafted the manuscript. SB conducted the animal exposures. SA
and CC carried out the particle characterization, data analysis, and drafted
the manuscript. SM performed the statistical analysis. FA, MDA, AR
conducted the dissolution study, the ICP-MS measurements, and related data
analysis. FC planned and supervised the dissolution study and ICP-MS
characterization of tissue distribution, and critically revised the manuscript.
CL was the project leader, and critically revised the manuscript. PM critically
revised the manuscript. ES participated in the planning of the study, super-
vised the histopathological analysis, and critically revised the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This research was supported by Fondazione Cariplo for the project
“Toxicology of chronic exposure to engineered silver nanoparticles”, under
the 2011 call”Nanoparticles, nanotechnologies and ultrafine particles”. We are
grateful to S. Rodighiero for assistance in the analysis at confocal
microscope, D. Marchesi for assistance in TEM imaging, and M. Losa for
technical histological support.
Author details
1Fondazione Filarete, 20139 Milan, Italy. 2Dipartimento di Scienze Veterinarie
e Sanità Pubblica (DIVET), Università degli Studi di Milano, 20133 Milan, Italy.
3Dipartimento di Fisica, Università degli Studi di Milano, 20133 Milan, Italy.
4Department of Food Safety and Veterinary Public Health, Istituto Superiore
di Sanità - National Health Institute, 00161 Rome, Italy. 5Centro
Interdisciplinare Materiali e Interfacce Nanostrutturati (CIMAINA), Università
degli Studi di Milano, 20133 Milan, Italy.
Received: 29 June 2015 Accepted: 22 February 2016
References
1. Völker C, Oetken M, Oehlmann J. The biological effects and possible modes
of action of nanosilver. Rev Environ Contam Toxicol. 2013;223:81–106.
2. Ahamed M, Alsalhi MS, Siddiqui MK. Silver nanoparticle applications and
human health. Clin Chim Acta. 2010;411:1841–8.
3. The Project on Emerging Nanotechnologies. Consumer Products Inventory.
2015. http://www.nanotechproject.org/cpi. Accessed 15 April 2015.
4. Schäfer B, Brocke JV, Epp A, Götz M, Herzberg F, Kneuer C, et al. State of the
art in human risk assessment of silver compounds in consumer products: a
conference report on silver and nanosilver held at the BfR in 2012. Arch
Toxicol. 2013;87:2249–62.
5. Schluesener JK, Schluesener HJ. Nanosilver: application and novel aspects of
toxicology. Arch Toxicol. 2013;87:569–76.
6. Mijnendonckx K, Leys N, Mahillon J, Silver S, Van Houdt R. Antimicrobial
silver: uses, toxicity and potential for resistance. Biometals. 2013;26:609–21.
7. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramirez JT, et al. The
bactericidal effect of silver nanoparticles. Nanotechnology. 2005;16:2346–53.
8. Stensberg MC, Wei Q, McLamore ES, Porterfield DM, Wei A, Sepúlveda MS.
Toxicological studies on silver nanoparticles: challenges and opportunities
in assessment, monitoring and imaging. Nanomedicine. 2011;6:879–98.
9. El Badawy AM, Silva RG, Morris B, Scheckel KG, Suidan MT, Tolaymat TM.
Surface charge-dependent toxicity of silver nanoparticles. Environ Sci
Technol. 2011;45:283–7.
10. Nguyen KC, Seligy VL, Massarsky A, Moon TW, Rippstein P, Tan J, et al.
Comparison of toxicity of uncoated and coated silver nanoparticles. J Phys
Conf Ser. 2013;429:012025.
11. Carlson C, Hussain SM, Schrand AM, Braydich-Stolle LK, Hess KL, Jones RL,
et al. Unique cellular interaction of silver nanoparticles: size-dependent
generation of reactive oxygen species. J Phys Chem B. 2008;112:13608–19.
12. Hsin YH, Chen CF, Huang S, Shih TS, Lai PS, Chueh PJ. The apoptotic effect of
nanosilver is mediated by a ROS- and JNK-dependent mechanism involving
the mitochondrial pathway in NIH3T3 cells. Toxicol Lett. 2008;179:130–9.
13. Kim TH, Kim M, Park HS, Shin US, Gong MS, Kim HW. Size-dependent
cellular toxicity of silver nanoparticles. J Biomed Mater Res A. 2012;100:
1033–43.
14. Park MV, Neigh AM, Vermeulen JP, de la Fonteyne LJ, Verharen HW, Briedé
JJ, et al. The effect of particle size on the cytotoxicity, inflammation,
developmental toxicity and genotoxicity of silver nanoparticles. Biomaterials.
2011;32:9810–7.
15. Sung JH, Ji JH, Park JD, Yoon JU, Kim DS, Jeon KS, et al. Subchronic
inhalation toxicity of silver nanoparticles. Toxicol Sci. 2009;108:452–61.
16. Kim YS, Song MY, Park JD, Song KS, Ryu HR, Chung YH, et al. Subchronic
oral toxicity of silver nanoparticles. Part Fibre Toxicol. 2010;7:20.
17. Park EJ, Bae E, Yi J, Kim Y, Choi K, Lee SH, et al. Repeated-dose toxicity and
inflammatory responses in mice by oral administration of silver
nanoparticles. Environ Toxicol Pharmacol. 2010;30:162–8.
18. Samberg ME, Oldenburg SJ, Monteiro-Riviere NA. Evaluation of silver
nanoparticle toxicity in skin in vivo and keratinocytes in vitro. Environ Health
Perspect. 2010;118:407–13.
19. Stebounova LV, Adamcakova-Dodd A, Kim JS, Park H, O’Shaughnessy PT,
Grassian VH, et al. Nanosilver induces minimal lung toxicity or inflammation
in a subacute murine inhalation model. Part Fibre Toxicol. 2011;8:5.
20. Hadrup N, Loeschner K, Bergström A, Wilcks A, Gao X, Vogel U, et al.
Subacute oral toxicity investigation of nanoparticulate and ionic silver in
rats. Arch Toxicol. 2012;86:543–51.
21. van der Zande M, Vandebriel RJ, Van Doren E, Kramer E, Herrera Rivera Z,
Serrano-Rojero CS, et al. Distribution, elimination, and toxicity of silver
nanoparticles and silver ions in rats after 28-day oral exposure. ACS Nano.
2012;6:7427–42.
22. Xue Y, Zhang S, Huang Y, Zhang T, Liu X, Hu Y, et al. Acute toxic effects and
gender-related biokinetics of silver nanoparticles following an intravenous
injection in mice. J Appl Toxicol. 2012;32:890–9.
Recordati et al. Particle and Fibre Toxicology  (2016) 13:12 Page 16 of 17
23. De Jong WH, Van Der Ven LT, Sleijffers A, Park MV, Jansen EH, Van Loveren H,
et al. Systemic and immunotoxicity of silver nanoparticles in an intravenous 28
days repeated dose toxicity study in rats. Biomaterials. 2013;34:8333–43.
24. Gaiser BK, Fernandes TF, Jepson MA, Lead JR, Tyler CR, Baalousha M, et al.
Interspecies comparisons on the uptake and toxicity of silver and cerium
dioxide nanoparticles. Environ Toxicol Chem. 2012;31:144–54.
25. Korani M, Rezayat SM, Arbabi BS. Sub-chronic dermal toxicity of silver
nanoparticles in guinea pig: special emphasis to heart, bone and kidney
toxicities. Iran J Pharm Res. 2013;12:511–9.
26. Shahare B, Yashpal M. Toxic effects of repeated oral exposure of silver
nanoparticles on small intestine mucosa of mice. Toxicol Mech Methods.
2013;23:161–7.
27. Reidy B, Haase A, Luch A, Dawson KA, Lynch I. Mechanisms of silver
nanoparticle release, transformation and toxicity: a critical review of current
knowledge and recommendations for future studies and applications.
Materials. 2013;6:2295–350.
28. Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide
the biological identity of nanosized materials. Nat Nanotechnol. 2012;7:779–86.
29. Warheit DB. Debunking some misconceptions about nanotoxicology. Nano
Lett. 2010;10:4777–82.
30. Lankveld DP, Oomen AG, Krystek P, Neigh A, Troost-de Jong A, Noorlander
CW, et al. The kinetics of the tissue distribution of silver nanoparticles of
different sizes. Biomaterials. 2010;31:8350–61.
31. Dziendzikowska K, Gromadzka-Ostrowska J, Lankoff A, Oczkowski M,
Krawczyńska A, Chwastowska J, et al. Time-dependent biodistribution and
excretion of silver nanoparticles in male Wistar rats. J Appl Toxicol.
2012;32:920–8.
32. Wang X, Ji Z, Chang CH, Zhang H, Wang M, Liao YP, et al. Use of coated silver
nanoparticles to understand the relationship of particle dissolution and
bioavailability to cell and lung toxicological potential. Small. 2014;10:385–98.
33. Seiffert J, Hussain F, Wiegman C, Li F, Bey L, Baker W, et al. Pulmonary
toxicity of instilled silver nanoparticles: influence of size, coating and rat
strain. PLoS One. 2015;10:e0119726.
34. SCENIHR (Scientific Committee on Emerging and Newly Identified Health
Risks). Nanosilver: safety, health and environmental effects and role in
antimicrobial resistance. 2014. http://ec.europa.eu/health/scientific_
committees/consultations/public_consultations/scenihr_consultation_17_en.
htm. Accessed 15 April 2015.
35. Gliga AR, Skoglund S, Wallinder IO, Fadeel B, Karlsson HL. Size-dependent
cytotoxicity of silver nanoparticles in human lung cells: the role of cellular
uptake, agglomeration and Ag release. Part Fibre Toxicol. 2014;11:11.
36. Ivask A, Kurvet I, Kasemets K, Blinova I, Aruoja V, Suppi S, et al. Size-
dependent toxicity of silver nanoparticles to bacteria, yeast, algae,
crustaceans and mammalian cells in vitro. PLoS One. 2014;9:e102108.
37. Noguez C. Surface plasmons on metal nanoparticles: the influence of shape
and physical environment. J Phys Chem C. 2007;111:3806–19.
38. Izquierdo-Lorenzo I, Kubackova J, Manchon D, Mosset A, Cottancin E,
Sanchez-Cortes S. Linking Ag nanoparticles by aliphatic α, ω-dithiols: a study
of the aggregation and formation of interparticle hot spots. J Phys Chem C.
2013;117:16203–12.
39. Shannahan JH, Podila R, Brown JM. A hyperspectral and toxicological
analysis of protein corona impact on silver nanoparticle properties,
intracellular modifications, and macrophage activation. Int J Nanomedicine.
2015;10:6509–21.
40. Bachler G, von Goetz N, Hungerbühler K. A physiologically based
pharmacokinetic model for ionic silver and silver nanoparticles. Int J
Nanomedicine. 2013;8:3365–82.
41. Loza K, Diendorf J, Sengstock C, Ruiz-Gonzalez L, Gonzalez-Calbet JM, Vallet-
Regi M, et al. The dissolution and biological effects of silver nanoparticles in
biological media. J Mater Chem B. 2014;2:1634–43.
42. Su C, Sun Y. Considerations of inductively coupled plasma mass
spectrometry techniques for characterizing the dissolution of metal-based
nanomaterials in biological tissues. J Anal At Spectrom. 2015;30:1689–705.
43. Utembe W, Potgieter K, Stefaniak AB, Gulumian M. Dissolution and
biodurability: Important parameters needed for risk assessment of
nanomaterials. Part Fibre Toxicol. 2015;12:11.
44. Roe D, Karandikar B, Bonn-Savage N, Gibbins B, Roullet JB. Antimicrobial
surface functionalization of plastic catheters by silver nanoparticles. J
Antimicrob Chemother. 2008;61:869–76.
45. Rigo C, Ferroni L, Tocco I, Roman M, Munivrana I, Gardin C, et al. Active
silver nanoparticles for wound healing. Int J Mol Sci. 2013;14:4817–40.
46. Schrand AM, Braydich-Stollel LK, Schlager JJ, Dai L, Hussain SM. Can silver
nanoparticles be useful as potential biological labels? Nanotechnology.
2008;19:235104.
47. Wei L, Lu J, Xu H, Patel A, Chen ZS, Chen G. Silver nanoparticles: synthesis,
properties, and therapeutic applications. Drug Discov Today. 2015;20:595–601.
48. Loeschner K, Hadrup N, Qvortrup K, Larsen A, Gao X, Vogel U, et al.
Distribution of silver in rats following 28 days of repeated oral exposure to
silver nanoparticles or silver acetate. Part Fibre Toxicol. 2011;8:18.
49. Kwon JT, Minai-Tehrani A, Hwang SK, Kim JE, Shin JY, Yu KN, et al. Acute
pulmonary toxicity and body distribution of inhaled metallic silver
nanoparticles. Toxicol Res. 2012;28:25–31.
50. Park K, Park EJ, Chun IK, Choi K, Lee SH, Yoon J, et al. Bioavailability and
toxicokinetics of citrate-coated silver nanoparticles in rats. Arch Pharm Res.
2011;34:153–8.
51. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human
studies revisited. FASEB J. 2008;22:659–61.
52. Sadauskas E, Wallin H, Stoltenberg M, Vogel U, Doering P, Larsen A, et al.
Kupffer cells are central in the removal of nanoparticles from the organism.
Part Fibre Toxicol. 2007;4:10.
53. Sadauskas E, Danscher G, Stoltenberg M, Vogel U, Larsen A, Wallin H.
Protracted elimination of gold nanoparticles from mouse liver.
Nanomedicine. 2009;5:162–9.
54. Danscher G, Stoltenberg M. Silver enhancement of quantum dots resulting
from (1) metabolism of toxic metals in animals and humans, (2) in vivo,
in vitro and immersion created zinc-sulphur/zinc-selenium nanocrystals, (3)
metal ions liberated from metal implants and particles. Prog Histochem
Cytochem. 2006;41:57–139.
55. Danscher G. Light and electron microscopic localization of silver in
biological tissue. Histochemistry. 1981;71:177–86.
56. Matsumura T, Kumakiri M, Ohkawara A, Himeno H, Numata T, Adachi R.
Detection of selenium in generalized and localized argyria: report of four
cases with X-ray microanalysis. J Dermatol. 1992;19:87–93.
57. Massi D, Santucci M. Human generalized argyria: a submicroscopic and X-
ray spectroscopic study. Ultrastruct Pathol. 1998;22:47–53.
58. Lee JH, Kim YS, Song KS, Ryu HR, Sung JH, Park JD, et al. Biopersistence of
silver nanoparticles in tissues from Sprague-Dawley rats. Part Fibre Toxicol.
2013;10:36.
59. Thoolen B, Maronpot RR, Harada T, Nyska A, Rousseaux C, Nolte T, et al.
Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary
system. Toxicol Pathol. 2010;38:5S–81S.
60. Haschek WM, Wallig MA, Rousseaux CG. The liver. In: Fundamentals of
Toxicologic Pathology. London: Academic; 2010. p. 197–235.
61. Shrivastava S, Bera T, Singh SK, Singh G, Ramachandrarao P, Dash D.
Characterization of antiplatelet properties of silver nanoparticles. ACS Nano.
2009;3:1357–64.
62. Sabella S, Carney RP, Brunetti V, Malvindi MA, Al-Juffali N, Vecchio G, et al. A
general mechanism for intracellular toxicity of metal-containing
nanoparticles. Nanoscale. 2014;6:7052–61.
63. De Matteis V, Malvindi MA, Galeone A, Brunetti V, De Luca E, Kote S, et al.
Negligible particle-specific toxicity mechanism of silver nanoparticles: The
role of Ag(+) ion release in the cytosol. Nanomedicine. 2015;11:731–9.
64. Walkey CD, Chan WCW. Understanding and controlling the interaction of
nanomaterials with proteins in a physiological environment. Chem Soc Rev.
2012;41:2780–99.
65. Walkey CD, Olsen JB, Song F, Liu R, Guo H, Olsen W, et al. Protein corona
fingerprinting predicts the cell association of gold nanoparticles. ACS Nano.
2014;8:2439–55.
66. Tejamaya M, Römer I, Merrifield RC, Lead JR. Stability of citrate, PVP, and
PEG coated silver nanoparticles in ecotoxicology media. Environ Sci
Technol. 2012;46:7011–7.
67. An Huynh K, Chen KL. Aggregation kinetics of citrate and
polyvinylpyrrolidone coated silver nanoparticles in monovalent and divalent
electrolyte solutions. Environ Sci Technol. 2011;45:5564–71.
68. Rehg JE, Bush D, Ward JM. The utility of immunohistochemistry for the
identification of hematopoietic and lymphoid cells in normal tissues and
interpretation of proliferative and inflammatory lesions of mice and rats.
Toxicol Pathol. 2012;40:345–74.
Recordati et al. Particle and Fibre Toxicology  (2016) 13:12 Page 17 of 17
eISSN 2056-5623 Future Sci. OA (2015) FSO6710.4155/fso.15.67 © Giovanni Bernardini
FSO
Future Sci. OA
Research Article 2015/08/30
1
1
00
2015
Background: Application of nanoenzymes, based on D-amino acid oxidase (DAAO) 
conjugated to magnetic nanoparticles (NPs), as anticancer system requires improvement 
of the synthesis protocol and in vivo distribution evaluation. Results: A new and more 
efficient synthesis via EDC-NHS produced an Fe3O4NP-APTES-DAAO system with a 
specific activity of 7 U/mg NPs. IR spectroscopy showed that all Fe3O4 NP sites are 
saturated with APTES and all available NH2 sites with DAAO. The acute cytotoxicity 
of the new system does not differ from that of the previous one. In vivo experiments 
showed that the system did not cause adverse effects, cross the brain–blood barrier 
and accumulate in the heart. Conclusions: Our results support the possibility to use 
enzymes conjugated to magnetic NPs for cancer treatment. Besides, we think that 
enzymes and other biological molecules efficiently conjugated to magnetic NPs might 
constitute a category of ‘bionanoparticles’ to be exploited, not only in medical, but 
also in industrial biotechnology.
Lay abstract: We have linked magnetic nanoparticles to D-amino acid oxidase, an 
enzyme capable of producing, in the presence of its substrate, reactive oxygen species. 
The scope is to use the magnetic properties of the enzyme-nanoparticle system to 
direct it to a desired area where its cytotoxicity can be controlled by the addition of 
exogenous substrate. Besides the possible applications in cancer therapy, we think 
that enzymes and other biological molecules linked to magnetic nanoparticles might 
also be exploited in industrial biotechnology.
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Published online: 11 September 2015
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Nanoparticles (NPs) and other nanomateri-
als permeate several areas of our everyday life. 
In industrial applications, they have become 
indispensable components of catalysts [1], 
sensors [2] and photovoltaic devices [3]. 
Unfortunately, the same peculiar properties 
that make nanomaterials so attractive may 
create potentially new and largely undefined 
risks for human health. NPs, in effect, are 
capable to cross biological barriers [4–6] and 
are readily taken up by cells [7] where they 
can exert their toxicity. However, NPs have 
also found widespread use in the biomedi-
cal field, as nanovaccines, nanodrugs and 
diagnostic imaging tools [8]. The increasing 
number of nanotechnology patents related to 
healthcare reflects the rapid expansion of this 
pioneering industry [9].
The impact of nanobiotechnology on 
oncology is huge and includes fields ranging 
from discovery of tumor biomarkers to devel-
opment of devices for cancer surgery [10,11]. In 
particular, drug-delivery, the most explored 
field, aims to design carriers that deliver 
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drugs more precisely to tumor cells and maintain them 
at therapeutic concentrations over a long period [12]. 
Besides considerable progress in cancer therapy and 
the many anticancer drugs available, the treatment of 
cancer has still a lot of side effects [13] and NPs could be 
an efficient alternative to conventional therapies, serv-
ing as carrier systems capable of enhancing efficacy, 
while simultaneously reducing side effects. Magnetic 
NPs can be functionalized with anticancer drugs and 
guided along an externally placed magnet into the 
tumor [14]. Moreover, magnetic NPs can produce heat 
through various energy losses under an external alter-
nating magnetic field, causing cancer destruction by 
hyperthermia [15–20].
In a previous work [21], we set up the synthesis of an 
NP-enzyme system for cancer therapy via glutaralde-
hyde. The system (Fe
3
O
4
-APTES-DAAO) was based 
on iron oxide magnetic NPs conjugated to the ROS-
producing enzyme D-amino acid oxidase from Rhodo-
torula gracilis (RgDAAO, EC 1.4.3.3). Fe
3
O
4
-APTES-
DAAO aims to combine the advantages of magnetic 
NPs (low acute toxicity, specific target by a magnetic 
field, ability to cross biological barriers) with those of 
RgDAAO (no acute toxicity, easy modulation of the 
activity, hence of ROS generation). The system can be 
intravenously injected and addressed by an external 
magnetic field in the tumor area, where D-amino acids 
(naturally present or externally injected) act as sub-
strate for the enzyme, causing H
2
O
2
 production and 
tumor cell death by apoptosis.
This work is on continuing the research of using 
magnetic NPs conjugated to DAAO for the potential 
treatment of cancer, a step forward in the possible real-
ization of this clinical technique. To this aim, we pres-
ent a new and more efficient synthesis of this system 
via EDC-NHS and the characterization by infra red 
(IR) spectroscopy of the two systems resulting from 
the old and the new methods of synthesis. Moreover, 
we have analyzed the in vivo distribution as well as the 
acute toxicity of the new system after single intrave-
nous administration in mice. We have also realized 
that enzymes conjugated to magnetic NPs could be of 
interest also for industrial purposes [22].
Materials & methods
Coating of magnetic NPs with APTES
Fe
3
O
4
 NPs were functionalized according to the pro-
tocol of Bava et al. [21]. Briefly, 150 mg of Fe
3
O
4
 NPs 
(Sigma, cat. number 637,106) were ultrasonicated in 
10 ml of H
2
O MilliQ for 15 min. A solution of 5 ml 
APTES (2% v/v, Sigma cat. number A3648) in H
2
O 
MilliQ was then added and the reaction was main-
tained under mechanical stirring for 5 h at 50°C. 
Fe
3
O
4
-APTES were then separated from unbound 
APTES by a commercial parallelepiped neodymium 
magnet (Webcraft GmbH, Uster, Switzerland; Ni-
Cu-Ni plated; magnetization: N45; size: 30 × 30 × 15 
mm), washed several times with water and anhydrifi-
cated with ethanol overnight. Fe
3
O
4
-APTES were sus-
pended again in water, ultrasonicated for 30 min and 
left at room temperature for 1 h, isolated and dried at 
50°C overnight.
Synthesis of Fe3O4NP-APTES-DAAO
Four milligrams of Fe
3
O
4
NP-APTES were suspended 
by sonication for 15 min with 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide (EDC, Sigma cat. number 
03450) and N-hydroxysuccinimide (NHS, Sigma, cat. 
number 130,672) in 3:2 (w/w) ratio in 5 mM sodium 
pyrophosphate (NaPPi) buffer, pH 8.5. Two hundred 
and fifty micrograms of recombinant RgDAAO [19] 
were added and the reaction was carried out for 4 h at 
4°C using a rotating plate tube stirrer. Subsequently, 
Fe
3
O
4
-APTES-DAAO were collected by a magnet and 
washed twice with 1 ml of 5 mM NaPPi pH 8.5. The 
supernatant was stored for further analysis.
DAAO activity assay
The activity of Fe
3
O
4
-APTES–DAAO was determined 
by measuring the absorbance increase accompanying 
the H
2
O
2
-induced oxidation of o-dianisidine [20]. One 
DAAO unit corresponds to the amount of enzyme that 
converts 1 μmol of substrate per min at 25°C and at 
0.253 mM oxygen concentration [23,24]. The standard 
assay mixture contained 890 μl of 100 mM D-alanine 
in 100 mM NaPPi buffer, pH 8.5 buffer, 100 μl of 
3.2 mg/ml o-dianisidine in water, 10 μl of 0.4 mg/ml 
horseradish peroxidase in 100 mM NaPPi buffer, pH 
8.5 buffer and 10 μl of 0.4 mg/ml Fe
3
O
4
NP-APTES-
DAAO in the same buffer. The reaction was initiated 
by the addition of the enzyme and the absorbance 
increase was monitored at 440 nm for 1 min using an 
UV-Vis Jasco V-560 spectrophotometer.
IR analysis
Fe
3
O
4
NP-APTES-DAAO were characterized by IR 
analysis in different conditions. Samples (disks of 2 
cm2 area) were placed in a quartz cell equipped with 
KBr windows. A movable quartz sample holder allows 
to adjust the pellet in the infrared beam for spectra 
recording and to displace it into a furnace at the top 
of the cell for thermal treatment. The cell was con-
nected to a vacuum line for evacuation (P
residual
 = ∼10–6 
torr) and for the introduction of gases into the infra-
red cell. Spectra were recorded at room temperature. 
The addition of well-known doses of gas in the cell was 
possible via a pressure gauge for the control of the gas 
pressure. A Nicolet Nexus spectrometer equipped with 
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a Mercury Cadmium Telluride (MCT) cryodetector 
and an extended KBr beam splitter was used for the 
acquisition of spectra in the 600–5500 cm-1 range. IR 
spectra are absorption spectra and the notation used is 
a.u. for absorption units. The resolution of the spectra 
was 4 cm-1, and 256 scans were accumulated for each 
spectrum.
Three kinds of experiments have been performed: 
first the samples have been dispersed in the KBr, then 
on the surface of a silica pellet; finally on a silicon disk. 
In details: a wafer containing 98 mg of KBr has been 
pressed at 4 tons/cm2, together with ∼2 mg of the tar-
geted sample; a wafer of 20 mg silica has been casted 
mixing in its center ∼6–7 mg of sample, then pressed 
to 2 tons /cm2 and ∼2 mg of powder have been dis-
persed on the surface of a 2 cm2 silicon disk by the help 
of a spot of ethanol.
Dynamic light scattering (DLS) analysis
Fe
3
O
4
, Fe
3
O
4
-APTES and Fe
3
O
4
-APTES-DAAO NPs 
were analyzed at concentrations of 250, 25 and 2.5 μg/
ml in water. Sample dilutions were done in order to 
analyze the effect of concentration on NP aggregation. 
Each measurement was preceded by an equilibration 
time of 90 s. Analyzes were performed with Zetasizer 
Nano ZS90 (Malvern, UK) instrument. Measures 
were reported as scattering intensity in function to 
diameter.
Cell viability
SKOV-3 cell lines were maintained as adherent cells 
in RPMI1640 medium (supplemented with 10% fetal 
bovine serum, 1% L-glutamine and 1% penicillin/
streptomycin solution) at 37°C in a humidified 5% 
CO
2
 atmosphere. Cells were passaged as needed using 
0.25% trypsin–EDTA.
Cell viability was determined as ATP content by 
using the CellTiter-Glo Luminescent Cell Viability 
Assay according to the manufacturer’s instruction. In 
details, 1 × 104 cells were seeded into 96-well assay 
plates and cultivated for 24 h at 37°C in 5% CO
2
 to 
equilibrate and become attached prior to the treat-
ment. Cells were then exposed to increasing amounts 
of Fe
3
O
4
-APTES-DAAO, in presence or not of its 
substrate, for 24 h in a final volume of 100 μl. Fol-
lowing the treatment, plates were equilibrated for 30 
min at room temperature and 100 μl of CellTiter-
Glo Reagent was then added to each well. Plates were 
shaken for 2 min and left at room temperature for 10 
min prior to the recording of luminescent signals using 
the Infinite F200 plate reader (Tecan Group, Män-
nedorf, Switzerland). The experiments were performed 
in triplicate. Cell viability, expressed as ATP content, 
was  normalized against control values.
In vivo studies
To evaluate the biodistribution and acute toxicity of 
NPs, two in vivo studies were performed. In both 
experiments, male CD-1(ICR) mice of 4–5 weeks were 
purchased from Charles River (Calco, Italy). They 
were acclimated to the environment for a week prior to 
the initiation of the study, with free access to water and 
a standard pellet diet ad libitum. The environmental 
conditions were set at a temperature of 22 ± 2°C, relative 
humidity of 55 ± 10% and a 12 h light:dark cycle. The 
mice (n = 3) were intravenously injected with a single 
dose of Fe
3
O
4
-APTES-DAAO (in the first experiment 
100 mg/kg bodyweight (bw) of NPs in NaCl 0.9%, 
and in the second experiment 20 mg/kg bw of NPs 
in NaPPi buffer at pH 7.4) and sacrificed 24 h after 
the treatment. The control groups were treated with 
the corresponding vehicle (NaCl 0.9% or NaPPi buf-
fer). Immediately after the treatment and the following 
hours, the general health and behavior of mice were 
monitored. The bodyweight of each mouse was mea-
sured before treatment and at sacrifice. The experiment 
was performed in accordance with the Italian Laws 
(D.L. 116/92 and following additions), which enforce 
EU 86/609 Directive (Council Directive 86/609/EEC 
of 24 November 1986, on the approximation of laws, 
regulations and administrative provisions of the mem-
ber states regarding the protection of animals used for 
experimental and other  scientific purposes).
Sacrifice, sampling & pathological examination 
procedures
Mice were euthanized at 24-h post-treatment accord-
ing to standard procedures and in compliance with 
local regulations, and underwent complete necropsy. 
Liver, spleen and kidney were weighed and the rela-
tive organ weight (wet organ/total bodyweight) was 
 calculated.
Liver, kidney, spleen, lung, heart, testis and brain 
were fixed in 10% neutral-buffered formalin, and 
routinely processed for paraffin embedding. Four 
micrometer sections from each tissue were stained with 
hematoxylin and eosin (HE) and Perls iron stain [25], 
and evaluated under a light microscope. Quantitative 
evaluation of iron deposits in Perls iron stained sections 
was performed by digital image analysis: area of Perls 
staining was measured in three 200× microscopic fields 
using the ImageJ analysis program [26], and the percent-
age of Perls positive area per field was then  calculated.
For immunofluorescence, liver sections were immu-
nostained with rabbit monoclonal anti-Iba1 antibody 
(Wako Chemicals, VA, USA, cat. number 019–19741), 
a pan-macrophage marker [27]. Secondary antibody, 
Alexa Fluor® 555 F(ab’)2 Fragment of Goat Anti-Rab-
bit IgG (H+L; Life Technologies Europe BV, Monza, 
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Italy, cat. number A-21430) was then added. Immuno-
fluorescently labeled sections were acquired with the 
Leica TCS SP5 confocal microscope (Leica Microsys-
tems GmbH, Wetzlar, Germany). The Alexa555 fluo-
rophore was excited with the 561 nm laser line and the 
emitted fluorescence (570–700 nm) acquired with a 
63×/1.4 oil immersion objective (Leica Microsystems, 
GmbH). Nuclei were visualized by DAPI staining 
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Figure 1. IR spectra of Fe3O4-APTES-DAAO prepared via glutaraldehyde (red) and via EDC/NHS (blue). Samples 
were dispersed in KBr (2% w/w).
Figure 2. IR spectral subtraction. Spectrum of Fe3O4-APTES-DAAO prepared with the first method minus those 
prepared with the second method.
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(405 nm laser line excitation, 415–500 nm acquisition 
window). Iron aggregates were visualized by reflection 
of light at 561 nm.
Statistical analysis
Data were analyzed using GraphPad Prism version 5.0 
(GraphPad Software, CA, USA). Statistical analyses 
Figure 3. IR spectra of samples dispersed in silica. Bottom: in blue, subtraction of glutaraldehyde and EDC/NHS samples, in cyan, 
magenta and green spectra of glutaraldehyde samples after NO and CO adsorption. Top: EDC/NHS samples spectra after CO 
adsorption. Arrow indicates peak at 1508 cm-1.
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of the results were performed using Mann–Whitney 
U test to compare the experimental conditions with 
controls. p-values <0.05 were considered statistically 
significant.
Results
Activity analysis
RgDAAO was conjugated to Fe
3
O
4
-APTES by means 
of EDC and NHS. Under best experimental condi-
tions, the amount of enzyme bound to NPs, deter-
mined as the difference between the protein amount 
added and that recovered in the supernatant, is close 
to 100%, with an enzymatic activity of approximately 
7 U/mg NP.
IR characterization
The spectra of Fe
3
O
4
-APTES-DAAO prepared with 
the two methods (the old one via glutaraldehyde and 
the new one presented here), dispersed in the KBr (to 
identify the structural components), are reported in 
Figure 1. The two spectra are similar. At the highest 
wavenumbers, we can observe the stretching of the OH 
groups of water adsorbed on KBr, likely 3425 cm-1. In 
the 3300–3000 cm-1 region, the ν(NH) vibrations are 
observed; they correspond to the NH
2
 moieties pres-
ent in the organic ligand. The corresponding bending 
mode is at 1650–1640 cm-1 and 1546 cm-1, partially 
overlapped with the δ(HOH) of water at ∼1630 cm-
1. Below 800 cm-1, only structural (saturated) bands 
are visible, containing bending, twisting and rocking 
modes, together with the stretches of M-O bonds. The 
other bands (in the 1600–1000 cm-1 region) are due to 
C-C and C-O bonds, while those in the 3000–2800 
cm-1 interval to C-H stretches, difficult to be discrimi-
nated at this step. Interestingly, no bands at ∼1745 
cm-1, typical of the C=O bonds of the aldehydes, can 
be distinguished. Performing a spectral subtraction 
(Figure 2) we can better scrutinize the differences in the 
two compounds: the vibrations associated to the NH
2
 
species almost disappear in the compound prepared via 
EDC/NHS, as indicated by the bands in positive in 
the difference spectrum (3400–3000 cm-1 region, plus 
1649 and 1546 cm-1 peaks) and by the absence of the 
corresponding bands in the blue spectrum in Figure 1. 
A very weak feature appears at 1735 cm-1, accounting 
for aldehyde typical vibration.
Figure 5. Spectra of samples collected on a silicon wafer. A and B refer to glutaraldehyde samples while C and D 
refers to EDC/NHS samples.
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When dispersing the samples on silica as a support 
(Figure 3), the observed bands essentially deal with OH 
groups on silica (3746 cm-1) and adsorbed water (∼3450 
and 1630 cm-1). The features at 1972 and 1867 cm-1 are 
overtones and combination bands of the silica frame-
work (massif below 1300 cm-1) (spectrum blue, Figure 3). 
The sample has been probed by adsorption of CO and 
NO, two molecules adapted to reveal (and quantify) the 
presence of coordinatively unsaturated iron cations [28]. 
After CO or NO adsorptions, no remarkable differences 
can be distinguished especially on the glutaraldehyde 
sample (Figure 3, spectra cyan, magenta and green). In 
the case of the EDC/NHS sample, a weak component 
appears at 1508 cm-1 (Figure 3, spectrum red, red arrow), 
which cannot be related directly with the probe mol-
ecules. Eventually, it could be ascribed to CO interac-
tions with some accessible ligand in the organic part, 
inducing a shift in a C–C or C–O vibration. Subtrac-
tion spectra (Figure 4) confirm that no effect of probe 
molecule adsorption can be detected, so suggesting the 
absence of unsaturated iron moieties.
Spectra of the samples characterized after deposi-
tion on a silicon wafer (to discard any potential inter-
action with a support) are reported in Figure 5. Besides 
the interference fringes due to the specular surfaces 
of the Si disks, we can observe only bands due to the 
organic ligands, already mentioned above. Comparing 
the spectra during the adsorption of CO as probe mol-
ecule and after evacuation (B and A for glutaraldehyde, 
respectively, and C and D for EDC/NHS), we can-
not observe any difference, if we exclude the changes 
in the baseline, irrelevant for the present study. Even, 
this latter approach for the sample analysis seems less 
appropriate, providing spectra of relatively low quality.
DLS analysis
In all samples, production of NP aggregates of 300 nm 
or more is evident. The size of the aggregates varies 
with the dilution: at increased dilution the diameter 
decreases. Aggregation of metal NPs in aqueous envi-
ronment has been demonstrated to depend on several 
factors, concentration included [29]. Moreover, the 
polydispersity index (pdi) increases from Fe
3
O
4
 NPs to 
Fe
3
O
4
-APTES-DAAO (Figure 6).
Cytotoxicity
The cytotoxicity of the two systems was tested on 
SKOV-3 cells with and without the substrate D-ala-
nine (1 mM). As reported in Figure 7, no significant 
differences were evident: both systems in the pres-
ence of the substrate fully depleted the ATP content at 
3.5 mU of DAAO.
Table 1. Mean bodyweight gain (%) and relative organ weight (%) following intravenous 
administration of vehicle, 100 and 20 mg/kg bodyweight of nanoparticles in mice.
EXP Group Bodyweight gain Liver Spleen Kidney
1 Vehicle (0.9% NaCl) -1.6 ± 1.9 6.6 ± 1.2 0.5 ± 0.1 1.9 ± 0.0
 Fe3O4-DAAO 100 mg/kg -3.5 ± 2.2 7.8 ± 0.3 0.6 ± 0.1 1.6 ± 0.1
2 Vehicle (NaPPi) -2.9 ± 0.4 6.7 ± 0.1 0.5 ± 0.1 1.8 ± 0.1
 Fe3O4-DAAO 20 mg/kg -3.5 ± 2.8 6.9 ± 0.2 0.5 ± 0.1 1.6 ± 0.2
Results are expressed as means ± SD.
Figure 7. Comparison of cytotoxicity, on SKOV-3, of Fe3O4-APTES-DAAO prepared with the two methods, without 
and with 1 mM D-Ala.
100
50
0
0.0 3.5 7.0 14.0
First method
Second method
Fe3O4-APTES-DAAO+D-Ala 1 mM (mU)
100
50
0
0.0 3.5 7.0 14.0
Fe3O4-APTES-DAAO (mU)
(%
) 
A
T
P
 c
o
n
te
n
t
www.future-science.com 10.4155/fso.15.67future science group
New synthesis & biodistribution of the D-amino acid oxidase-magnetic nanoparticle system    Research Article
In vivo study
Mice treated with 100 mg NP/kg
Immediately after the administration of NPs, and dur-
ing the following hours, all mice appeared healthy and 
no relevant behavioral alterations were observed. At 
necropsy, the liver of three out of three treated mice 
had a diffuse mild black-brown discoloration com-
pared with control mice. No significant differences in 
bodyweight gain and relative organ weights of liver, 
spleen and kidney were observed between control and 
Fe
3
O
4
-APTES-DAAO treated group (Table 1). Histo-
logically, in three out of three treated mice, intracyto-
plasmic brown granular material (consistent with iron 
pigment, as confirmed by Perls iron stain) was found in 
HE stained sections of the liver, spleen and lung, and 
only occasionally in the kidney (at level of blood vessels) 
Figure 8. Histology of liver, spleen, lung, and kidney of mice treated with vehicle (A), 100 mg/kg ([B]; EXP 1), 
and 20 mg/kg ([C]; EXP 2) of NPs (upper panel: HE; lower panel: Perls stain; scale bar = 25 μm). Brown granular 
material is evident in HE stained sections (arrowheads) of NP treated mice, consistent with iron aggregates, as 
confirmed by Perls stain (blue).
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(Figure 8). The results of the quantitative evaluation of 
the iron deposits detected in Perls iron stained sections 
of examined organs is reported in Table 2. In the liver 
the iron pigment was found mainly in the cytoplasm of 
Kupffer cells (immunostained with Iba1), but occasion-
ally also within spindle-shaped cells, likely consistent 
with hepatic sinusoidal endothelial cells (Figure 9). In 
the lung, there were moderate numbers of cells (mono-
cytes/macrophages) with intracytoplasmic iron pigment 
infiltrating the alveolar septa, throughout the pulmo-
nary parenchyma. Multifocally, intravascular up to 100 
μm in diameter iron aggregates (emboli) surrounded by 
granulocytes, were found in association with interstitial 
infiltrates of histiocytes expanding the alveolar septa 
(Figure 8). In the spleen, large numbers of histiocytes 
with intracytoplasmic iron pigment were found in the 
red pulp, marginal zone, and PALS/germinal center. 
The white pulp was affected by mild-to-moderate fol-
licular reactive hyperplasia. No iron  deposits were 
observed in the heart, and brain of treated mice.
Mice treated with 20 mg NP/kg
No relevant behavioral alterations and no significant 
differences of bodyweight gain, and relative organ 
weights of liver, spleen and kidney were observed 
between control and Fe
3
O
4
-APTES-DAAO-treated 
group (Table 1). Grossly, a moderate splenomegaly was 
observed only in one out of three treated mice. His-
tologically, in three out of three treated mice, small-
to-moderate amount of iron pigment was found in the 
liver (Kupffer cells), spleen (macrophages/histiocytes 
in the marginal zone, red pulp and PALS/germinal 
center) and rarely in the kidney (interstitial capillaries). 
In one out of three treated mice, only rare and small 
intracytoplasmic iron aggregates (monocytes/macro-
phages) were found in the lung alveolar septa (Figure 8). 
No iron deposits were observed in the heart, testis and 
brain. Reduced amount of iron-containing deposits 
were detected in liver and spleen compared with those 
found in mice treated with 100 mg NP/kg (Table 2).
Discussion
In our previous work, we designed a protocol for 
the immobilization of RgDAAO on magnetic iron 
oxide NPs for antitumor therapy (Fe
3
O
4
-APTES-
DAAO) [21]. The conjugation was performed via glu-
taraldehyde obtaining a system with an activity of 4 
U/mg NP. In this work, we improved the protocol for 
Table 2. Quantitative evaluation of iron deposits detected in Perls iron stained sections.
Group Liver Spleen Lung Kidney Brain Heart
Vehicle 0.02 ± 0.02 0.02 ± 0.00 0.05 ± 0.02 0.04 ± 0.01 0.00 ± 0.00 0.00 ± 0.00
Fe3O4-DAAO 100 mg/kg 2.98 ± 1.11 1.40 ± 0.55 0.51 ± 0.13 0.09 ± 0.05 0.00 ± 0.00 0.00 ± 0.00
Fe3O4-DAAO 20 mg/kg 0.23 ± 0.07 0.17 ± 0,06 0.13 ± 0.08 0.04 ± 0.01 0.00 ± 0.00 0.00 ± 0.00
Results are expressed as means ± SD.
Figure 9. Histological examination of mouse liver. (A) Brown aggregates of iron-containing NPs within the cytoplasm 
of Kupffer cells lining hepatic sinusoids (HE staining). (B) Iron-containing NPs (green) are mainly found in the 
cytoplasm of Iba1+ Kupffer cells (red, arrows) and occasionally in spindled cells (*). Nuclei stained with DAPI (cyan).
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the synthesis of Fe
3
O
4
-APTES-DAAO, enhancing the 
yield by 40%, reaching 100% of conjugated enzyme 
in term of activity and quantity. The conjugation of 
RgDAAO occurs by means of EDC and NHS and 
the reaction times are reduced by 2 h. The new system 
has an activity of 7 U/mg NP, 1.5-fold more than the 
old one (characterized by 4.5 U/mg NP). A schematic 
representation of the two protocols of conjugation is 
reported in Figure 10.
The comparison of the two systems by IR analysis 
demonstrates that all the ligands are functionalized in 
the EDC-NHS sample, whereas a small portion of them 
present free coordination ends in the glutaraldehyde 
compound (Figures 1 & 2). In light of this, we can say 
that the EDC-NHS sample higher activity in respect 
with the glutaraldehyde sample is due to a higher effi-
ciency of bound. In fact, apparently all available NH
2
 
sites are saturated with DAAO, while glutaraldehyde 
Figure 10. Schematic representation of the two DAAO conjugation methods on Fe3O4-APTES: (A) Conjugation via glutaraldehyde; 
(B) Conjugation via EDC and NHS.
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sample shows some free NH
2
 and aldehyde sites. More-
over all conjugation sites of Fe
3
O
4
 NPs are saturated, 
signifying that APTES functionalization is absolute.
DLS analysis shows that the population of Fe
3
O
4
-
APTES-DAAO is stable around a dimension of 1 
μm indicating that the enzyme conjugation process 
induces aggregation of NPs. However, more informa-
tion on the hydrodynamic diameter of the iron core, 
the magnetization capabilities and the iron content 
would allow to better compare these newly created 
particles to others.
The cytotoxicity analysis does not highlight any 
difference between the two systems; indeed, both 
completely deplete the ATP content at 3.5 mU in the 
presence of the DAAO substrate D-alanine. Worthy of 
note is that the second system employs a lower amount 
of Fe
3
O
4
 NPs, because of the higher enzymatic activity.
In the present paper, we have also evaluated the in 
vivo safety of the Fe
3
O
4
-APTES-DAAO system pro-
duced with the EDC-NHS procedure. In the first 
experiment, after intravenous injection in mice of 100 
mg NP/kg diluted in 0.9% NaCl no significant altera-
tions of behavior, bodyweight gain and relative organ 
weight of liver, spleen and kidney were observed. Histo-
logically, iron deposits were detected in the liver, spleen, 
lungs and kidneys, while none was found in the heart 
and brain. Mainly, iron deposits were found in the cyto-
plasm of monocytes/macrophages/histiocytes, indicat-
ing that most of injected particles were removed from 
blood circulation by phagocytic cells, as previously 
reported for other nanoparticles [30]. However, presence 
of intravascular iron deposits associated with interstitial 
inflammation were found in the lung, indicating that 
pulmonary embolization occurred after intravenous 
administration of aggregated NPs, as confirmed by the 
results of DLS analysis. In the spleen of mice treated 
with 100 mg/kg, reactive follicular hyperplasia was 
observed. This finding may be interpreted as an anti-
genic response, likely directed against the enzymatic 
portion of the NP system. In general, no overt adverse 
effects have been observed 24 h after intravenous 
administration of 100 mg Fe
3
O
4
-APTES-DAAO/kg, 
however, the presence of pulmonary embolization of 
iron aggregates prompted us to perform a second exper-
iment using a lower dose (20 mg NP/kg), and a dif-
ferent vehicle (NaPPi buffer instead of 0.9% NaCl) in 
order to prevent particle aggregation. No clinicopatho-
logical adverse effects were observed after intravenous 
administration of 20 mg NP/kg, and histologically, a 
dose-dependent decrease of iron deposits was found in 
the liver and spleen. In addition, absence of detectable 
iron deposits in the brain and testis (examined only for 
20 mg Fe
3
O
4
-DAAO/kg) suggests that our system is 
not able to cross biological barriers, or, at least, not in 
the absence of an external magnetic field and under 
tested conditions.
We also think that biological molecules, such as 
enzymes, polysaccharides [31,32], antibiotics, antibodies 
and nucleic acids [33], efficiently conjugated to mag-
netic NPs might constitute a category of ‘bionanopar-
ticles’ to be exploited in medical as well as industrial 
biotechnology.
Conclusion
We have improved the synthesis protocol of Fe
3
O
4
-
APTES-DAAO, reaching the highest activity allowed 
by the system. The acute cytotoxicity of the newly syn-
thesized nanoenzyme does not differ from the previ-
ously synthesized one. Moreover, no relevant adverse 
effects were observed after in vivo intravenous admin-
istration in mice of a single dose of 20 mg NP/kg bw.
Future perspective
Future aim will be the investigation of the biodistri-
bution of NPs under application of an external mag-
netic field. The ability of an external magnetic field to 
accumulate NPs in a determined area as well as that to 
make NPs crossing biological barriers will be investi-
gated. The ability of the system to destroy tumors will 
also be tested in vivo.
Moreover, we are convinced that flavoenzymes effi-
ciently conjugated to magnetic NPs could be exploited 
also in industrial biotechnology [34].
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